CA3147801A1 - Prodrugs of the tyrosine kinase inhibitor for treating cancer - Google Patents
Prodrugs of the tyrosine kinase inhibitor for treating cancer Download PDFInfo
- Publication number
- CA3147801A1 CA3147801A1 CA3147801A CA3147801A CA3147801A1 CA 3147801 A1 CA3147801 A1 CA 3147801A1 CA 3147801 A CA3147801 A CA 3147801A CA 3147801 A CA3147801 A CA 3147801A CA 3147801 A1 CA3147801 A1 CA 3147801A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- compound
- mmol
- axitinib
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 49
- 239000000651 prodrug Substances 0.000 title claims description 34
- 229940002612 prodrug Drugs 0.000 title claims description 34
- 201000011510 cancer Diseases 0.000 title claims description 18
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title description 6
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title description 6
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 132
- 150000003839 salts Chemical class 0.000 claims abstract description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 201000010099 disease Diseases 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims abstract description 16
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims abstract description 16
- 150000002148 esters Chemical class 0.000 claims abstract description 16
- 230000001404 mediated effect Effects 0.000 claims abstract description 11
- 230000005764 inhibitory process Effects 0.000 claims abstract 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 135
- 229960003005 axitinib Drugs 0.000 claims description 134
- -1 heteroalkoxycarbonyl Chemical group 0.000 claims description 114
- 238000000034 method Methods 0.000 claims description 44
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 229910052757 nitrogen Inorganic materials 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 125000002252 acyl group Chemical group 0.000 claims description 22
- 125000006239 protecting group Chemical group 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 13
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 239000011593 sulfur Substances 0.000 claims description 9
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 7
- 201000002510 thyroid cancer Diseases 0.000 claims description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 5
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims description 5
- 125000004029 hydroxymethyl group Chemical class [H]OC([H])([H])* 0.000 claims description 5
- 230000004060 metabolic process Effects 0.000 claims description 5
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 125000005499 phosphonyl group Chemical group 0.000 claims description 4
- 230000036470 plasma concentration Effects 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 claims description 3
- 125000005116 aryl carbamoyl group Chemical group 0.000 claims description 3
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 claims description 3
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 claims 2
- 229910019590 Cr-N Inorganic materials 0.000 claims 1
- 229910019588 Cr—N Inorganic materials 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 231
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 220
- 239000000203 mixture Substances 0.000 description 171
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 85
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 82
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 81
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 70
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 70
- 239000000741 silica gel Substances 0.000 description 70
- 229910002027 silica gel Inorganic materials 0.000 description 70
- 229960001866 silicon dioxide Drugs 0.000 description 70
- 239000003480 eluent Substances 0.000 description 59
- 239000000463 material Substances 0.000 description 59
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 57
- 238000006243 chemical reaction Methods 0.000 description 54
- 239000012044 organic layer Substances 0.000 description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 239000012267 brine Substances 0.000 description 42
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 42
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 37
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 37
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 37
- 101150041968 CDC13 gene Proteins 0.000 description 36
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 34
- 239000000243 solution Substances 0.000 description 34
- 238000005160 1H NMR spectroscopy Methods 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 33
- 239000012299 nitrogen atmosphere Substances 0.000 description 25
- 239000003814 drug Substances 0.000 description 24
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 19
- 229940079593 drug Drugs 0.000 description 19
- 239000002253 acid Substances 0.000 description 17
- 239000005457 ice water Substances 0.000 description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 13
- 238000004679 31P NMR spectroscopy Methods 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 9
- 239000002198 insoluble material Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- IYUKFAFDFHZKPI-DFWYDOINSA-N methyl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](C)N IYUKFAFDFHZKPI-DFWYDOINSA-N 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 5
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 229940125773 compound 10 Drugs 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 5
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 5
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000012258 stirred mixture Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- BLAOQYUKUBIXCF-UHFFFAOYSA-N 1-dichlorophosphoryloxynaphthalene Chemical compound C1=CC=C2C(OP(Cl)(=O)Cl)=CC=CC2=C1 BLAOQYUKUBIXCF-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 229960003767 alanine Drugs 0.000 description 4
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 239000011343 solid material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 3
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- SNIABFMMCKVXSY-UHFFFAOYSA-N benzoylazanium;chloride Chemical compound Cl.NC(=O)C1=CC=CC=C1 SNIABFMMCKVXSY-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011369 resultant mixture Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- XPNGNIFUDRPBFJ-UHFFFAOYSA-N (2-methylphenyl)methanol Chemical compound CC1=CC=CC=C1CO XPNGNIFUDRPBFJ-UHFFFAOYSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- BLJJFFADYSFMGJ-UHFFFAOYSA-N (4-nitrophenyl) 2,2,2-trifluoroethyl carbonate Chemical compound [O-][N+](=O)C1=CC=C(OC(=O)OCC(F)(F)F)C=C1 BLJJFFADYSFMGJ-UHFFFAOYSA-N 0.000 description 2
- LHJRDRXJWVYZHX-UHFFFAOYSA-N (4-nitrophenyl) pentyl carbonate Chemical compound CCCCCOC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LHJRDRXJWVYZHX-UHFFFAOYSA-N 0.000 description 2
- YBADLXQNJCMBKR-UHFFFAOYSA-M (4-nitrophenyl)acetate Chemical compound [O-]C(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-M 0.000 description 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 2
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 2
- CCZMQYGSXWZFKI-UHFFFAOYSA-N 1-chloro-4-dichlorophosphoryloxybenzene Chemical compound ClC1=CC=C(OP(Cl)(Cl)=O)C=C1 CCZMQYGSXWZFKI-UHFFFAOYSA-N 0.000 description 2
- DRKYVZZJAKOILZ-UHFFFAOYSA-N 1-dichlorophosphoryloxy-4-fluorobenzene Chemical compound FC1=CC=C(OP(Cl)(Cl)=O)C=C1 DRKYVZZJAKOILZ-UHFFFAOYSA-N 0.000 description 2
- OSDCKQFKYUESEG-UHFFFAOYSA-N 1-dichlorophosphoryloxy-4-methylbenzene Chemical compound CC1=CC=C(OP(Cl)(Cl)=O)C=C1 OSDCKQFKYUESEG-UHFFFAOYSA-N 0.000 description 2
- PEBJXUZWQCMUAO-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethyl (4-nitrophenyl) carbonate Chemical compound COCCOCCOC(=O)OC1=CC=C([N+]([O-])=O)C=C1 PEBJXUZWQCMUAO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- UHMRXPAXSQROHN-UHFFFAOYSA-N 2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethyl (4-nitrophenyl) carbonate Chemical compound COCCOCCOCCOCCOC(=O)OC1=CC=C([N+]([O-])=O)C=C1 UHMRXPAXSQROHN-UHFFFAOYSA-N 0.000 description 2
- KUIABWSLGWSPOK-UHFFFAOYSA-N 2-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]ethyl (4-nitrophenyl) carbonate Chemical compound C(OCCOCCO[Si](C)(C)C(C)(C)C)(OC1=CC=C(C=C1)[N+](=O)[O-])=O KUIABWSLGWSPOK-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- YJYAGNPMQVHYAH-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxyethanol Chemical compound CC(C)(C)[Si](C)(C)OCCO YJYAGNPMQVHYAH-UHFFFAOYSA-N 0.000 description 2
- ZFXXZRONDIRWBU-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxyethyl (4-nitrophenyl) carbonate Chemical compound CC(C)(C)[Si](C)(C)OCCOC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ZFXXZRONDIRWBU-UHFFFAOYSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
- CDULPPOISZOUTK-UHFFFAOYSA-N 2-azaniumyl-3,4-dihydro-1h-naphthalene-2-carboxylate Chemical compound C1=CC=C2CC(N)(C(O)=O)CCC2=C1 CDULPPOISZOUTK-UHFFFAOYSA-N 0.000 description 2
- VICULOXVGGBWFP-UHFFFAOYSA-N 2-methoxyethyl (4-nitrophenyl) carbonate Chemical compound COCCOC(=O)OC1=CC=C([N+]([O-])=O)C=C1 VICULOXVGGBWFP-UHFFFAOYSA-N 0.000 description 2
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 2
- WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 description 2
- SHBHYINHXNTBRP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-methylsulfonylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(=O)(=O)C)C=CC=1 SHBHYINHXNTBRP-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-6-methylheptanoate Chemical compound CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 2
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 2
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 2
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical class FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- DUXZAXCGJSBGDW-HXUWFJFHSA-N Desfesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)O)=CC=CC=C1 DUXZAXCGJSBGDW-HXUWFJFHSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- OLNLSTNFRUFTLM-UHFFFAOYSA-N N-ethylasparagine Chemical compound CCNC(C(O)=O)CC(N)=O OLNLSTNFRUFTLM-UHFFFAOYSA-N 0.000 description 2
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 2
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 150000001733 carboxylic acid esters Chemical group 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 2
- WVPKAWVFTPWPDB-UHFFFAOYSA-M dichlorophosphinate Chemical compound [O-]P(Cl)(Cl)=O WVPKAWVFTPWPDB-UHFFFAOYSA-M 0.000 description 2
- TXFOLHZMICYNRM-UHFFFAOYSA-N dichlorophosphoryloxybenzene Chemical compound ClP(Cl)(=O)OC1=CC=CC=C1 TXFOLHZMICYNRM-UHFFFAOYSA-N 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- OFJLSOXXIMLDDL-UHFFFAOYSA-N ethyl (4-nitrophenyl) carbonate Chemical compound CCOC(=O)OC1=CC=C([N+]([O-])=O)C=C1 OFJLSOXXIMLDDL-UHFFFAOYSA-N 0.000 description 2
- 125000003838 furazanyl group Chemical group 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000023611 glucuronidation Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 2
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- YAQKNCSWDMGPOY-JEDNCBNOSA-N propan-2-yl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.CC(C)OC(=O)[C@H](C)N YAQKNCSWDMGPOY-JEDNCBNOSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 208000037922 refractory disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- POBDBYGSGKMZPH-NSHDSACASA-N (2,5-dioxopyrrolidin-1-yl) (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](C(C)C)C(=O)ON1C(=O)CCC1=O POBDBYGSGKMZPH-NSHDSACASA-N 0.000 description 1
- POBDBYGSGKMZPH-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound CC(C)(C)OC(=O)NC(C(C)C)C(=O)ON1C(=O)CCC1=O POBDBYGSGKMZPH-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- FQRURPFZTFUXEZ-MRVPVSSYSA-N (2s)-2,3,3,3-tetrafluoro-2-(n-fluoroanilino)propanoic acid Chemical compound OC(=O)[C@](F)(C(F)(F)F)N(F)C1=CC=CC=C1 FQRURPFZTFUXEZ-MRVPVSSYSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 description 1
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 1
- NRCSJHVDTAAISV-QMMMGPOBSA-N (2s)-2-amino-3-(3,4-dichlorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Cl)C(Cl)=C1 NRCSJHVDTAAISV-QMMMGPOBSA-N 0.000 description 1
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
- GTVVZTAFGPQSPC-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-nitrophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-QMMMGPOBSA-N 0.000 description 1
- LOVPHSMOAVXQIH-UHFFFAOYSA-N (4-nitrophenyl) hydrogen carbonate Chemical compound OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LOVPHSMOAVXQIH-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WAPNOHKVXSQRPX-ZETCQYMHSA-N (S)-1-phenylethanol Chemical compound C[C@H](O)C1=CC=CC=C1 WAPNOHKVXSQRPX-ZETCQYMHSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NQRKYASMKDDGHT-UHFFFAOYSA-N (aminooxy)acetic acid Chemical compound NOCC(O)=O NQRKYASMKDDGHT-UHFFFAOYSA-N 0.000 description 1
- NYPYHUZRZVSYKL-UHFFFAOYSA-N -3,5-Diiodotyrosine Natural products OC(=O)C(N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- GUOSQNAUYHMCRU-UHFFFAOYSA-N 11-Aminoundecanoic acid Chemical compound NCCCCCCCCCCC(O)=O GUOSQNAUYHMCRU-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HAWJUUUDZFZUKG-UHFFFAOYSA-N 2,2-diaminoheptanedioic acid Chemical compound OC(=O)C(N)(N)CCCCC(O)=O HAWJUUUDZFZUKG-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- AGWKUHGLWHMYTG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound COCCOCCOCCOCCOCCOCCOCCO AGWKUHGLWHMYTG-UHFFFAOYSA-N 0.000 description 1
- VHPXSBIFWDAFMB-UHFFFAOYSA-N 2-amino-Delta(2)-thiazoline-4-carboxylic acid Chemical compound NC1=[NH+]C(C([O-])=O)CS1 VHPXSBIFWDAFMB-UHFFFAOYSA-N 0.000 description 1
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 1
- DGYHPLMPMRKMPD-UHFFFAOYSA-N 2-azaniumylpent-4-ynoate Chemical compound OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- NYCRCTMDYITATC-UHFFFAOYSA-N 2-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1F NYCRCTMDYITATC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
- NYPYHUZRZVSYKL-ZETCQYMHSA-N 3,5-diiodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-ZETCQYMHSA-N 0.000 description 1
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
- XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- ACWBBAGYTKWBCD-ZETCQYMHSA-N 3-chloro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Cl)=C1 ACWBBAGYTKWBCD-ZETCQYMHSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- UQTZMGFTRHFAAM-ZETCQYMHSA-N 3-iodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(I)=C1 UQTZMGFTRHFAAM-ZETCQYMHSA-N 0.000 description 1
- MQHLULPKDLJASZ-QMMMGPOBSA-N 3-methyl-L-tyrosine zwitterion Chemical compound CC1=CC(C[C@H](N)C(O)=O)=CC=C1O MQHLULPKDLJASZ-QMMMGPOBSA-N 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- UEOHATPGKDSULR-UHFFFAOYSA-N 9h-carbazol-4-ol Chemical compound N1C2=CC=CC=C2C2=C1C=CC=C2O UEOHATPGKDSULR-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000002375 Hand-Foot Syndrome Diseases 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- LOOZZTFGSTZNRX-VIFPVBQESA-N L-Homotyrosine Chemical compound OC(=O)[C@@H](N)CCC1=CC=C(O)C=C1 LOOZZTFGSTZNRX-VIFPVBQESA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- PEMUHKUIQHFMTH-UHFFFAOYSA-N P-Bromo-DL-phenylalanine Chemical compound OC(=O)C(N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- QQLNORNXFOWSJJ-OZZZDHQUSA-N [(1S)-1-phenylethyl] (2S)-2-aminopropanoate hydrochloride Chemical compound Cl.C1(=CC=CC=C1)[C@H](C)OC([C@@H](N)C)=O QQLNORNXFOWSJJ-OZZZDHQUSA-N 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- BOGSOFADOWIECK-UHFFFAOYSA-N [N].C=1C=NNC=1 Chemical compound [N].C=1C=NNC=1 BOGSOFADOWIECK-UHFFFAOYSA-N 0.000 description 1
- PDKXJKWLFFZPPF-UHFFFAOYSA-N [dimethylamino-(3-oxidotriazolo[4,5-b]pyridin-3-ium-1-yl)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(C(N(C)C)=[N+](C)C)N=[N+]([O-])C2=N1 PDKXJKWLFFZPPF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005157 alkyl carboxy group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-UHFFFAOYSA-N alpha-phenylglycine Chemical compound OC(=O)C(N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000005512 benztetrazolyl group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- LPCWKMYWISGVSK-UHFFFAOYSA-N bicyclo[3.2.1]octane Chemical compound C1C2CCC1CCC2 LPCWKMYWISGVSK-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- JCZLABDVDPYLRZ-AWEZNQCLSA-N biphenylalanine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C1=CC=CC=C1 JCZLABDVDPYLRZ-AWEZNQCLSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004986 diarylamino group Chemical group 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 description 1
- 229960002978 fesoterodine Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- QNRXNRGSOJZINA-UHFFFAOYSA-N indoline-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)CC2=C1 QNRXNRGSOJZINA-UHFFFAOYSA-N 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- CQYBNXGHMBNGCG-RNJXMRFFSA-N octahydroindole-2-carboxylic acid Chemical compound C1CCC[C@H]2N[C@H](C(=O)O)C[C@@H]21 CQYBNXGHMBNGCG-RNJXMRFFSA-N 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- LDEKQSIMHVQZJK-CAQYMETFSA-N tenofovir alafenamide Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 description 1
- 229960004946 tenofovir alafenamide Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical class C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- JLGLQAWTXXGVEM-UHFFFAOYSA-N triethylene glycol monomethyl ether Chemical compound COCCOCCOCCO JLGLQAWTXXGVEM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
There are provided compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, useful for inhibition or modulation of the activity of tyrosine kinases and treatment of disease states or conditions mediated by tyrosine kinases, including cancers. (I)
Description
Prodrugs of the Tyrosine Kinase Inhibitor for Treating Cancer CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to Chinese application no.
201910818779.0 filed August 30, 2019; Chinese application no. 201910817505.X
filed August 30, 2019; Chinese application no. 201910818675.X filed August 30, 2019;
and U.S. application no. 62/994,364 filed March 25, 2020; the entire contents of each of which are hereby incorporated by reference.
FIELD
[0001] This application claims the benefit of priority to Chinese application no.
201910818779.0 filed August 30, 2019; Chinese application no. 201910817505.X
filed August 30, 2019; Chinese application no. 201910818675.X filed August 30, 2019;
and U.S. application no. 62/994,364 filed March 25, 2020; the entire contents of each of which are hereby incorporated by reference.
FIELD
[0002] The present disclosure relates to prodrugs of N-methy1-24(3-41E)-2-(2-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide and compositions thereof that are tyrosine kinase inhibitors (TKIs), and uses thereof to treat disease states or conditions mediated by tyrosine kinases, such as cancers.
BACKGROUND
BACKGROUND
[0003] Axitinib (chemical name: N-methy1-2-03-41E)-2-(2-pyridinyfletheny1)-1H-indazol-6-yOthio)benzamide; trade name: Inlyta0) is a small molecule tyrosine kinase inhibitor (TM) used for treating cancer (see, for example, International PCT
Application Publication no. W02001002369; the compound's structure is shown below).
Axitinib has been shown to significantly inhibit growth of breast cancer in animal xenograft models (WiImes, L.J. et al., Magn. Reson. Imaging, 2007, 25(3):319¨ 327). The drug has shown partial responses in clinical trials for renal cell carcinoma (RCC) (Rini, B.
et al., J. of Clin.
Oncol. 2005, ASCO Annual Meeting Proceedings, 23 (165): 4509), and for several other tumor types (Rugo, H. S. et al., J. Clin. Oncol., 2005, 23:5474-5483).
Axitinib was approved for treatment of RCC by the U.S. Food and Drug Administration after showing a modest increase in progression-free survival.
Application Publication no. W02001002369; the compound's structure is shown below).
Axitinib has been shown to significantly inhibit growth of breast cancer in animal xenograft models (WiImes, L.J. et al., Magn. Reson. Imaging, 2007, 25(3):319¨ 327). The drug has shown partial responses in clinical trials for renal cell carcinoma (RCC) (Rini, B.
et al., J. of Clin.
Oncol. 2005, ASCO Annual Meeting Proceedings, 23 (165): 4509), and for several other tumor types (Rugo, H. S. et al., J. Clin. Oncol., 2005, 23:5474-5483).
Axitinib was approved for treatment of RCC by the U.S. Food and Drug Administration after showing a modest increase in progression-free survival.
[0004] The structure of axitinib is shown here:
H
N-._CH3 0 ---., S
N-
H
N-._CH3 0 ---., S
N-
[0005]
Axitinib is used as a targeted anti-cancer therapy since it targets and binds to the vascular endothelial growth factor receptors (VEGFR) on the inside of cancer cells.
VEGFR is found on the surface of many normal and cancerous cells. By binding to these receptors, axitinib blocks an important pathway that promotes angiogenesis (the formation of new blood vessels by tumors) (Escudier, B. and Gore, M., "Axitinib for the Management of Metastatic Renal Cell Carcinoma", Drugs in R&D, 2011, 11(2):113-126).
Axitinib is used as a targeted anti-cancer therapy since it targets and binds to the vascular endothelial growth factor receptors (VEGFR) on the inside of cancer cells.
VEGFR is found on the surface of many normal and cancerous cells. By binding to these receptors, axitinib blocks an important pathway that promotes angiogenesis (the formation of new blood vessels by tumors) (Escudier, B. and Gore, M., "Axitinib for the Management of Metastatic Renal Cell Carcinoma", Drugs in R&D, 2011, 11(2):113-126).
[0006]
Further, data from a multi-center phase II study in patients with advanced differentiated (papillary, follicular, or Hurthle) thyroid cancer supports the use of axitinib in the management of I131-refractory disease or in patients who could not receive 1131 (Cohen, Ezra E. W. et al., J. Clin. Oncol., 2008, 26(29):4708-4713). Another multi-center phase II study in advanced thyroid cancer also supports the use of axitinib in the management of I131-refractory disease (Locati, L. D. et al., Cancer, 2014, 120(17):2694-2703). Therefore, axitinib is also used off-label for the treatment of thyroid cancer (differentiated, advanced).
Further, data from a multi-center phase II study in patients with advanced differentiated (papillary, follicular, or Hurthle) thyroid cancer supports the use of axitinib in the management of I131-refractory disease or in patients who could not receive 1131 (Cohen, Ezra E. W. et al., J. Clin. Oncol., 2008, 26(29):4708-4713). Another multi-center phase II study in advanced thyroid cancer also supports the use of axitinib in the management of I131-refractory disease (Locati, L. D. et al., Cancer, 2014, 120(17):2694-2703). Therefore, axitinib is also used off-label for the treatment of thyroid cancer (differentiated, advanced).
[0007]
One problematic aspect of using axitinib in the treatment of cancer is its side effects. Many different adverse effects have been reported, including diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, hand-foot syndrome, weight decrease, vomiting, asthenia, and constipation, with the most common side effects occurring in more than 20% of patients (FDA Prescribing Information, January 30, 2012).
One problematic aspect of using axitinib in the treatment of cancer is its side effects. Many different adverse effects have been reported, including diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, hand-foot syndrome, weight decrease, vomiting, asthenia, and constipation, with the most common side effects occurring in more than 20% of patients (FDA Prescribing Information, January 30, 2012).
[0008]
As seen with other orally administered drugs, including other tyrosine kinase inhibitors, Axitinib's pharmacokinetics (PK) were variable in healthy volunteers as well as in cancer patients (Garrett, M. et al., Br. I Glitz. Pharmacol., 2013, 77(3): 48(Y492). Notably, a large variability in axitinib PK was evident from the estimated residual standard deviation of 50.9% for oral administration and 34.2% for intravenous administration of axitinib, which could not be reduced by introduction of inter-occasion variability in the model.
As seen with other orally administered drugs, including other tyrosine kinase inhibitors, Axitinib's pharmacokinetics (PK) were variable in healthy volunteers as well as in cancer patients (Garrett, M. et al., Br. I Glitz. Pharmacol., 2013, 77(3): 48(Y492). Notably, a large variability in axitinib PK was evident from the estimated residual standard deviation of 50.9% for oral administration and 34.2% for intravenous administration of axitinib, which could not be reduced by introduction of inter-occasion variability in the model.
[0009]
The exact causes for this variability in axitinib PK are yet to be elucidated.
Axitinib is known to be heavily metabolized (Smith, B. J. et al., Drug Metab.
Dispos., 2014,42:918-931; and Zientek, M. A, et al., Drug Mew. Dispos., 2016, 44(1):102-114).
Among the three major metabolites, one is a product of glucuronidation at the nitrogen atom of the central pyrazole ring (M7), and the other two are metabolic products initiated from a mono-oxygenation step. Because axitinib is primarily metabolized by CYP3A4/5, it has been speculated that one major source of variability may be differences in CYP3A4/5 expression and/or activity in the liver and intestine (a 10- to 40-fold variability in expression of CYP3A4/5 has been reported in healthy subjects).
Since axitinib is a low extraction drug, the metabolic clearance of axitinib may be particularly sensitive to variable levels of hepatic and intestinal metabolizing enzymes.
Another possible explanation is variability in plasma binding of axitinib between subjects. With regard to high residual (intra-subject) variability, it is plausible that differences in dissolution and subsequent gastrointestinal absorption of axitinib may be a contributing factor. Since axitinib solubility is pH-dependent, with solubility declining with increasing pH, changes in pH values in stomach and duodenum may lead to variable dissolution of axitinib.
The exact causes for this variability in axitinib PK are yet to be elucidated.
Axitinib is known to be heavily metabolized (Smith, B. J. et al., Drug Metab.
Dispos., 2014,42:918-931; and Zientek, M. A, et al., Drug Mew. Dispos., 2016, 44(1):102-114).
Among the three major metabolites, one is a product of glucuronidation at the nitrogen atom of the central pyrazole ring (M7), and the other two are metabolic products initiated from a mono-oxygenation step. Because axitinib is primarily metabolized by CYP3A4/5, it has been speculated that one major source of variability may be differences in CYP3A4/5 expression and/or activity in the liver and intestine (a 10- to 40-fold variability in expression of CYP3A4/5 has been reported in healthy subjects).
Since axitinib is a low extraction drug, the metabolic clearance of axitinib may be particularly sensitive to variable levels of hepatic and intestinal metabolizing enzymes.
Another possible explanation is variability in plasma binding of axitinib between subjects. With regard to high residual (intra-subject) variability, it is plausible that differences in dissolution and subsequent gastrointestinal absorption of axitinib may be a contributing factor. Since axitinib solubility is pH-dependent, with solubility declining with increasing pH, changes in pH values in stomach and duodenum may lead to variable dissolution of axitinib.
[0010]
Since not only the toxicity but also the clinical benefit of axitinib may be affected by its plasma exposure, it is critical to identify clinical factors that contribute to the variability in axitinib PK. In order to reduce toxicity and to maintain stable therapeutic benefit, it is desirable to eliminate or reduce the PK variability of axitinib.
Since not only the toxicity but also the clinical benefit of axitinib may be affected by its plasma exposure, it is critical to identify clinical factors that contribute to the variability in axitinib PK. In order to reduce toxicity and to maintain stable therapeutic benefit, it is desirable to eliminate or reduce the PK variability of axitinib.
[0011]
A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug (see for example, Rautio, I et at, "The expanding role of prodrugs in contemporary drug design and development", Nat. Rev. Drug Discov., 2018, 17, 559-587; and Miles H., et al., Pharmacology: Principles and Practice. Academic Press, Jun 19, 2009, pp. 216-217).
Inactive prodrugs are pharmacologically inactive medications that are metabolized into an active form within the body. Thus, instead of administering a drug directly, a corresponding prodrug may be used to improve how a medicine is absorbed, distributed, metabolized, and/or excreted (ADME) (for example, see Malhotra, B., et al., "The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine", Curr. Med. Chem., 2009, 16 (33): 4481-9; and Stella, V.J., et al, "Prodrugs. Do they have advantages in clinical practice?", Drugs, 1985, 29 (5): 455-73). A prodrug may be used to improve how selectively a drug interacts with cells or processes that are not its intended target. This can reduce adverse or unintended effects of a drug, which is especially important for treatments like chemotherapy that often have severe unintended and undesirable side effects. For example, tenofovir alafenamide (TAP), a novel prodrug of tenofovir, was developed to deliver enhanced antiviral potency and reduced systemic toxicity (Byrne, R., et al., Therap.
Adv.
Gastroenterol., 2018, 11:1-12).
SUMMARY
A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug (see for example, Rautio, I et at, "The expanding role of prodrugs in contemporary drug design and development", Nat. Rev. Drug Discov., 2018, 17, 559-587; and Miles H., et al., Pharmacology: Principles and Practice. Academic Press, Jun 19, 2009, pp. 216-217).
Inactive prodrugs are pharmacologically inactive medications that are metabolized into an active form within the body. Thus, instead of administering a drug directly, a corresponding prodrug may be used to improve how a medicine is absorbed, distributed, metabolized, and/or excreted (ADME) (for example, see Malhotra, B., et al., "The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine", Curr. Med. Chem., 2009, 16 (33): 4481-9; and Stella, V.J., et al, "Prodrugs. Do they have advantages in clinical practice?", Drugs, 1985, 29 (5): 455-73). A prodrug may be used to improve how selectively a drug interacts with cells or processes that are not its intended target. This can reduce adverse or unintended effects of a drug, which is especially important for treatments like chemotherapy that often have severe unintended and undesirable side effects. For example, tenofovir alafenamide (TAP), a novel prodrug of tenofovir, was developed to deliver enhanced antiviral potency and reduced systemic toxicity (Byrne, R., et al., Therap.
Adv.
Gastroenterol., 2018, 11:1-12).
SUMMARY
[0012]
It is an object of the present invention to ameliorate at least some of the deficiencies present in the prior art. Embodiments of the present technology have been developed based at least in part on the inventors' appreciation that there is a need for modifying or improving the pharmacokinetic profile of N-methy1-243-((1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide for its therapeutic applications through developing a prodrug of this particular compound. These and other needs can be satisfied by the disclosure herein of axitinib derivatives and/or prodrugs, pharmaceutical compositions and uses thereof to inhibit or modulate the activity of tyrosine kinase and to treat disease states or conditions mediated by tyrosine kinases, such as cancers.
It is an object of the present invention to ameliorate at least some of the deficiencies present in the prior art. Embodiments of the present technology have been developed based at least in part on the inventors' appreciation that there is a need for modifying or improving the pharmacokinetic profile of N-methy1-243-((1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide for its therapeutic applications through developing a prodrug of this particular compound. These and other needs can be satisfied by the disclosure herein of axitinib derivatives and/or prodrugs, pharmaceutical compositions and uses thereof to inhibit or modulate the activity of tyrosine kinase and to treat disease states or conditions mediated by tyrosine kinases, such as cancers.
[0013]
Without wishing to be limited by theory, it is believed that a proper prodrug strategy with axitinib would be able to modulate the pharmacokinetic profile of the drug, through changing the course and/or rate of metabolic pathways of the drug. As one example, protection of the ring nitrogen atoms in axitinib may modify the electron density of the system and thus modulate the rate of oxidation and subsequently modulate the metabolism of the compound. When such a protection is introduced to the pyrazole nitrogen, it may avoid, at least to a certain extent, glucuronidation at this nitrogen.
Without wishing to be limited by theory, it is believed that a proper prodrug strategy with axitinib would be able to modulate the pharmacokinetic profile of the drug, through changing the course and/or rate of metabolic pathways of the drug. As one example, protection of the ring nitrogen atoms in axitinib may modify the electron density of the system and thus modulate the rate of oxidation and subsequently modulate the metabolism of the compound. When such a protection is introduced to the pyrazole nitrogen, it may avoid, at least to a certain extent, glucuronidation at this nitrogen.
[0014]
In a first aspect, there are provided compounds of Formula I, or pharmaceutically acceptable salts, esters, solvates, or polymorphs thereof:
I
S
N
I -m--N
R3 N.
RI
(I), where RIand R2 are independently a hydrogen (H) or a protecting group (P); R3, which may be present or absent, is a protecting group, and when R3 is present, the nitrogen atom is positively charged and a counterion is also present; provided that the compound of Formula I is not axitinib. In embodiments where both RI and R2 are a protecting group (P), the protecting groups may be the same or different.
In a first aspect, there are provided compounds of Formula I, or pharmaceutically acceptable salts, esters, solvates, or polymorphs thereof:
I
S
N
I -m--N
R3 N.
RI
(I), where RIand R2 are independently a hydrogen (H) or a protecting group (P); R3, which may be present or absent, is a protecting group, and when R3 is present, the nitrogen atom is positively charged and a counterion is also present; provided that the compound of Formula I is not axitinib. In embodiments where both RI and R2 are a protecting group (P), the protecting groups may be the same or different.
[0015]
In some embodiments, compounds provided herein are prodrugs of axitinib, i.e., are metabolized or converted in a subject to axitinib.
In some embodiments, compounds provided herein are prodrugs of axitinib, i.e., are metabolized or converted in a subject to axitinib.
[0016]
In one embodiment, a compound of Formula I is a compound of Formula II, or a pharmaceutically acceptable salt, ester, solvate, or polymorph thereof:
i --.õ
S
N----N
\
(II), where Wand R2 are independently a hydrogen (H) or a protecting group (P), and when both Wand R2 are a protecting group, the protecting groups may be the same or different.
In one embodiment, a compound of Formula I is a compound of Formula II, or a pharmaceutically acceptable salt, ester, solvate, or polymorph thereof:
i --.õ
S
N----N
\
(II), where Wand R2 are independently a hydrogen (H) or a protecting group (P), and when both Wand R2 are a protecting group, the protecting groups may be the same or different.
[0017]
In another embodiment, a compound of Formula I is a compound of Formula HI, or a pharmaceutically acceptable salt, ester, solvate, or polymorph thereof:
T-I
N-ThcH3 0 ---.,_ S
k R' (HI), C} õ
where R3 is a protecting group (P), and i is a counterion.
In another embodiment, a compound of Formula I is a compound of Formula HI, or a pharmaceutically acceptable salt, ester, solvate, or polymorph thereof:
T-I
N-ThcH3 0 ---.,_ S
k R' (HI), C} õ
where R3 is a protecting group (P), and i is a counterion.
[0018]
In one embodiment, a protecting group is selected from acyl group, alkylcarbonyl group, arylcarbonyl group, alkylthiocarbonyl group, arylthiocarbonyl group, alkylcarbamoyl group, arylcarbamoyl group, substituted or unsubstituted acetyl, substituted or unsubstituted aminoalkanoyl, substituted or unsubstituted a-aminoalkanoyl, acyl group derived from a natural or an unnatural amino acid with or without substitution, acyl group of a peptide residue, phosphonyl, phosphinyl, aminophophinyl, alkylaminophophinyl, sulfonyl, cycloalkane-carbonyl, heterocycloalkane-carbonyl, alkoxycarbonyl, aryloxycarbonyl, heteroalkoxycarbonyl, heteroaryloxycarbonyl, and 0-substituted hydroxymethyl group with or without substituents.
In one embodiment, a protecting group is selected from acyl group, alkylcarbonyl group, arylcarbonyl group, alkylthiocarbonyl group, arylthiocarbonyl group, alkylcarbamoyl group, arylcarbamoyl group, substituted or unsubstituted acetyl, substituted or unsubstituted aminoalkanoyl, substituted or unsubstituted a-aminoalkanoyl, acyl group derived from a natural or an unnatural amino acid with or without substitution, acyl group of a peptide residue, phosphonyl, phosphinyl, aminophophinyl, alkylaminophophinyl, sulfonyl, cycloalkane-carbonyl, heterocycloalkane-carbonyl, alkoxycarbonyl, aryloxycarbonyl, heteroalkoxycarbonyl, heteroaryloxycarbonyl, and 0-substituted hydroxymethyl group with or without substituents.
[0019]
In another embodiment, a protecting group is selected from R4W(R5R6C)õ,¨, where: m is an integer selected from 0 to 6; W is oxygen (-0-), sulfur (-S-), nitrogen (-NH-), or absent; R5 and R6 are independently a hydrogen or a lower alkyl group; and R4 FY
\
ORs 7 0 0 I I _________ II
R7X¨P¨ X P R7X¨S¨ R7X¨C¨
II fl II
II
is 0 , o , o , or o , where X is oxygen (-0-), sulfur (-S-), nitrogen (-NH-), or a methylene (-CH2-) group, R6 and R7 are independently a hydrogen, a substituted or unsubstituted alkyl or cycloallcyl, an aryl or heteroaryl group without or with substitution, a PEG moiety (such as le)¨(OCH2CH2).¨, where n =
1 to 10 and Rm is a hydrogen or a lower alkyl), an ester-forming group such as a lower alkyl or an aryl group; or a salt-forming moiety when X is oxygen or sulfur, such as a sodium, a potassium, a terraethylammonium, or a tetrabutylammonium; or, the combination of R6 and X is an &Icy or aryl group with or without further substitution; provided that the compound of Formula I, II, or III is not axitinib.
In another embodiment, a protecting group is selected from R4W(R5R6C)õ,¨, where: m is an integer selected from 0 to 6; W is oxygen (-0-), sulfur (-S-), nitrogen (-NH-), or absent; R5 and R6 are independently a hydrogen or a lower alkyl group; and R4 FY
\
ORs 7 0 0 I I _________ II
R7X¨P¨ X P R7X¨S¨ R7X¨C¨
II fl II
II
is 0 , o , o , or o , where X is oxygen (-0-), sulfur (-S-), nitrogen (-NH-), or a methylene (-CH2-) group, R6 and R7 are independently a hydrogen, a substituted or unsubstituted alkyl or cycloallcyl, an aryl or heteroaryl group without or with substitution, a PEG moiety (such as le)¨(OCH2CH2).¨, where n =
1 to 10 and Rm is a hydrogen or a lower alkyl), an ester-forming group such as a lower alkyl or an aryl group; or a salt-forming moiety when X is oxygen or sulfur, such as a sodium, a potassium, a terraethylammonium, or a tetrabutylammonium; or, the combination of R6 and X is an &Icy or aryl group with or without further substitution; provided that the compound of Formula I, II, or III is not axitinib.
[0020]
In some embodiments, a counterion is selected from, but not limited to, halide ion (F, a-, Br-, and F), sulfate ion, methanesulfonate ion, toluenesulfonate ion, oxalate ion, and other pharmaceutically accepted anionic moiety.
In some embodiments, a counterion is selected from, but not limited to, halide ion (F, a-, Br-, and F), sulfate ion, methanesulfonate ion, toluenesulfonate ion, oxalate ion, and other pharmaceutically accepted anionic moiety.
[0021]
In some embodiments, the compound of Formula I is a compound shown in Table 1, or a pharmaceutically-acceptable salt, ester, chelator, hydrate, solvate, stereoisomer, or polymorphic form thereof.
Table 1. Examples of axitinib derivative compounds.
/\
N -N
rri 0 le / \
N ----, N i µINI
0 . r / \
N ---Ni Op ____---O
/
N
N / iS
N
N
I.
ri 0 H
_r rj fl $ 0 N
k /\
N-7 N, 0zH N S 0 N..-0)-1- 0/P--..-a /\
N-N' IP
N
----µ0 ille---/ \
N.-N..--F
in H
/ \
N-N./ 110 f OHN s 0 N, 0a 0FL_ N ../.
----t 1 ---fie /\
N-11 i_ Iski 0 N,P
a = \
N'-).____ Iski le 0 r *a / \
N ----N /
N.--HN, IN H
Boc / \
14 N¨
Ni Sr HN.,õc.,N
/\
N-N" 1101 0)'---( rsho 1 I' ---- o a F
/\
N-/ IP
16 , P--0)----c cc a /\
N ~
RI' 101 N-- ii, / 00 ) - ' - - 1 - ' -0 0 r a /\
N---Ree IP18 /
F---o 00 Fle-a = \
N -NI le N-- /
f--o *
CI
/\
N ---NIp 1110 N----Si H
\ i 4c0 /\
N-N" isN
-Th/-10.1,0-.....At---0 0 r ) 0\r0 0õ,,___ /
. , N-
In some embodiments, the compound of Formula I is a compound shown in Table 1, or a pharmaceutically-acceptable salt, ester, chelator, hydrate, solvate, stereoisomer, or polymorphic form thereof.
Table 1. Examples of axitinib derivative compounds.
/\
N -N
rri 0 le / \
N ----, N i µINI
0 . r / \
N ---Ni Op ____---O
/
N
N / iS
N
N
I.
ri 0 H
_r rj fl $ 0 N
k /\
N-7 N, 0zH N S 0 N..-0)-1- 0/P--..-a /\
N-N' IP
N
----µ0 ille---/ \
N.-N..--F
in H
/ \
N-N./ 110 f OHN s 0 N, 0a 0FL_ N ../.
----t 1 ---fie /\
N-11 i_ Iski 0 N,P
a = \
N'-).____ Iski le 0 r *a / \
N ----N /
N.--HN, IN H
Boc / \
14 N¨
Ni Sr HN.,õc.,N
/\
N-N" 1101 0)'---( rsho 1 I' ---- o a F
/\
N-/ IP
16 , P--0)----c cc a /\
N ~
RI' 101 N-- ii, / 00 ) - ' - - 1 - ' -0 0 r a /\
N---Ree IP18 /
F---o 00 Fle-a = \
N -NI le N-- /
f--o *
CI
/\
N ---NIp 1110 N----Si H
\ i 4c0 /\
N-N" isN
-Th/-10.1,0-.....At---0 0 r ) 0\r0 0õ,,___ /
. , N-
22 N' SI
N
__I'S) N.....-=
/\
N-
N
__I'S) N.....-=
/\
N-
23 N," IP
N
H
'ox N
N
N
H
'ox N
N
24 S
o Os /
N-Sr N
S
26 r /40 N
i-i / \
N --27 N?DiIITJL
0, N
lik / \
N NThITh /
, -PC
IP
/ \
N -H
111,-0 0,-13( Ir \ , N
N /
4.
, H µr,,N õ...=
N-1-\\n (S) / \
N ---, , N S
H
......-N
HO, I
...13,-, /\
N-N.,/ Ill C N2y40 N ..---N-- iii H
/ \
N ¨
CH3S0c YA
N /
1'4 H
en i-i /
34 µN H S 0 N
o N
N /
N
13, rd 0 0 /
N
N /
s 0 0=P-0 o-40 )-0 oto 0 To /
N
I. 04-0 01 \-0 /
0 \
/
N Cr (c) Nef ce) (0 N
N /
39 µN
NH
un H
/\
N---N,/ *
N
r H2N is) 0 0 /\
N---N'$41 , N
-: CL
N" '1=0 zo--eCH
411 r o ea /\
N---N,/ OS
N
10--µ 40 Ne¨
0 Fsr C' N-µN
/ \
N-44 N' 0 ---"µ
r j 0 40 r ,0 1st¨
N = 110 0 4, ri 0 0 isr re 0---' /
/ \
N ¨
, N
0 ¨4 46 N
..---rore' 0 H
r--/
0-Po /\
N-IN
H
/\
N"---1µ1 0 --µ=
ri 0 0 r HO
/\
N ---HCI -----= IS
N
49'N
r j 0 0 til"
r0 HO-j /\
N---HCI -----0'4 N ..---ri 0 SO H
re 0 0 ---j ral HO
/\
N ---HCI --.
RI 4Il N
µ
r_/ 0 * Ft r---"
j--0 HO
/\
N ---, / Ss N
52 , 0 H, IN
N, 0, 11 .......
(0 /
/ \
N¨
N' (110 , /
OHN
Zo 0 H
4) Qs) CO
i /\
N ---, Nµ= 1110 N
54 5 ) 5 "---cl ? ?sip (0 S
o) \ (.0 /
/\
N ----55 / N,, P--/
0e--1 00 --)23 N
/ \
N -Ni 56 0/ H NOp S 0 P--r 0 11----'µ --0\____µ 0 'I
diScill / \
N -, 0 HN s 0 P-- ...--r 0 d----( --NO 140) H
/ \
N'-58 N:" SI
V
P---d---Thi cl-OS
H
/ \
N ¨
/
0 H iN
Sli HN---/ \
NI Ill III
HN ---i *
/ \
N-N" IP
P--0)---( CC
Sin 1 *
i N H
/\
N-/
NI
N 0)-c 0 /.III
P-- N ----r 0 ----H
N a ii.õ
N H
/\
N ---NI ali 63 0, H N
N - /
P.--1 ' 0 0 r , fik , S
/ \
N ---64 0" H µN S 0 P--N.---.
H
N a C-;----N
/ \
N ---N / 65 0/ H µNIP S 0 N /
0)----( 0 7----o 0 N se--H
/\
N N" IS
N-- /
0)----c c0 r----c= 0 N....-.
H
NH
N-N' IP
N-P--r 0 0)---t 0 -- ar ccr N-Ni N
N
H
/
N
N
0 H µN S 0 N..-NH
/\
N --= 110 / N, N-- /
P-- Ns-/ S
1-----( 0 --a /\
N -Ni 071 0zH N
N.' .,--le NI
lika / \
N-72 0,LH Ni 0 1 iN
N, crt t s a /\
N ----)_ NI 0 ),...tN -- FL
..
/\
N-74 P. Ni 110 Ci s1-1 N
N.---Ort /NS
SIP H
*
/\
N ---(N,F1, o 6 -s le N---***
/\
N--0---0 H NµN 111 S 0 ft- i P--NI .----i S
lel i-i a /\
N -77 0-'0 H NµN 1111 S 0 S
N ---,i P--..---(II. 0 --sIP rl **
/\
N ----78 P Nl 0 P-- .----a /\
N --N.-1 , ----o)----( 6t'0 401 ri ..
= \
N--N-- i P---N --et lel I.
/\
N---81 a0 H IsiµN 5 S 0 N-- I
P--...--0-----c ' --CP
ISO ril ea / \
N'-NI, I-P-- N.---.
0)----( Co i a - N
/ \
N ---N' --FL
N----0)---( C
Sin H
N a /\
N ---NI is84 V
N /
- P--, 0 0)-----( 0,_--r-S
N$
/
N-N
H
/
N --N
r N
/
N
Rie NH
/ \
N ---= (110 N, /
N /
Ns-4111) H
1 *
i N
\
/ \
N --N( 111 Ni--P--/
0)----( .--0 ril a ....õ, /\
N --, NI
, 0)--1N-- I
th P--N.---cr Olt H
, 41111r /\
N--/ ill N
r j 0 * r j--0 HO
/\
N --N / Ill N
r j 0 001 rr r--0 r--1 HO
/\
N--N,/ 01 N
r j 0 MI i-i ro r-i r0 HO-J
/ \
N----N /
µN
0---Lo 0 Nee-r) H
94 Of rei of H
f H
_0 , , N-:F ill ---OFI N
P--n in H
IIP
/\
N ¨
-, N / ill 96 ."0 H N S 0 N- i P-110 0d)---7( if isi ---ase / \
N-'N S 0 ic=.0___:z___. j 0 / \
N¨
,/ (1101 N
ad\o N ---S SI H
HO
[0022]
In a second broad aspect, there are provided pharmaceutical compositions comprising a compound described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In some embodiments, there are provided pharmaceutical compositions comprising a compound of Formula I, II, or DI, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0023]
In a third broad aspect, there are provided methods of inhibiting or modulating the activity of tyrosine kinases. In some embodiments, there are provided methods of treating disease states or conditions mediated by tyrosine kinases in a subject in need thereof comprising administering to the subject an effective amount of a compound and/or a pharmaceutical composition described herein. Non-limiting examples of disease states or conditions mediated by tyrosine kinases that may be treated according to methods provided herein include various tumors and cancers. Examples of tumors and cancers that may be treated include, without limitation, renal cell carcinoma (RCC), breast cancer, thyroid cancer, and other solid tumors.
[0024]
In some embodiments, compounds of Formula I, II or III and/or pharmaceutical compositions thereof are administered to modulate the phartnacokinetic profile of axitinib, e.g., to increase bioavailability, change duration of the effective plasma concentration, decrease the variability of plasma levels, reduce the side effects of axitinib, and/or improve the therapeutic effect in a subject, as compared to administration of axitinib itself.
o Os /
N-Sr N
S
26 r /40 N
i-i / \
N --27 N?DiIITJL
0, N
lik / \
N NThITh /
, -PC
IP
/ \
N -H
111,-0 0,-13( Ir \ , N
N /
4.
, H µr,,N õ...=
N-1-\\n (S) / \
N ---, , N S
H
......-N
HO, I
...13,-, /\
N-N.,/ Ill C N2y40 N ..---N-- iii H
/ \
N ¨
CH3S0c YA
N /
1'4 H
en i-i /
34 µN H S 0 N
o N
N /
N
13, rd 0 0 /
N
N /
s 0 0=P-0 o-40 )-0 oto 0 To /
N
I. 04-0 01 \-0 /
0 \
/
N Cr (c) Nef ce) (0 N
N /
39 µN
NH
un H
/\
N---N,/ *
N
r H2N is) 0 0 /\
N---N'$41 , N
-: CL
N" '1=0 zo--eCH
411 r o ea /\
N---N,/ OS
N
10--µ 40 Ne¨
0 Fsr C' N-µN
/ \
N-44 N' 0 ---"µ
r j 0 40 r ,0 1st¨
N = 110 0 4, ri 0 0 isr re 0---' /
/ \
N ¨
, N
0 ¨4 46 N
..---rore' 0 H
r--/
0-Po /\
N-IN
H
/\
N"---1µ1 0 --µ=
ri 0 0 r HO
/\
N ---HCI -----= IS
N
49'N
r j 0 0 til"
r0 HO-j /\
N---HCI -----0'4 N ..---ri 0 SO H
re 0 0 ---j ral HO
/\
N ---HCI --.
RI 4Il N
µ
r_/ 0 * Ft r---"
j--0 HO
/\
N ---, / Ss N
52 , 0 H, IN
N, 0, 11 .......
(0 /
/ \
N¨
N' (110 , /
OHN
Zo 0 H
4) Qs) CO
i /\
N ---, Nµ= 1110 N
54 5 ) 5 "---cl ? ?sip (0 S
o) \ (.0 /
/\
N ----55 / N,, P--/
0e--1 00 --)23 N
/ \
N -Ni 56 0/ H NOp S 0 P--r 0 11----'µ --0\____µ 0 'I
diScill / \
N -, 0 HN s 0 P-- ...--r 0 d----( --NO 140) H
/ \
N'-58 N:" SI
V
P---d---Thi cl-OS
H
/ \
N ¨
/
0 H iN
Sli HN---/ \
NI Ill III
HN ---i *
/ \
N-N" IP
P--0)---( CC
Sin 1 *
i N H
/\
N-/
NI
N 0)-c 0 /.III
P-- N ----r 0 ----H
N a ii.õ
N H
/\
N ---NI ali 63 0, H N
N - /
P.--1 ' 0 0 r , fik , S
/ \
N ---64 0" H µN S 0 P--N.---.
H
N a C-;----N
/ \
N ---N / 65 0/ H µNIP S 0 N /
0)----( 0 7----o 0 N se--H
/\
N N" IS
N-- /
0)----c c0 r----c= 0 N....-.
H
NH
N-N' IP
N-P--r 0 0)---t 0 -- ar ccr N-Ni N
N
H
/
N
N
0 H µN S 0 N..-NH
/\
N --= 110 / N, N-- /
P-- Ns-/ S
1-----( 0 --a /\
N -Ni 071 0zH N
N.' .,--le NI
lika / \
N-72 0,LH Ni 0 1 iN
N, crt t s a /\
N ----)_ NI 0 ),...tN -- FL
..
/\
N-74 P. Ni 110 Ci s1-1 N
N.---Ort /NS
SIP H
*
/\
N ---(N,F1, o 6 -s le N---***
/\
N--0---0 H NµN 111 S 0 ft- i P--NI .----i S
lel i-i a /\
N -77 0-'0 H NµN 1111 S 0 S
N ---,i P--..---(II. 0 --sIP rl **
/\
N ----78 P Nl 0 P-- .----a /\
N --N.-1 , ----o)----( 6t'0 401 ri ..
= \
N--N-- i P---N --et lel I.
/\
N---81 a0 H IsiµN 5 S 0 N-- I
P--...--0-----c ' --CP
ISO ril ea / \
N'-NI, I-P-- N.---.
0)----( Co i a - N
/ \
N ---N' --FL
N----0)---( C
Sin H
N a /\
N ---NI is84 V
N /
- P--, 0 0)-----( 0,_--r-S
N$
/
N-N
H
/
N --N
r N
/
N
Rie NH
/ \
N ---= (110 N, /
N /
Ns-4111) H
1 *
i N
\
/ \
N --N( 111 Ni--P--/
0)----( .--0 ril a ....õ, /\
N --, NI
, 0)--1N-- I
th P--N.---cr Olt H
, 41111r /\
N--/ ill N
r j 0 * r j--0 HO
/\
N --N / Ill N
r j 0 001 rr r--0 r--1 HO
/\
N--N,/ 01 N
r j 0 MI i-i ro r-i r0 HO-J
/ \
N----N /
µN
0---Lo 0 Nee-r) H
94 Of rei of H
f H
_0 , , N-:F ill ---OFI N
P--n in H
IIP
/\
N ¨
-, N / ill 96 ."0 H N S 0 N- i P-110 0d)---7( if isi ---ase / \
N-'N S 0 ic=.0___:z___. j 0 / \
N¨
,/ (1101 N
ad\o N ---S SI H
HO
[0022]
In a second broad aspect, there are provided pharmaceutical compositions comprising a compound described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In some embodiments, there are provided pharmaceutical compositions comprising a compound of Formula I, II, or DI, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0023]
In a third broad aspect, there are provided methods of inhibiting or modulating the activity of tyrosine kinases. In some embodiments, there are provided methods of treating disease states or conditions mediated by tyrosine kinases in a subject in need thereof comprising administering to the subject an effective amount of a compound and/or a pharmaceutical composition described herein. Non-limiting examples of disease states or conditions mediated by tyrosine kinases that may be treated according to methods provided herein include various tumors and cancers. Examples of tumors and cancers that may be treated include, without limitation, renal cell carcinoma (RCC), breast cancer, thyroid cancer, and other solid tumors.
[0024]
In some embodiments, compounds of Formula I, II or III and/or pharmaceutical compositions thereof are administered to modulate the phartnacokinetic profile of axitinib, e.g., to increase bioavailability, change duration of the effective plasma concentration, decrease the variability of plasma levels, reduce the side effects of axitinib, and/or improve the therapeutic effect in a subject, as compared to administration of axitinib itself.
[0025]
In other embodiments, compounds of Formula I, II or HI and/or pharmaceutical compositions thereof are administered to improve biodistribution, reduce the metabolism, and/or broaden the therapeutic application of axitinib in a subject, as compared to administration of axitinib itself.
In other embodiments, compounds of Formula I, II or HI and/or pharmaceutical compositions thereof are administered to improve biodistribution, reduce the metabolism, and/or broaden the therapeutic application of axitinib in a subject, as compared to administration of axitinib itself.
[0026]
In another embodiment, compounds of Formula I, II or III and/or pharmaceutical compositions thereof are administrated to increase or modulate the half-life of axitinib through modification of the PK profile, and thereby decrease dose frequency of the compound to a subject, as compared to administration of axitinib itself.
In another embodiment, compounds of Formula I, II or III and/or pharmaceutical compositions thereof are administrated to increase or modulate the half-life of axitinib through modification of the PK profile, and thereby decrease dose frequency of the compound to a subject, as compared to administration of axitinib itself.
[0027]
In some embodiments, there are provided methods of treating a disease state or condition mediated by tyrosine kinases in a subject in need thereof, the method comprising administering an effective amount of a compound of Formula I, II or III or a pharmaceutical composition thereof to the subject, such that the disease state or condition is treated. In an embodiment, there is provided a method of treating a tumor or a cancer in a subject in need thereof, the method comprising administering an effective amount of a compound of Formula I, ll or III or a pharmaceutical composition thereof to the subject, such that the tumor or the cancer is treated.
In some embodiments, there are provided methods of treating a disease state or condition mediated by tyrosine kinases in a subject in need thereof, the method comprising administering an effective amount of a compound of Formula I, II or III or a pharmaceutical composition thereof to the subject, such that the disease state or condition is treated. In an embodiment, there is provided a method of treating a tumor or a cancer in a subject in need thereof, the method comprising administering an effective amount of a compound of Formula I, ll or III or a pharmaceutical composition thereof to the subject, such that the tumor or the cancer is treated.
[0028]
In another broad aspect, the compounds and methods of the present invention are used alone in treating a disease state or condition mediated by tyrosine kinases in a subject. In some embodiment, for the treatment of a disease state or condition mediated by tyrosine kinases in a subject, the compounds and methods of the present invention are used in combination with therapeutic agents or methods, including, but not limited to, programmed cell death 1 (PD-I) and programmed cell death ligand 1 (PD-L1) inhibitors.
In another broad aspect, the compounds and methods of the present invention are used alone in treating a disease state or condition mediated by tyrosine kinases in a subject. In some embodiment, for the treatment of a disease state or condition mediated by tyrosine kinases in a subject, the compounds and methods of the present invention are used in combination with therapeutic agents or methods, including, but not limited to, programmed cell death 1 (PD-I) and programmed cell death ligand 1 (PD-L1) inhibitors.
[0029]
In further broad aspect, there are provided kits comprising one or more compound or pharmaceutical composition described herein. A kit may further comprise one or more additional therapeutic agents and/or instructions, for example, instructions for using the kit to treat a subject having disease states or conditions mediated by tyrosine kinases.
BRIEF DESCRIPTION OF THE DRAWINGS
In further broad aspect, there are provided kits comprising one or more compound or pharmaceutical composition described herein. A kit may further comprise one or more additional therapeutic agents and/or instructions, for example, instructions for using the kit to treat a subject having disease states or conditions mediated by tyrosine kinases.
BRIEF DESCRIPTION OF THE DRAWINGS
[0030]
For a better understanding of the invention and to show more clearly how it may be carried into effect, reference will now be made by way of example to the accompanying drawings, which illustrate aspects and features according to embodiments of the present invention, and in which:
For a better understanding of the invention and to show more clearly how it may be carried into effect, reference will now be made by way of example to the accompanying drawings, which illustrate aspects and features according to embodiments of the present invention, and in which:
[0031]
FIG. 1 shows plasma axitinib concentration-time curves in mice after oral administration of axitinib, compounds 1, 5, and 10 to the animals at a mole-equivalent dose of 30 mg/kg for all compounds: ¨0¨, compound 1; ¨0¨, compound 2, ¨x¨, compound 10; and ¨A¨, axitinib.
FIG. 1 shows plasma axitinib concentration-time curves in mice after oral administration of axitinib, compounds 1, 5, and 10 to the animals at a mole-equivalent dose of 30 mg/kg for all compounds: ¨0¨, compound 1; ¨0¨, compound 2, ¨x¨, compound 10; and ¨A¨, axitinib.
[0032]
FIG. 2 gives tumor volumes (mm3) from the control group and all the treatment groups at the end of 19-day treatment: all the doses refer to a molar equivalent dose for axitinib; G 1, Control; G2, axitinib-10 mg/kg; G3, axitinib-30 mg/kg, G4, compound 1-10 mg/kg; G5, compound 1-30 mg/kg; Go, compound 5-10 mg/kg; G7, compound 5-30 mg/kg; G8, compound 10-10 mg/kg; G9, compound 10-30 mg/kg.
FIG. 2 gives tumor volumes (mm3) from the control group and all the treatment groups at the end of 19-day treatment: all the doses refer to a molar equivalent dose for axitinib; G 1, Control; G2, axitinib-10 mg/kg; G3, axitinib-30 mg/kg, G4, compound 1-10 mg/kg; G5, compound 1-30 mg/kg; Go, compound 5-10 mg/kg; G7, compound 5-30 mg/kg; G8, compound 10-10 mg/kg; G9, compound 10-30 mg/kg.
[0033]
FIG. 3 shows a bar-graph representing average tumor weights (g) from different animal groups (control group and all the treatment groups) at the end of 19-day treatment: all the doses refer to an molar equivalent dose for axitinib; GI, Control; G2, axitinib-10 mg,/kg; G3, axitinib-30 mg/kg, G4, compound 1-10 mg/kg; G5, compound 1-30 mg/kg; Go, compound 5-10 mg/kg; G7, compound 5-30 mg/kg; G8, compound 10-10 mg/kg; G9, compound 10-30 mg/kg.
DETAILED DESCRIPTION
Definitions
FIG. 3 shows a bar-graph representing average tumor weights (g) from different animal groups (control group and all the treatment groups) at the end of 19-day treatment: all the doses refer to an molar equivalent dose for axitinib; GI, Control; G2, axitinib-10 mg,/kg; G3, axitinib-30 mg/kg, G4, compound 1-10 mg/kg; G5, compound 1-30 mg/kg; Go, compound 5-10 mg/kg; G7, compound 5-30 mg/kg; G8, compound 10-10 mg/kg; G9, compound 10-30 mg/kg.
DETAILED DESCRIPTION
Definitions
[0034]
In order to provide a clear and consistent understanding of the terms used in the present specification, a number of definitions are provided below.
Moreover, unless defined otherwise, all technical and scientific terms as used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention pertains.
In order to provide a clear and consistent understanding of the terms used in the present specification, a number of definitions are provided below.
Moreover, unless defined otherwise, all technical and scientific terms as used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention pertains.
[0035]
The use of the word "a" or "an"
when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one", but it is also consistent with the meaning of "one or mom", "at least one", and "one or more than one".
Similarly, the word "another" may mean at least a second or more.
The use of the word "a" or "an"
when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one", but it is also consistent with the meaning of "one or mom", "at least one", and "one or more than one".
Similarly, the word "another" may mean at least a second or more.
[0036]
As used in this specification and claim(s), the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have' and "has"), "including" (and any form of including, such as "include" and "includes") or "containing" (and any form of containing, such as "contain"
and "contains"), are inclusive or open-ended and do not exclude additional, unrecited elements or process steps.
As used in this specification and claim(s), the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have' and "has"), "including" (and any form of including, such as "include" and "includes") or "containing" (and any form of containing, such as "contain"
and "contains"), are inclusive or open-ended and do not exclude additional, unrecited elements or process steps.
[0037]
The term "about" is used to indicate that a value includes an inherent variation of error for the device or the method being employed to determine the value.
The term "about" is used to indicate that a value includes an inherent variation of error for the device or the method being employed to determine the value.
[0038]
The term "derivative" as used herein, is understood as being a substance similar in structure to another compound but differing in some slight structural detail.
The term "derivative" as used herein, is understood as being a substance similar in structure to another compound but differing in some slight structural detail.
[0039]
The present description refers to a number of chemical terms and abbreviations used by those skilled in the art. Nevertheless, definitions of selected terms are provided for clarity and consistency.
The present description refers to a number of chemical terms and abbreviations used by those skilled in the art. Nevertheless, definitions of selected terms are provided for clarity and consistency.
[0040]
As used herein, the term "substituted" or "with substitution" refers to a parent compound or a moiety has at least one (1) substituent group. The term "unsubstituted" or "without substitution" refers to a parent compound or a moiety has no
As used herein, the term "substituted" or "with substitution" refers to a parent compound or a moiety has at least one (1) substituent group. The term "unsubstituted" or "without substitution" refers to a parent compound or a moiety has no
41 other substituent group except that the unidentified valence is chemically saturated with hydrogen atoms.
[0041]
As used herein, a "substituent"
or a "substituent group" refers to a group selected from halogen (F, Cl, Br, or I), hydroxy, sulfhydryl, amino, nitro, carbonyl, carboxyl, alkyl, alkoxyl, alkylamino, aryl, aryloxyl, arylamino, acyl, thionyl, sulfonyl, phosphonyl, or other organic moiety as used and accepted in general organic chemistry.
[0041]
As used herein, a "substituent"
or a "substituent group" refers to a group selected from halogen (F, Cl, Br, or I), hydroxy, sulfhydryl, amino, nitro, carbonyl, carboxyl, alkyl, alkoxyl, alkylamino, aryl, aryloxyl, arylamino, acyl, thionyl, sulfonyl, phosphonyl, or other organic moiety as used and accepted in general organic chemistry.
[0042]
As used herein, the term "alkyl"
refers to saturated hydrocarbons having from one to twelve carbon atoms, including linear, branched, and cyclic alkyl groups.
Examples of alkyl groups include, without limitation, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, isopropyl, tert-butyl, sec-butyl, isobutyl, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. The term alkyl includes both unsubstituted alkyl groups and substituted alkyl groups. The term "C1-Cnallcyl", wherein n is an integer from 2 to 12, refers to an alkyl group having from 1 to the indicated "Jr number of carbon atoms. Alkyl residues may be substituted or unsubstituted. In some embodiments, for example, alkyl may be substituted by hydroxyl, amino, carboxyl, carboxylic ester, amide, carbamate, or aminoalkyl.
As used herein, the term "alkyl"
refers to saturated hydrocarbons having from one to twelve carbon atoms, including linear, branched, and cyclic alkyl groups.
Examples of alkyl groups include, without limitation, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, isopropyl, tert-butyl, sec-butyl, isobutyl, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. The term alkyl includes both unsubstituted alkyl groups and substituted alkyl groups. The term "C1-Cnallcyl", wherein n is an integer from 2 to 12, refers to an alkyl group having from 1 to the indicated "Jr number of carbon atoms. Alkyl residues may be substituted or unsubstituted. In some embodiments, for example, alkyl may be substituted by hydroxyl, amino, carboxyl, carboxylic ester, amide, carbamate, or aminoalkyl.
[0043]
Unless the number of carbons is otherwise specified, "lower" as in "lower aliphatic," "lower alkyl," "lower alkenyl," and "lower allcylnyl", as used herein means that the moiety has at least one (two for allcenyl and alkynyl) and equal to or less than 6 carbon atoms.
Unless the number of carbons is otherwise specified, "lower" as in "lower aliphatic," "lower alkyl," "lower alkenyl," and "lower allcylnyl", as used herein means that the moiety has at least one (two for allcenyl and alkynyl) and equal to or less than 6 carbon atoms.
[0044]
The terms "cycloalkyl", "alicyclic", "carbocyclic" and equivalent expressions refer to a group comprising a saturated or partially unsaturated carbocyclic ring in a single, Spiro (sharing one atom), or fused (sharing at least one bond) carbocyclic ring system having from three to fifteen ring members. Examples of cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopenten-l-yl, cyclopenten-2-yl, cyclopenten-3-yl, cyclohexyl, cyclohexen-l-yl, cyclohexen-2-yl, cyclohexen-3-yl, cycloheptyl, bicyclo[4,3,01nonanyl, norbornyl, and the like.
The term cycloalkyl includes both unsubstituted cycloalkyl groups and substituted cycloalkyl groups. The term "C3-00cycloalky1", wherein n is an integer from 4 to 15, refers to a cycloalkyl group having from 3 to the indicated "n" number of carbon atoms in the ring structure. Unless the number of carbons is otherwise specified, "lower cycloalkyl" groups as herein used, have at least 3 and equal to or less than 8 carbon atoms in their ring structure.
The terms "cycloalkyl", "alicyclic", "carbocyclic" and equivalent expressions refer to a group comprising a saturated or partially unsaturated carbocyclic ring in a single, Spiro (sharing one atom), or fused (sharing at least one bond) carbocyclic ring system having from three to fifteen ring members. Examples of cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopenten-l-yl, cyclopenten-2-yl, cyclopenten-3-yl, cyclohexyl, cyclohexen-l-yl, cyclohexen-2-yl, cyclohexen-3-yl, cycloheptyl, bicyclo[4,3,01nonanyl, norbornyl, and the like.
The term cycloalkyl includes both unsubstituted cycloalkyl groups and substituted cycloalkyl groups. The term "C3-00cycloalky1", wherein n is an integer from 4 to 15, refers to a cycloalkyl group having from 3 to the indicated "n" number of carbon atoms in the ring structure. Unless the number of carbons is otherwise specified, "lower cycloalkyl" groups as herein used, have at least 3 and equal to or less than 8 carbon atoms in their ring structure.
[0045]
Cycloalkyl residues can be saturated or contain one or more double bonds within the ring system. In particular they can be saturated or contain one double bond within the ring system. In unsaturated cycloalkyl residues the double bonds can be present in any suitable positions. Monocycloalkyl residues are, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl or cyclotetradecyl, which can also be substituted, for example by C1-4 alkyl.
Examples of substituted cycloalkyl residues are 4-methylcyclohexyl and 2,3-dimethylcyclopentyl.
Examples of parent structures of bicyclic ring systems are norbornane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane and bicyclo[3.2.1]octane.
Cycloalkyl residues can be saturated or contain one or more double bonds within the ring system. In particular they can be saturated or contain one double bond within the ring system. In unsaturated cycloalkyl residues the double bonds can be present in any suitable positions. Monocycloalkyl residues are, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl or cyclotetradecyl, which can also be substituted, for example by C1-4 alkyl.
Examples of substituted cycloalkyl residues are 4-methylcyclohexyl and 2,3-dimethylcyclopentyl.
Examples of parent structures of bicyclic ring systems are norbornane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane and bicyclo[3.2.1]octane.
[0046]
The term "heterocycloalkyl" and equivalent expressions refer to a group comprising a saturated or partially unsaturated carbocyclic ring in a single, spiro (sharing one atom), or fused (sharing at least one bond) carbocyclic ring system having from three to fifteen ring members, including one to six heteroatoms (e.g., N, 0, S. P) or groups containing such heteroatoms (e.g., Nii, NRx (Rx is alkyl, acyl, aryl, heteroaryl or cycloalkyl), P02, SO, SO2, and the like). Heterocycloalkyl groups may be C-attached or heteroatom-attached (e.g., via a nitrogen atom) where such is possible.
Examples of heterocycloalkyl groups include, without limitation, pyrrolidino, tetrahydrofuranyl, tetrahydrodithienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 211-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-a zabicyclo[3,1,0]hexanyl, 3-azabicyclo[4,1,0]heptanyl, 3H-indolyl, quinolizinyl, and sugars, and the like.
The term heterocycloalkyl includes both unsubstituted heterocycloalkyl groups and substituted heterocycloalkyl groups. The term "C3-Cnheterocycloalkyl", wherein n is an integer from 4 to 15, refers to a heterocycloalkyl group having from 3 to the indicated "n"
number of atoms in the ring structure, including at least one hetero group or atom as defined above.
Unless the number of carbons is otherwise specified, "lower heterocycloallcyr groups as herein used, have at least 3 and equal to or less than 8 carbon atoms in their ring structure.
The term "heterocycloalkyl" and equivalent expressions refer to a group comprising a saturated or partially unsaturated carbocyclic ring in a single, spiro (sharing one atom), or fused (sharing at least one bond) carbocyclic ring system having from three to fifteen ring members, including one to six heteroatoms (e.g., N, 0, S. P) or groups containing such heteroatoms (e.g., Nii, NRx (Rx is alkyl, acyl, aryl, heteroaryl or cycloalkyl), P02, SO, SO2, and the like). Heterocycloalkyl groups may be C-attached or heteroatom-attached (e.g., via a nitrogen atom) where such is possible.
Examples of heterocycloalkyl groups include, without limitation, pyrrolidino, tetrahydrofuranyl, tetrahydrodithienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 211-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-a zabicyclo[3,1,0]hexanyl, 3-azabicyclo[4,1,0]heptanyl, 3H-indolyl, quinolizinyl, and sugars, and the like.
The term heterocycloalkyl includes both unsubstituted heterocycloalkyl groups and substituted heterocycloalkyl groups. The term "C3-Cnheterocycloalkyl", wherein n is an integer from 4 to 15, refers to a heterocycloalkyl group having from 3 to the indicated "n"
number of atoms in the ring structure, including at least one hetero group or atom as defined above.
Unless the number of carbons is otherwise specified, "lower heterocycloallcyr groups as herein used, have at least 3 and equal to or less than 8 carbon atoms in their ring structure.
[0047]
The terms "aryl" and "aryl ring"
refer to aromatic groups having "411+2".pi.(pi) electrons, wherein a is an integer from 1 to 3, in a conjugated monocyclic or polycyclic system (fused or not) and having six to fourteen ring atoms. A
polycyclic ring system includes at least one aromatic ring. Aryl may be directly attached, or connected via a Ci-C3alkyl group (also referred to as arylalkyl or aralkyl).
Examples of aryl groups include, without limitation, phenyl, benzyl, phenetyl, 1-phenylethyl, tolyl, naphthyl, biphenyl, terphenyl, indenyl, benzocyclooctenyl, benzocycloheptenyl, azulenyl, acenaphthylenyl, fluorenyl, phenanthernyl, anthracenyl, and the like. The term aryl includes both unsubstituted aryl groups and substituted aryl groups. The term "C6-Caryl", wherein n is an integer from 6 to 15, refers to an aryl group having from 6 to the indicated "n" number of atoms in the ring structure, including at least one hetero group or atom as defined above.
The terms "aryl" and "aryl ring"
refer to aromatic groups having "411+2".pi.(pi) electrons, wherein a is an integer from 1 to 3, in a conjugated monocyclic or polycyclic system (fused or not) and having six to fourteen ring atoms. A
polycyclic ring system includes at least one aromatic ring. Aryl may be directly attached, or connected via a Ci-C3alkyl group (also referred to as arylalkyl or aralkyl).
Examples of aryl groups include, without limitation, phenyl, benzyl, phenetyl, 1-phenylethyl, tolyl, naphthyl, biphenyl, terphenyl, indenyl, benzocyclooctenyl, benzocycloheptenyl, azulenyl, acenaphthylenyl, fluorenyl, phenanthernyl, anthracenyl, and the like. The term aryl includes both unsubstituted aryl groups and substituted aryl groups. The term "C6-Caryl", wherein n is an integer from 6 to 15, refers to an aryl group having from 6 to the indicated "n" number of atoms in the ring structure, including at least one hetero group or atom as defined above.
[0048]
The terms "heteroaryl" and "heteroaryl ring" refer to an aromatic groups having "4n+2".pi.(pi) electrons, wherein n is an integer from 1 to 3, in a conjugated monocyclic or polycyclic system (fused or not) and having five to fourteen ring members, including one to six heteroatoms (e.g. N, 0, S) or groups containing such heteroatoms (e.g. NH, NRõ (R, is alkyl, acyl, aryl, heteroaryl or cycloalkyl), SO, and the like). A
polycyclic ring system includes at least one heteroaromatic ring. Heteroaryls may be directly attached, or connected via a Ci-C3alkyl group (also referred to as heteroarylalkyl or heteroaralkyl). Heteroaryl groups may be C-attached or heteroatom-attached (e.g., via a nitrogen atom), where such is possible. Examples of heteroaryl groups include, without limitation, pyridyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, tetrazolyl, furyl, thienyl;
isooxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrollyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, chromenyl, isochromenyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, pyrazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothienyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinolizinyl, quinolonyl, isoquinolonyl, quinoxalinyl, naphthyridinyl, furopyridinyl, carbazolyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxazinyl, dibenzofurnayl, and the like. The term heteroaryl includes both unsubstituted heteroaryl groups and substituted heteroaryl groups. The term "C5-00heteroary1", wherein n is an integer from 6 to 15, refers to a heteroaryl group having from 5 to the indicated "n" number of atoms in the ring structure, including at least one hetero group or atom as defined above.
The terms "heteroaryl" and "heteroaryl ring" refer to an aromatic groups having "4n+2".pi.(pi) electrons, wherein n is an integer from 1 to 3, in a conjugated monocyclic or polycyclic system (fused or not) and having five to fourteen ring members, including one to six heteroatoms (e.g. N, 0, S) or groups containing such heteroatoms (e.g. NH, NRõ (R, is alkyl, acyl, aryl, heteroaryl or cycloalkyl), SO, and the like). A
polycyclic ring system includes at least one heteroaromatic ring. Heteroaryls may be directly attached, or connected via a Ci-C3alkyl group (also referred to as heteroarylalkyl or heteroaralkyl). Heteroaryl groups may be C-attached or heteroatom-attached (e.g., via a nitrogen atom), where such is possible. Examples of heteroaryl groups include, without limitation, pyridyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, tetrazolyl, furyl, thienyl;
isooxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrollyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, chromenyl, isochromenyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, pyrazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothienyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinolizinyl, quinolonyl, isoquinolonyl, quinoxalinyl, naphthyridinyl, furopyridinyl, carbazolyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxazinyl, dibenzofurnayl, and the like. The term heteroaryl includes both unsubstituted heteroaryl groups and substituted heteroaryl groups. The term "C5-00heteroary1", wherein n is an integer from 6 to 15, refers to a heteroaryl group having from 5 to the indicated "n" number of atoms in the ring structure, including at least one hetero group or atom as defined above.
[0049]
The terms "heterocycle" or "heterocyclic" include heterocycloalkyl and heteroaryl groups. Examples of heterocycles include, without limitation, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 11-1-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 311-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, qutinazolinyl, quinolinyl, 411-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-friazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl, and the like. The term heterocycle includes both unsubstituted heterocyclic groups and substituted heterocyclic groups.
The terms "heterocycle" or "heterocyclic" include heterocycloalkyl and heteroaryl groups. Examples of heterocycles include, without limitation, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 11-1-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 311-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, qutinazolinyl, quinolinyl, 411-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-friazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl, and the like. The term heterocycle includes both unsubstituted heterocyclic groups and substituted heterocyclic groups.
[0050]
The term "amine" or "amino," as used herein, refers to an unsubstituted or substituted moiety of the formula --NRaRb, in which Ra and le are each independently hydrogen, alkyl, aryl, or heterocyclyl, or Ra and Rh, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring. The term amino includes compounds or moieties in which a nitrogen atom is covalently bonded to at least one carbon or heteroatom. Thus, the terms "alkylanaino" and "dialkylamino" as used herein mean an amine group having respectively one and at least two Ci-C6alkyl groups attached thereto.
The terms "arylamino" and "diarylamino" include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively. The terms "amide" or "aminocarbonyl"
include compounds or moieties which contain a nitrogen atom which is bound to the carbon of a carbonyl or a thiocarbonyl group. The term "acylamino" refers to an amino group directly attached to an acyl group as defined herein.
The term "amine" or "amino," as used herein, refers to an unsubstituted or substituted moiety of the formula --NRaRb, in which Ra and le are each independently hydrogen, alkyl, aryl, or heterocyclyl, or Ra and Rh, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring. The term amino includes compounds or moieties in which a nitrogen atom is covalently bonded to at least one carbon or heteroatom. Thus, the terms "alkylanaino" and "dialkylamino" as used herein mean an amine group having respectively one and at least two Ci-C6alkyl groups attached thereto.
The terms "arylamino" and "diarylamino" include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively. The terms "amide" or "aminocarbonyl"
include compounds or moieties which contain a nitrogen atom which is bound to the carbon of a carbonyl or a thiocarbonyl group. The term "acylamino" refers to an amino group directly attached to an acyl group as defined herein.
[0051]
The term "allcylthio" refers to an alkyl group, having a sulfhydryl group attached thereto. Suitable alkylthio groups include groups having 1 to about 12 carbon atoms, preferably from 1 to about 6 carbon atoms. The term "alkylcarboxyl" as used herein means an alkyl group having a carboxyl group attached thereto.
The term "allcylthio" refers to an alkyl group, having a sulfhydryl group attached thereto. Suitable alkylthio groups include groups having 1 to about 12 carbon atoms, preferably from 1 to about 6 carbon atoms. The term "alkylcarboxyl" as used herein means an alkyl group having a carboxyl group attached thereto.
[0052]
The terms "alkoxy" or "lower alkoxy" as used herein mean an alkyl group having an oxygen atom attached thereto. Representative alkoxy groups include groups having 1 to about 6 carbon atoms, e.g., methoxy, ethoxy, propoxy, tert-butoxy and the like. Examples of alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy, pentoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy groups, and the like. The term "alkoxy"
includes both unsubstituted or substituted alkoxy groups, etc., as well as perhalogenated alkyloxy groups.
The terms "alkoxy" or "lower alkoxy" as used herein mean an alkyl group having an oxygen atom attached thereto. Representative alkoxy groups include groups having 1 to about 6 carbon atoms, e.g., methoxy, ethoxy, propoxy, tert-butoxy and the like. Examples of alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy, pentoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy groups, and the like. The term "alkoxy"
includes both unsubstituted or substituted alkoxy groups, etc., as well as perhalogenated alkyloxy groups.
[0053]
The terms "carbonyl" or "carboxy" include compounds and moieties which contain a carbon connected with a double bond to an oxygen atom. Examples of moieties which contain a carbonyl include aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc.
The terms "carbonyl" or "carboxy" include compounds and moieties which contain a carbon connected with a double bond to an oxygen atom. Examples of moieties which contain a carbonyl include aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc.
[0054]
The term "acyl" refers to a carbonyl group that is attached through its carbon atom to a hydrogen (i.e., formyl), an aliphatic group (C1-C6alkyl, C1-C6alkenyl, C1-C6a1kynyl, e.g., acetyl), a cycloalkyl group (C3-C8cycloalkyl), a heterocyclic group (C3-C8 heterocycloalkyl and C5-C6 heteroaryl), an aromatic group (C6 aryl, e.g., benzoyl), and the like. Acyl groups may be unsubstituted or substituted acyl groups (e.g., salicyloyl).
The term "acyl" refers to a carbonyl group that is attached through its carbon atom to a hydrogen (i.e., formyl), an aliphatic group (C1-C6alkyl, C1-C6alkenyl, C1-C6a1kynyl, e.g., acetyl), a cycloalkyl group (C3-C8cycloalkyl), a heterocyclic group (C3-C8 heterocycloalkyl and C5-C6 heteroaryl), an aromatic group (C6 aryl, e.g., benzoyl), and the like. Acyl groups may be unsubstituted or substituted acyl groups (e.g., salicyloyl).
[0055]
The term "solvate" refers to a physical association of a compound with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances, a solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid. "Solvate" encompasses both solution-phase and isolable solvates.
Exemplary solvates include, without limitation, hydrates, ethanolates, methanolates, hemiethanolates, and the like.
The term "solvate" refers to a physical association of a compound with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances, a solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid. "Solvate" encompasses both solution-phase and isolable solvates.
Exemplary solvates include, without limitation, hydrates, ethanolates, methanolates, hemiethanolates, and the like.
[0056]
A "pharmaceutically acceptable salt" of a compound means a salt of a compound that is pharmaceutically acceptable. Desirable are salts of a compound that retain or improve the biological effectiveness and properties of the free acids and bases of the parent compound as defined herein or that take advantage of an intrinsically basic, acidic or charged functionality on the molecule and that are not biologically or otherwise undesirable. Examples of pharmaceutically acceptable salts are also described, for example, in Berge et al., "Pharmaceutical Salts", J. Pharm. Sci. 66, 1-19 (1977). Non-limiting examples of such salts include:
A "pharmaceutically acceptable salt" of a compound means a salt of a compound that is pharmaceutically acceptable. Desirable are salts of a compound that retain or improve the biological effectiveness and properties of the free acids and bases of the parent compound as defined herein or that take advantage of an intrinsically basic, acidic or charged functionality on the molecule and that are not biologically or otherwise undesirable. Examples of pharmaceutically acceptable salts are also described, for example, in Berge et al., "Pharmaceutical Salts", J. Pharm. Sci. 66, 1-19 (1977). Non-limiting examples of such salts include:
[0057]
(1) acid addition salts, formed on a basic or positively charged functionality, by the addition of inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, nitric acid, phosphoric acid, carbonate forming agents, and the like; or formed with organic acids such as acetic acid, propionic acid, lactic acid, oxalic, glycolic acid, pivalic acid, t-butylacetic acid, 13-hydroxybutyric acid, valeric acid, hexanoic acid, cyclopentanepropionic acid, pyruvic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyDbenzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, cyclohexylaminosulfonic acid, benzenesulfonic acid, sulfanilic acid, 4-chlorobenzenesulfonic acid, 2-napthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 3-phenyl propionic acid, lauryl sulphonic acid, lauryl sulfuric acid, oleic acid, palmitic acid, stearic acid, lauric acid, embonic (pamoic) acid, palmoic acid, pantothenic acid, lactobionic acid, alginic acid, galactaric acid, galacturonic acid, gluconic acid, glucoheptonic acid, glutamic acid, naphthoic acid, hydroxynapthoic acid, salicylic acid, ascorbic acid, stearic acid, muconic acid, and the like;
(1) acid addition salts, formed on a basic or positively charged functionality, by the addition of inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, nitric acid, phosphoric acid, carbonate forming agents, and the like; or formed with organic acids such as acetic acid, propionic acid, lactic acid, oxalic, glycolic acid, pivalic acid, t-butylacetic acid, 13-hydroxybutyric acid, valeric acid, hexanoic acid, cyclopentanepropionic acid, pyruvic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyDbenzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, cyclohexylaminosulfonic acid, benzenesulfonic acid, sulfanilic acid, 4-chlorobenzenesulfonic acid, 2-napthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 3-phenyl propionic acid, lauryl sulphonic acid, lauryl sulfuric acid, oleic acid, palmitic acid, stearic acid, lauric acid, embonic (pamoic) acid, palmoic acid, pantothenic acid, lactobionic acid, alginic acid, galactaric acid, galacturonic acid, gluconic acid, glucoheptonic acid, glutamic acid, naphthoic acid, hydroxynapthoic acid, salicylic acid, ascorbic acid, stearic acid, muconic acid, and the like;
[0058]
(2) base addition salts, formed when an acidic proton present in the parent compound either is replaced by a metal ion, including, an alkali metal ion (e.g., lithium, sodium, potassium), an alkaline earth ion (e.g., magnesium, calcium, barium), or other metal ions such as aluminum, zinc, iron and the like; or coordinates with an organic base such as ammonia, ethylamine, diethylarnine, ethylenediamine, dibenzylethylenediamine, ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, piperazine, chloroprocain, procain, choline, lysine and the like.
(2) base addition salts, formed when an acidic proton present in the parent compound either is replaced by a metal ion, including, an alkali metal ion (e.g., lithium, sodium, potassium), an alkaline earth ion (e.g., magnesium, calcium, barium), or other metal ions such as aluminum, zinc, iron and the like; or coordinates with an organic base such as ammonia, ethylamine, diethylarnine, ethylenediamine, dibenzylethylenediamine, ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, piperazine, chloroprocain, procain, choline, lysine and the like.
[0059]
Pharmaceutically acceptable salts may be synthesized from a parent compound that contains a basic or acidic moiety, by conventional chemical methods.
Generally, such salts are prepared by reacting the free acid or base forms of compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two. Salts may be prepared in situ, during the final isolation or purification of a compound or by separately reacting a compound in its free acid or base form with the desired corresponding base or acid, and isolating the salt thus formed. The term "pharmaceutically acceptable salts" also include zwitterionic compounds containing a cationic group covalently bonded to an anionic group, as they are "internal salts". It should be understood that all acid, salt, base, and other ionic and non-ionic forms of compounds described herein are intended to be encompassed.
For example, if a compound is shown as an acid herein, the salt forms of the compound are also encompassed. Likewise, if a compound is shown as a salt, the acid and/or basic forms are also encompassed.
Pharmaceutically acceptable salts may be synthesized from a parent compound that contains a basic or acidic moiety, by conventional chemical methods.
Generally, such salts are prepared by reacting the free acid or base forms of compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two. Salts may be prepared in situ, during the final isolation or purification of a compound or by separately reacting a compound in its free acid or base form with the desired corresponding base or acid, and isolating the salt thus formed. The term "pharmaceutically acceptable salts" also include zwitterionic compounds containing a cationic group covalently bonded to an anionic group, as they are "internal salts". It should be understood that all acid, salt, base, and other ionic and non-ionic forms of compounds described herein are intended to be encompassed.
For example, if a compound is shown as an acid herein, the salt forms of the compound are also encompassed. Likewise, if a compound is shown as a salt, the acid and/or basic forms are also encompassed.
[0060]
As used herein the term "effective amount" refers to the amount or dose of a therapeutic agent, such as a compound, upon single or multiple dose administration to a subject, which provides the desired therapeutic, diagnostic, or prognostic effect in the subject. An effective amount can be readily determined by an attending physician or diagnostician using known techniques and by observing results obtained under analogous circumstances. In determining the effective amount or dose of compound administered, a number of factors are considered including, but not limited to: the size, age, and general health of the subject; the specific disease involved; the degree of or involvement or the severity of the disease or condition to be treated; the response of the individual subject;
the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected;
the use of concomitant medication(s); and other relevant considerations.
As used herein the term "effective amount" refers to the amount or dose of a therapeutic agent, such as a compound, upon single or multiple dose administration to a subject, which provides the desired therapeutic, diagnostic, or prognostic effect in the subject. An effective amount can be readily determined by an attending physician or diagnostician using known techniques and by observing results obtained under analogous circumstances. In determining the effective amount or dose of compound administered, a number of factors are considered including, but not limited to: the size, age, and general health of the subject; the specific disease involved; the degree of or involvement or the severity of the disease or condition to be treated; the response of the individual subject;
the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected;
the use of concomitant medication(s); and other relevant considerations.
[0061]
"Pharmaceutically acceptable"
refers to drugs, medicaments, inert ingredients etc., which the term describes, suitable for use in contact with the cells or tissues of humans and animals without undue toxicity, incompatibility, instability, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio. It generally refers to a compound or composition that is approved or approvable by a regulatory agency of the Federal or state government or listed in the U.S.
Pharmacopoeia or other generally recognized pharmacopoeia for use in animals and more particularly in humans.
"Pharmaceutically acceptable"
refers to drugs, medicaments, inert ingredients etc., which the term describes, suitable for use in contact with the cells or tissues of humans and animals without undue toxicity, incompatibility, instability, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio. It generally refers to a compound or composition that is approved or approvable by a regulatory agency of the Federal or state government or listed in the U.S.
Pharmacopoeia or other generally recognized pharmacopoeia for use in animals and more particularly in humans.
[0062]
"Pharmaceutically acceptable vehicle" refers to a diluent, adjuvant, excipient, vehicle or carrier with which a compound is administered. The terms "Pharmaceutically acceptable vehicle" and "Pharmaceutically acceptable carrier" are used interchangeably herein.
"Pharmaceutically acceptable vehicle" refers to a diluent, adjuvant, excipient, vehicle or carrier with which a compound is administered. The terms "Pharmaceutically acceptable vehicle" and "Pharmaceutically acceptable carrier" are used interchangeably herein.
[0063]
"Pharmaceutical composition"
refers to a composition comprising a compound as described herein and at least one component comprising a pharmaceutically acceptable carrier, diluent, adjuvant, excipient, or vehicle, such as a preserving agent, a filler, a disintegrating agent, a wetting agent, an emulsifying agent, a suspending agent, a sweetening agent, a flavoring agent, a perfuming agent, an antibacterial agent, an antifungal agent, a lubricating agent, a dispensing agent, and the like, depending on the nature of the mode of administration and dosage forms. "Preventing" or "prevention" is intended to refer to at least the reduction of likelihood of the risk of (or susceptibility to) acquiring a disease or disorder (i.e., causing at least one of the clinical symptoms of the disease not to develop in a patient that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease).
"Pharmaceutical composition"
refers to a composition comprising a compound as described herein and at least one component comprising a pharmaceutically acceptable carrier, diluent, adjuvant, excipient, or vehicle, such as a preserving agent, a filler, a disintegrating agent, a wetting agent, an emulsifying agent, a suspending agent, a sweetening agent, a flavoring agent, a perfuming agent, an antibacterial agent, an antifungal agent, a lubricating agent, a dispensing agent, and the like, depending on the nature of the mode of administration and dosage forms. "Preventing" or "prevention" is intended to refer to at least the reduction of likelihood of the risk of (or susceptibility to) acquiring a disease or disorder (i.e., causing at least one of the clinical symptoms of the disease not to develop in a patient that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease).
[0064]
"Treating" or "treatment" of any disease or disorder refers, in some embodiments, to ameliorating at least one disease or disorder. In certain embodiments "treating" or "treatment" refers to ameliorating at least one physical parameter, which may or may not be discernible by the patient. In certain embodiments, "treating" or "treatment" refers to inhibiting the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In some embodiments, "treating" or "treatment" refers to improving the quality of life or reducing the symptoms or side effects of a disease in a subject in need thereof. "Therapeutically effective amount" means the amount of a compound that, when administered to a subject for treating or preventing a disease, is sufficient to effect such treatment or prevention of the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject having the disease to be treated or prevented. As used herein, the term "therapeutically effective amount" refers to an amount of a compound or composition sufficient to prevent, treat, inhibit, reduce, ameliorate or eliminate one or more causes, symptoms, or complications of a disease such as cancers.
"Treating" or "treatment" of any disease or disorder refers, in some embodiments, to ameliorating at least one disease or disorder. In certain embodiments "treating" or "treatment" refers to ameliorating at least one physical parameter, which may or may not be discernible by the patient. In certain embodiments, "treating" or "treatment" refers to inhibiting the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In some embodiments, "treating" or "treatment" refers to improving the quality of life or reducing the symptoms or side effects of a disease in a subject in need thereof. "Therapeutically effective amount" means the amount of a compound that, when administered to a subject for treating or preventing a disease, is sufficient to effect such treatment or prevention of the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject having the disease to be treated or prevented. As used herein, the term "therapeutically effective amount" refers to an amount of a compound or composition sufficient to prevent, treat, inhibit, reduce, ameliorate or eliminate one or more causes, symptoms, or complications of a disease such as cancers.
[0065]
The term "subject" includes animals, including mammals and humans, particularly humans.
The term "subject" includes animals, including mammals and humans, particularly humans.
[0066]
The term "prodrug" and equivalent expressions refer to agents which can be converted in vitro or in vivo directly or indirectly to an active form (see, e.g., R. B.
Silverman, 1992, "The Organic Chemistry of Drug Design and Drug Action,"
Academic Press, Chap. 8; Bundgaard, Hans; Editor. Neth. (1985), "Design of Prodrugs".
360 pp.
Elsevier, Amsterdam; Stella, V.; Borchardt, R.; Hageman, M.; Oliyai, R.; Moog, H.;
Tilley, J. (Eds.) (2007), "Prodrugs: Challenges and Rewards, XVIII, 1470 p.
Springer).
Prodrugs can be used to alter the bio-distribution (e.g., to allow agents which would not typically enter the reactive site of a protease) or the pharmacolcinetics for a particular agent. A wide variety of groups have been used to modify compounds to form prodrugs, for example, esters, ethers, phosphates, etc. When a prodrug is administered to a subject, the group is cleaved, enzymatically or non-enzymatically, reductively, oxidatively, or hydrolytically, or otherwise to reveal the active form. As used herein, "prodrug" includes pharmaceutically acceptable salts thereof, or pharmaceutically acceptable solvates as well as crystalline forms of any of the foregoing. Prodrugs are frequently, although not necessarily, pharmacologically inactive until converted to the active form.
The term "prodrug" and equivalent expressions refer to agents which can be converted in vitro or in vivo directly or indirectly to an active form (see, e.g., R. B.
Silverman, 1992, "The Organic Chemistry of Drug Design and Drug Action,"
Academic Press, Chap. 8; Bundgaard, Hans; Editor. Neth. (1985), "Design of Prodrugs".
360 pp.
Elsevier, Amsterdam; Stella, V.; Borchardt, R.; Hageman, M.; Oliyai, R.; Moog, H.;
Tilley, J. (Eds.) (2007), "Prodrugs: Challenges and Rewards, XVIII, 1470 p.
Springer).
Prodrugs can be used to alter the bio-distribution (e.g., to allow agents which would not typically enter the reactive site of a protease) or the pharmacolcinetics for a particular agent. A wide variety of groups have been used to modify compounds to form prodrugs, for example, esters, ethers, phosphates, etc. When a prodrug is administered to a subject, the group is cleaved, enzymatically or non-enzymatically, reductively, oxidatively, or hydrolytically, or otherwise to reveal the active form. As used herein, "prodrug" includes pharmaceutically acceptable salts thereof, or pharmaceutically acceptable solvates as well as crystalline forms of any of the foregoing. Prodrugs are frequently, although not necessarily, pharmacologically inactive until converted to the active form.
[0067]
The term "ester" refers to compounds that can be represented by the formula RCOOR (carboxylic ester) or the formula RSO3R' (sulfonate ester), usually respectively formed by the reaction between a carboxylic or a sulfonic acid and an alcohol usually with the elimination of water.
The term "ester" refers to compounds that can be represented by the formula RCOOR (carboxylic ester) or the formula RSO3R' (sulfonate ester), usually respectively formed by the reaction between a carboxylic or a sulfonic acid and an alcohol usually with the elimination of water.
[0068]
The term "amino acid" generally refers to an organic compound comprising both a carboxylic acid group and an amine group. The term "amino acid"
includes both "natural" and "unnatural" or "non-natural" amino acids. Additionally, the term amino acid includes 0-alkylated and N-alkylated amino acids, as well as amino acids having nitrogen or oxygen-containing side chains (such as Lys, Cys, or Ser) in which the nitrogen or oxygen atom has been acylated or alkylated. Amino acids may be pure L or D
isomers or mixtures of L and D isomers, including (but not limited to) racemic mixtures.
The term "amino acid" generally refers to an organic compound comprising both a carboxylic acid group and an amine group. The term "amino acid"
includes both "natural" and "unnatural" or "non-natural" amino acids. Additionally, the term amino acid includes 0-alkylated and N-alkylated amino acids, as well as amino acids having nitrogen or oxygen-containing side chains (such as Lys, Cys, or Ser) in which the nitrogen or oxygen atom has been acylated or alkylated. Amino acids may be pure L or D
isomers or mixtures of L and D isomers, including (but not limited to) racemic mixtures.
[0069]
The term "natural amino acid"
and equivalent expressions refer to L-amino acids commonly found in naturally-occurring proteins. Examples of natural amino acids include, without limitation, alanine (Ala), cysteine (Cys), aspartic acid (Asp), glutamic acid (Glu), phenylalanine (Phe), glycine (Gly), histidine (His), isoleucine (Ile), lysine (Lys), leucine (Len), methionine (Met), asparagine (Asn), proline (Pro), glutamine (Gin), arginine (Arg), serine (Ser), threonine (Thr), valine (Val), tryptophan (Trp), tyrosine (Tyr),13-alanine ((3-Ala), and 7-aminobutyric acid (GABA).
The term "natural amino acid"
and equivalent expressions refer to L-amino acids commonly found in naturally-occurring proteins. Examples of natural amino acids include, without limitation, alanine (Ala), cysteine (Cys), aspartic acid (Asp), glutamic acid (Glu), phenylalanine (Phe), glycine (Gly), histidine (His), isoleucine (Ile), lysine (Lys), leucine (Len), methionine (Met), asparagine (Asn), proline (Pro), glutamine (Gin), arginine (Arg), serine (Ser), threonine (Thr), valine (Val), tryptophan (Trp), tyrosine (Tyr),13-alanine ((3-Ala), and 7-aminobutyric acid (GABA).
[0070]
The term "unnatural amino acid"
refers to any derivative of a natural amino acid including D forms, and a- and I3-amino acid derivatives. The terms "unnatural amino acid" and "non-natural amino acid" are used interchangeably herein. It is noted that certain amino acids, e.g., hydroxyproline, that are classified as a non-natural amino acid herein, may be found in nature within a certain organism or a particular protein. Amino acids with many different protecting groups appropriate for immediate use in the solid phase synthesis of peptides are commercially available. In addition to the twenty most common naturally occurring amino acids, the following examples of non-natural amino acids and amino acid derivatives may be used according to the invention (common abbreviations in parentheses): 2-aminoadipic acid (Aad), 3-aminoadipic acid ((3-Aad), 2-aminobutyric acid (2-Abu), a43-dehydro-2-aminobutyric acid (8-AU), 1-aminocyclopropane-1-carboxylic acid (ACPC), aminoisobutyric acid (Aib), 3-aminoisobutyric acid (13-Aib), 2-amino-thiazoline-4-carboxylic acid, 5-aminovaleric acid (5-Ava), 6-aminohexanoic acid (6-Ahx), 2-aminoheptanoic acid (Ahe), 8-aminooctanoic acid (8-Aoc), 11-aminoundecanoic acid (11-Aun), 12-aminododecartoic acid (12-Ado), 2-aminobenzoic acid (2-Abz), 3-aminobenzoic acid (3-Abz), 4-aminobenzoic acid (4-Abz), 4-amino-3-hydroxy-6-methylheptanoic acid (Statine, Sta), aminooxyacetic acid (Aoa), 2-aminotetraline-2-carboxylic acid (ATC), 4-amino-5-cyclohexy1-3-hydroxypentanoic acid (ACHPA), para-aminophenylalanine (4-1µ1112-Phe), 2-aminopimelic acid (Apm), biphenylalanine (Bip), para-bromophenylalanine (4-Br-Phe), ortho-chlorophenylalanine (2-C1-Phe), meta-chlorophenylalanine (3-Cl-Phe), para-chlorophenylalanine (4-C1-Phe), meta-chlorotyrosine (3-C1-Tyr), para-benzoylphenylalanine (Bpa), tert-butylglycine (TLG), cyclohexylalanine (Cha), cyclohexylglycine (Chg), desmosine (Des), 2,2-diaminopimelic acid (Dpm), 2,3-diaminopropionic acid (Dpr), 2,4-diaminobutyric acid (Dbu), 3,4-dichlorophenylalanine (3,4-C1-2-Phe), 3,4-difluororphenylalanine (3,4-F2-Phe), 3,5-diiodotyrosine (3,5-12-Tyr), N-ethylglycine (EtGly), N-ethylasparagine (EtAsn), ortho-fluorophenylalanine (2-F-Phe), meta-fluorophenylalanine (3-F-Phe), para-fluorophenylalanine (4-F-Phe), meta-fluorotyro sine (3-F-Tyr), homoserine (Hse), homophenylalanine (life), homotyrosine (Htyr), hydroxylysine (Hyl), allo-hydroxylysine (aHyl), 5-hydroxytryptophan (5-0H-Trp), 3- or 4-hydroxyproline (3- or 4-Hyp), pan-iodophenylalanine (4-I-Phe), 3-iodotyrosine (3-11-Tyr), indoline-2-carboxylic acid (Idc), isodesmosine (Ide), allo-isoleucine (a-lie), isonipecotic acid (hw), N-methylisoleucine (Melle), N-methyllysine (MeLys), meta-methyltyrosine (3-Me-Tyr), N-methylvaline (MeVal), 1-naphthylalanine (1-Nat), 2-naphthylalanine (2-Nal), para-nitrophenylalanine (4-NO2-Phe), 3-nitrotyrosine (3-NO2-Tyr), norleucine (Nile), norvaline (Nva), ornithine (Om), ortho-phosphotyrosine (H2P03-Tyr), octahydroindole-2-carboxylic acid (Oic), penicillamine (Pen), pentafluorophenylalanine (F5-Phe), phenylglycine (Phg), pipecolic acid (Pip), propargylglycine (Pra), pyroglutamic acid (PGLU), sarcosine (Sar), tetrahydroisoquinoline-3-carboxylic acid (Tic), thienylalartine, and thiazolidine-4-carboxylic acid (thioproline, Th).
The term "unnatural amino acid"
refers to any derivative of a natural amino acid including D forms, and a- and I3-amino acid derivatives. The terms "unnatural amino acid" and "non-natural amino acid" are used interchangeably herein. It is noted that certain amino acids, e.g., hydroxyproline, that are classified as a non-natural amino acid herein, may be found in nature within a certain organism or a particular protein. Amino acids with many different protecting groups appropriate for immediate use in the solid phase synthesis of peptides are commercially available. In addition to the twenty most common naturally occurring amino acids, the following examples of non-natural amino acids and amino acid derivatives may be used according to the invention (common abbreviations in parentheses): 2-aminoadipic acid (Aad), 3-aminoadipic acid ((3-Aad), 2-aminobutyric acid (2-Abu), a43-dehydro-2-aminobutyric acid (8-AU), 1-aminocyclopropane-1-carboxylic acid (ACPC), aminoisobutyric acid (Aib), 3-aminoisobutyric acid (13-Aib), 2-amino-thiazoline-4-carboxylic acid, 5-aminovaleric acid (5-Ava), 6-aminohexanoic acid (6-Ahx), 2-aminoheptanoic acid (Ahe), 8-aminooctanoic acid (8-Aoc), 11-aminoundecanoic acid (11-Aun), 12-aminododecartoic acid (12-Ado), 2-aminobenzoic acid (2-Abz), 3-aminobenzoic acid (3-Abz), 4-aminobenzoic acid (4-Abz), 4-amino-3-hydroxy-6-methylheptanoic acid (Statine, Sta), aminooxyacetic acid (Aoa), 2-aminotetraline-2-carboxylic acid (ATC), 4-amino-5-cyclohexy1-3-hydroxypentanoic acid (ACHPA), para-aminophenylalanine (4-1µ1112-Phe), 2-aminopimelic acid (Apm), biphenylalanine (Bip), para-bromophenylalanine (4-Br-Phe), ortho-chlorophenylalanine (2-C1-Phe), meta-chlorophenylalanine (3-Cl-Phe), para-chlorophenylalanine (4-C1-Phe), meta-chlorotyrosine (3-C1-Tyr), para-benzoylphenylalanine (Bpa), tert-butylglycine (TLG), cyclohexylalanine (Cha), cyclohexylglycine (Chg), desmosine (Des), 2,2-diaminopimelic acid (Dpm), 2,3-diaminopropionic acid (Dpr), 2,4-diaminobutyric acid (Dbu), 3,4-dichlorophenylalanine (3,4-C1-2-Phe), 3,4-difluororphenylalanine (3,4-F2-Phe), 3,5-diiodotyrosine (3,5-12-Tyr), N-ethylglycine (EtGly), N-ethylasparagine (EtAsn), ortho-fluorophenylalanine (2-F-Phe), meta-fluorophenylalanine (3-F-Phe), para-fluorophenylalanine (4-F-Phe), meta-fluorotyro sine (3-F-Tyr), homoserine (Hse), homophenylalanine (life), homotyrosine (Htyr), hydroxylysine (Hyl), allo-hydroxylysine (aHyl), 5-hydroxytryptophan (5-0H-Trp), 3- or 4-hydroxyproline (3- or 4-Hyp), pan-iodophenylalanine (4-I-Phe), 3-iodotyrosine (3-11-Tyr), indoline-2-carboxylic acid (Idc), isodesmosine (Ide), allo-isoleucine (a-lie), isonipecotic acid (hw), N-methylisoleucine (Melle), N-methyllysine (MeLys), meta-methyltyrosine (3-Me-Tyr), N-methylvaline (MeVal), 1-naphthylalanine (1-Nat), 2-naphthylalanine (2-Nal), para-nitrophenylalanine (4-NO2-Phe), 3-nitrotyrosine (3-NO2-Tyr), norleucine (Nile), norvaline (Nva), ornithine (Om), ortho-phosphotyrosine (H2P03-Tyr), octahydroindole-2-carboxylic acid (Oic), penicillamine (Pen), pentafluorophenylalanine (F5-Phe), phenylglycine (Phg), pipecolic acid (Pip), propargylglycine (Pra), pyroglutamic acid (PGLU), sarcosine (Sar), tetrahydroisoquinoline-3-carboxylic acid (Tic), thienylalartine, and thiazolidine-4-carboxylic acid (thioproline, Th).
[0071]
For compounds provided herein, it is intended that, in some embodiments, salts thereof are also encompassed, including pharmaceutically acceptable salts. Those skilled in the art will appreciate that many salt forms (e.g., TFA salt, tetrazolium salt, sodium salt, potassium salt, etc,) are possible; appropriate salts are selected based on considerations known in the art. The term "pharmaceutically acceptable salt"
refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases. For example, for compounds that contain a basic nitrogen, salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids. Suitable pharmaceutically acceptable acid addition salts for the compounds of the present invention include without limitation acetic, benzenesulfonic (besylate), benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, martdelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic, and the like. When the compounds contain an acidic side chain, suitable pharmaceutically acceptable base addition salts for the compounds of the present invention include without limitation metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,W-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine.
For compounds provided herein, it is intended that, in some embodiments, salts thereof are also encompassed, including pharmaceutically acceptable salts. Those skilled in the art will appreciate that many salt forms (e.g., TFA salt, tetrazolium salt, sodium salt, potassium salt, etc,) are possible; appropriate salts are selected based on considerations known in the art. The term "pharmaceutically acceptable salt"
refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases. For example, for compounds that contain a basic nitrogen, salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids. Suitable pharmaceutically acceptable acid addition salts for the compounds of the present invention include without limitation acetic, benzenesulfonic (besylate), benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, martdelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic, and the like. When the compounds contain an acidic side chain, suitable pharmaceutically acceptable base addition salts for the compounds of the present invention include without limitation metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,W-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine.
[0072]
In some embodiments, there are provided methods of increasing the therapeutic effectiveness of axitinib in a subject in need thereof, comprising administering an effective amount of a compound of Formula I, II or HI or a pharmaceutical composition thereof as described herein to the subject, such that the therapeutic effectiveness of axitinib is increased as compared to administration of axitinib itself. In some embodiments, the compound is a prodrug of axitinib.
In some embodiments, there are provided methods of increasing the therapeutic effectiveness of axitinib in a subject in need thereof, comprising administering an effective amount of a compound of Formula I, II or HI or a pharmaceutical composition thereof as described herein to the subject, such that the therapeutic effectiveness of axitinib is increased as compared to administration of axitinib itself. In some embodiments, the compound is a prodrug of axitinib.
[0073]
In some embodiments, one or more of the following is increased by administration of a compound, an axitinib prodrug, or a pharmaceutical composition provided herein: bioavailability of axitinib; AUC of axitinib in blood or plasma; C. of axitinib; T. of axitinib; LA of axitinib; therapeutic biodistribution of axitinib; therapeutic level of axitinib in a selected tissue; and/or bioabsorption of axitinib in a subject, as compared to administration of axitinib itself. In some embodiments, one or more of the following is reduced by administration of a compound, an axitinib prodrug, or a pharmaceutical composition provided herein: metabolism of axitinib; and side effects of axitinib in a subject, as compared to administration of axitinib itself.
In some embodiments, one or more of the following is increased by administration of a compound, an axitinib prodrug, or a pharmaceutical composition provided herein: bioavailability of axitinib; AUC of axitinib in blood or plasma; C. of axitinib; T. of axitinib; LA of axitinib; therapeutic biodistribution of axitinib; therapeutic level of axitinib in a selected tissue; and/or bioabsorption of axitinib in a subject, as compared to administration of axitinib itself. In some embodiments, one or more of the following is reduced by administration of a compound, an axitinib prodrug, or a pharmaceutical composition provided herein: metabolism of axitinib; and side effects of axitinib in a subject, as compared to administration of axitinib itself.
[0074]
In some embodiments, there are provided methods of attaining a target pharmacokinetic parameter for axitinib in a subject, comprising administering an effective amount of a compound, an axitinib prodrug, or a pharmaceutical composition thereof as described herein to the subject, such that the target pharmacokinetic parameter for axitinib is attained in the subject. Non-limiting examples of target pharmacokinetic parameters include a target bioavailability, AUC in blood or plasma, Cmax, Tmax, bio-distribution, level in a selected tissue, half-life (t1/2), bioabsorption, and amount or rate of metabolism. Pharmacokinetic parameters may be calculated using methods known in the art.
Compositions
In some embodiments, there are provided methods of attaining a target pharmacokinetic parameter for axitinib in a subject, comprising administering an effective amount of a compound, an axitinib prodrug, or a pharmaceutical composition thereof as described herein to the subject, such that the target pharmacokinetic parameter for axitinib is attained in the subject. Non-limiting examples of target pharmacokinetic parameters include a target bioavailability, AUC in blood or plasma, Cmax, Tmax, bio-distribution, level in a selected tissue, half-life (t1/2), bioabsorption, and amount or rate of metabolism. Pharmacokinetic parameters may be calculated using methods known in the art.
Compositions
[0075]
In an embodiment, there is provided a pharmaceutical composition comprising a compound of the invention, e.g., a compound of Formula I, II, or IH, or a pharmaceutically acceptable salt, ester, solvate or polymorph thereof, and a pharmaceutically acceptable carrier.
In an embodiment, there is provided a pharmaceutical composition comprising a compound in Table 1, or a pharmaceutically acceptable salt, ester, solvate or polymorph thereof, and a pharmaceutically acceptable carrier. In another embodiment, there is provided a pharmaceutical composition comprising a compound of Formula I, II, or III or a compound in Table 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Examples
In an embodiment, there is provided a pharmaceutical composition comprising a compound of the invention, e.g., a compound of Formula I, II, or IH, or a pharmaceutically acceptable salt, ester, solvate or polymorph thereof, and a pharmaceutically acceptable carrier.
In an embodiment, there is provided a pharmaceutical composition comprising a compound in Table 1, or a pharmaceutically acceptable salt, ester, solvate or polymorph thereof, and a pharmaceutically acceptable carrier. In another embodiment, there is provided a pharmaceutical composition comprising a compound of Formula I, II, or III or a compound in Table 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Examples
[0076]
The present invention will be more readily understood by referring to the following examples, which are provided to illustrate the invention and are not to be construed as limiting the scope thereof in any manner.
The present invention will be more readily understood by referring to the following examples, which are provided to illustrate the invention and are not to be construed as limiting the scope thereof in any manner.
[0077]
Unless defined otherwise or the context clearly dictates otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It should be understood that any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention_
Unless defined otherwise or the context clearly dictates otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It should be understood that any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention_
[0078]
Example 1: Synthesis of N-methy1-24(1-pentoxycarbony1-34(1E)-2-(2-nridinvfletheny1)-1H-indazol-6-y1)thio)benzamide (compound 1).
Example 1: Synthesis of N-methy1-24(1-pentoxycarbony1-34(1E)-2-(2-nridinvfletheny1)-1H-indazol-6-y1)thio)benzamide (compound 1).
[0079]
In a flask were added 1-pentanol (500 mg, 5.67 mmol, 1.0 eq.), THF (10 mL) and triethylamine (1.15 g, 11.3 mmol., 2.0 eq.). The mixture was cooled to 0 C with an ice-water bath, followed by addition of a solution of p-nitrophenyl chloroformate in THF
(1.25 g, in 10 mL). The reaction mixture was warmed to room temperature (rt), and stirred for 1 hour (h) (TLC showed completion of the reaction.), followed by concentration to remove most of the solvent. To the residual material were added water and ethyl acetate (40 mL each) for extraction. The organic layer was separated and concentrated. The residual material was purified on a silica-gel column (eluent: pet-ether and ethyl acetate from 100:0 to 100:10), giving 4-nitrophenyl pentyl carbonate (1.0 g, 69%): 111 NMR (500 MHz, CDC13): 6 ppm 0.92 (t, J=6.0 Hz, 311), 1.39 (t, J=8.2 Hz, 411), 1.63-1.84 (m, 2H), 4.17-4.35 (m, 2H), 7.37 (dd, J=9.0, 1.9 Hz, 2H), 8.26 (dd, J=9.0, 1.9 Hz, 211).
In a flask were added 1-pentanol (500 mg, 5.67 mmol, 1.0 eq.), THF (10 mL) and triethylamine (1.15 g, 11.3 mmol., 2.0 eq.). The mixture was cooled to 0 C with an ice-water bath, followed by addition of a solution of p-nitrophenyl chloroformate in THF
(1.25 g, in 10 mL). The reaction mixture was warmed to room temperature (rt), and stirred for 1 hour (h) (TLC showed completion of the reaction.), followed by concentration to remove most of the solvent. To the residual material were added water and ethyl acetate (40 mL each) for extraction. The organic layer was separated and concentrated. The residual material was purified on a silica-gel column (eluent: pet-ether and ethyl acetate from 100:0 to 100:10), giving 4-nitrophenyl pentyl carbonate (1.0 g, 69%): 111 NMR (500 MHz, CDC13): 6 ppm 0.92 (t, J=6.0 Hz, 311), 1.39 (t, J=8.2 Hz, 411), 1.63-1.84 (m, 2H), 4.17-4.35 (m, 2H), 7.37 (dd, J=9.0, 1.9 Hz, 2H), 8.26 (dd, J=9.0, 1.9 Hz, 211).
[0080]
In a flask were placed axitinib (100 mg, 0.259 mmol, 1.0 eq.), DMF (4 mL) and triethylamine (79 mg, 0.776 mmol, 3.0 eq.). To the stirred mixture was added 4-nitrophenyl pentyl carbonate (100 mg, 0.259 mmol, 1.0 eq.); and the obtained mixture was stirred at it for 3 h, followed by addition of water (20 nth) and ethyl acetate (30 mL).
The organic layer was separated and washed with brine (3 x 30 mL), and concentrated.
The residual material was purified on a silica-gel column (eluent: DCM-methanol, from 100:0 to 100:3), providing compound 1 (100 mg, 77%): 111 NMR (500 MHz, DMSO-d6): 6 ppm 0.89 (t, J=6.9 Hz, 311), 1.36 (d, J=3.1 Hz, 411), 1.66-1.81 (m, 211), 2.75 (d, J=4.6 Hz, 3H), 4.43 (t, J=6.7 Hz, 2H), 7.20 (d, J=6.9 Hz, 1H), 7.37 (dt, J=12.9, 7.6 Hz, 4H), 7.49-7.54 (m, 1H), 7.74-7.82 (m, 2H), 7.86 (t, J=7.6 Hz, 1H), 7.92 (d, J=16.4 Hz, 1H), 8.12 (s, 1H), 8.31 (d, J=8.4 Hz, 1H), 8.39 (d, J=4.6 Hz, 1H), 8.65 (d, J=4.0 Hz, 1H);
13C NMR (125 MHz, CDC13): 6 ppm 14.03, 22.37, 26.85, 27.88, 28.42, 68.48, 116.88, 121.68, 122.03, 122.71, 123.17, 123.81, 127.17, 127.83, 128.99, 130.95, 133.03, 133.33, 134.30, 137.04, 137.73, 137.91, 141.52, 147.75, 149.73, 150.64, 154.54, 168.49; miz (ESI+): 501.0 (M + H).
In a flask were placed axitinib (100 mg, 0.259 mmol, 1.0 eq.), DMF (4 mL) and triethylamine (79 mg, 0.776 mmol, 3.0 eq.). To the stirred mixture was added 4-nitrophenyl pentyl carbonate (100 mg, 0.259 mmol, 1.0 eq.); and the obtained mixture was stirred at it for 3 h, followed by addition of water (20 nth) and ethyl acetate (30 mL).
The organic layer was separated and washed with brine (3 x 30 mL), and concentrated.
The residual material was purified on a silica-gel column (eluent: DCM-methanol, from 100:0 to 100:3), providing compound 1 (100 mg, 77%): 111 NMR (500 MHz, DMSO-d6): 6 ppm 0.89 (t, J=6.9 Hz, 311), 1.36 (d, J=3.1 Hz, 411), 1.66-1.81 (m, 211), 2.75 (d, J=4.6 Hz, 3H), 4.43 (t, J=6.7 Hz, 2H), 7.20 (d, J=6.9 Hz, 1H), 7.37 (dt, J=12.9, 7.6 Hz, 4H), 7.49-7.54 (m, 1H), 7.74-7.82 (m, 2H), 7.86 (t, J=7.6 Hz, 1H), 7.92 (d, J=16.4 Hz, 1H), 8.12 (s, 1H), 8.31 (d, J=8.4 Hz, 1H), 8.39 (d, J=4.6 Hz, 1H), 8.65 (d, J=4.0 Hz, 1H);
13C NMR (125 MHz, CDC13): 6 ppm 14.03, 22.37, 26.85, 27.88, 28.42, 68.48, 116.88, 121.68, 122.03, 122.71, 123.17, 123.81, 127.17, 127.83, 128.99, 130.95, 133.03, 133.33, 134.30, 137.04, 137.73, 137.91, 141.52, 147.75, 149.73, 150.64, 154.54, 168.49; miz (ESI+): 501.0 (M + H).
[0081]
Example 2: Synthesis of N-methy1-24(1-oxododecy1-34(1E)-2- (2-pyridinynetheny1)-11/-indazol-6-y1)thio)benzamide (compound 2).
Example 2: Synthesis of N-methy1-24(1-oxododecy1-34(1E)-2- (2-pyridinynetheny1)-11/-indazol-6-y1)thio)benzamide (compound 2).
[0082]
In a flask were added axitinib (200 mg, 0.517 mmol, 1.0 eq.), DMF (4 mL), Lauric acid (126 mg, 0.621 mmol, 1.2 eq.), diisopropylamine (110 mg, 0.776 mmol, 1.5 eq.), and HATU (1- [Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophospha te, hexafluorophospha te a n benzotriazole tetramethyl uronium) (236 mg, 0.621 mmol, 1.2 eq.). The mixture was stirred at rt overnight, and TLC monitoring indicated the completion of the reaction. Water (20 mL) and ethyl acetate (30 mL) were added to the flask and the content was extracted in a separatory funnel. The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified on a silica-gel column (eluent: DCM-methanol, from 100:0 to 100:3), giving compound 2 (200 mg, 68%): 1H NMR (500 MHz, CDC13): 6 ppm 0.87 (t, J=6.5 Hz, 311), 1.31 (d, J=51.8 Hz, 1411), 1.43 (d, 3=7.3 Hz, 211), 1.76-1.86 (m, 211), 2.94 (d, J=4.5 Hz, 311), 3.20 (t, J=7.5 Hz, 211), 6.39 (s, 111), 7.24 (d, J=5.8 Hz, 1H), 7.33 (d, J=7.8 Hz, 4H), 7.50 (d, J=7.6 Hz, 1H), 7.64 (s, 1H), 7.68 (d, J=16.3 Hz, 1H), 7.73 (t, J=7.6 Hz, 1H), 7.85 (d, J=16.3 Hz, 1H), 7.93 (d, J=8.4 Hz, 1H), 8.50 (s, 1H), 8.66 (d, 3=4.1 Hz, 1H); 13C NMR (125 MHz, CDC13): 5 ppm 14.26, 22.82, 24.73, 26.90, 29.39, 29.48, 29.52, 29.64, 29.77, 32.04, 35.23, 117.98, 121.43, 123.00, 123.33, 124.21, 125.75, 127.94, 129.12, 131.02, 133.18, 133.35, 137.50, 137.76, 138.05, 140.89, 146.97, 149.40, 154.30, 168.57, 174.15; miz (ESI+): 569.2 (M + II).
In a flask were added axitinib (200 mg, 0.517 mmol, 1.0 eq.), DMF (4 mL), Lauric acid (126 mg, 0.621 mmol, 1.2 eq.), diisopropylamine (110 mg, 0.776 mmol, 1.5 eq.), and HATU (1- [Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophospha te, hexafluorophospha te a n benzotriazole tetramethyl uronium) (236 mg, 0.621 mmol, 1.2 eq.). The mixture was stirred at rt overnight, and TLC monitoring indicated the completion of the reaction. Water (20 mL) and ethyl acetate (30 mL) were added to the flask and the content was extracted in a separatory funnel. The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified on a silica-gel column (eluent: DCM-methanol, from 100:0 to 100:3), giving compound 2 (200 mg, 68%): 1H NMR (500 MHz, CDC13): 6 ppm 0.87 (t, J=6.5 Hz, 311), 1.31 (d, J=51.8 Hz, 1411), 1.43 (d, 3=7.3 Hz, 211), 1.76-1.86 (m, 211), 2.94 (d, J=4.5 Hz, 311), 3.20 (t, J=7.5 Hz, 211), 6.39 (s, 111), 7.24 (d, J=5.8 Hz, 1H), 7.33 (d, J=7.8 Hz, 4H), 7.50 (d, J=7.6 Hz, 1H), 7.64 (s, 1H), 7.68 (d, J=16.3 Hz, 1H), 7.73 (t, J=7.6 Hz, 1H), 7.85 (d, J=16.3 Hz, 1H), 7.93 (d, J=8.4 Hz, 1H), 8.50 (s, 1H), 8.66 (d, 3=4.1 Hz, 1H); 13C NMR (125 MHz, CDC13): 5 ppm 14.26, 22.82, 24.73, 26.90, 29.39, 29.48, 29.52, 29.64, 29.77, 32.04, 35.23, 117.98, 121.43, 123.00, 123.33, 124.21, 125.75, 127.94, 129.12, 131.02, 133.18, 133.35, 137.50, 137.76, 138.05, 140.89, 146.97, 149.40, 154.30, 168.57, 174.15; miz (ESI+): 569.2 (M + II).
[0083]
Example 3: Synthesis of N-methyl-2-((1- (N-(t-butoxycarbony1)-L-valy1)-3-((lE)-2-(2-pyridinyl)etheny1)-1H-indazol-6-y1)thio)benzamide (compound 3).
Example 3: Synthesis of N-methyl-2-((1- (N-(t-butoxycarbony1)-L-valy1)-3-((lE)-2-(2-pyridinyl)etheny1)-1H-indazol-6-y1)thio)benzamide (compound 3).
[0084]
In a flask were added axitinib (150 mg, 0.388 mmol, 1.0 eq.), DMF (4 mL), Boc-Val-OSu (N-Boc-L-valine N-succinimidyl ester) (134 mg, 0.426 mmol, 1.2 eq.), and triethylamine (117 mg, 1.16 mmol, 3.0 eq.). The mixture was stirred at a overnight. The reaction was monitored by TLC, until the starting material disappeared. To the reaction flask were added water (20 mL) and ethyl acetate (30 mL), and the content was extracted in a separatory funnel. The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel column;
eluent DCM-methanol from 100:0 to 100:3), giving compound 3 (150 mg, 66%): 111 NMR (500 MHz, CD30D): 5 ppm 0.95 (dd, J=32.0, 6.0 Hz, 6H), 1.16-1.53 (m, 9H), 2.34 (s, 1H), 2.78 (s, 3H), 5.43 (s, 1H), 7.02 (d, J=8.6 Hz, 1H), 7.26-7.40 (m, 5H), 7.44 (s, 1H), 7.67-7.89 (m, 4H), 8.05 (d, J=8.3 Hz, 1H), 8.38 (s, 1H), 8.54 (s, 1H); 13C NMR (125 MHz, CD30D): 5 ppm 17.92, 20.07, 26.75, 28.73, 32.15, 59.56, 80.66, 118.51, 122.66, 123.19, 124.23, 124.67, 125.09, 128.81, 129.25, 131.83, 134.05, 134.73, 135.29, 138.77, 140.03, 140.19, 141.93, 148.83, 150.47, 155.65, 158.25, 171.51, 173.97; ink (ESI+): 586.1 (M +
H).
In a flask were added axitinib (150 mg, 0.388 mmol, 1.0 eq.), DMF (4 mL), Boc-Val-OSu (N-Boc-L-valine N-succinimidyl ester) (134 mg, 0.426 mmol, 1.2 eq.), and triethylamine (117 mg, 1.16 mmol, 3.0 eq.). The mixture was stirred at a overnight. The reaction was monitored by TLC, until the starting material disappeared. To the reaction flask were added water (20 mL) and ethyl acetate (30 mL), and the content was extracted in a separatory funnel. The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel column;
eluent DCM-methanol from 100:0 to 100:3), giving compound 3 (150 mg, 66%): 111 NMR (500 MHz, CD30D): 5 ppm 0.95 (dd, J=32.0, 6.0 Hz, 6H), 1.16-1.53 (m, 9H), 2.34 (s, 1H), 2.78 (s, 3H), 5.43 (s, 1H), 7.02 (d, J=8.6 Hz, 1H), 7.26-7.40 (m, 5H), 7.44 (s, 1H), 7.67-7.89 (m, 4H), 8.05 (d, J=8.3 Hz, 1H), 8.38 (s, 1H), 8.54 (s, 1H); 13C NMR (125 MHz, CD30D): 5 ppm 17.92, 20.07, 26.75, 28.73, 32.15, 59.56, 80.66, 118.51, 122.66, 123.19, 124.23, 124.67, 125.09, 128.81, 129.25, 131.83, 134.05, 134.73, 135.29, 138.77, 140.03, 140.19, 141.93, 148.83, 150.47, 155.65, 158.25, 171.51, 173.97; ink (ESI+): 586.1 (M +
H).
[0085]
Example 4: Synthesis of N-methy1-24(1-(t-butoxycarbony1)-3-((lE)-242-vvridinylletheny1)-1H-indazol-6-y1)thio)benzamide (compound 4).
Example 4: Synthesis of N-methy1-24(1-(t-butoxycarbony1)-3-((lE)-242-vvridinylletheny1)-1H-indazol-6-y1)thio)benzamide (compound 4).
[0086]
In a flask were placed axitinib (100 mg, 0.259 mmol, 1.0 eq.), DMF (4 mL), di-tert-butyl decarbonate (diBoc, 63 mg, 0.285 mmol, 1.1 eq.), and triethylamine (52 mg, 0.516 mmol, 2.0 eq). The reaction mixture was stirred at it overnight. The reaction was monitored by TLC until the starting material disappeared. Then water (20 mL) and ethyl acetate (30 mL) were added to the mixture. The mixture was transferred into a separatory funnel. The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified on a silica-gel column (eluent: DCM-methanol from 100:0 to 100:3), giving compound 4 (110 mg, 87%): 1H NMR (500 MHz, CD30D): 6 ppm 1.64 (s, 9H), 2.84 (s, 3H), 7.36-7.43 (m, J=21.9, 12.9 Hz, 5H), 7.51 (d, J=6.5 Hz, 1H), 7.74 (t, J=12.6 Hz, 2H), 7.81-7.90 (m, 2H), 8.08 (d, J=7.6 Hz, 2H), 8.59 (s, 1H); 13C NMR (125 MHz, CDC13): 5 ppm 26.64, 26.78, 28.09, 85.57, 116.85, 121.50, 122.14, 122.73, 123.11, 123.75, 126.74, 127.71, 128.92, 130.88, 133.00, 133.35, 133.54, 137.17, 137.60, 137.73, 141.18, 147.02, 148.86, 149.44, 154.48, 168.50; rrilz (ESI+): 486.9 (M + H).
In a flask were placed axitinib (100 mg, 0.259 mmol, 1.0 eq.), DMF (4 mL), di-tert-butyl decarbonate (diBoc, 63 mg, 0.285 mmol, 1.1 eq.), and triethylamine (52 mg, 0.516 mmol, 2.0 eq). The reaction mixture was stirred at it overnight. The reaction was monitored by TLC until the starting material disappeared. Then water (20 mL) and ethyl acetate (30 mL) were added to the mixture. The mixture was transferred into a separatory funnel. The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified on a silica-gel column (eluent: DCM-methanol from 100:0 to 100:3), giving compound 4 (110 mg, 87%): 1H NMR (500 MHz, CD30D): 6 ppm 1.64 (s, 9H), 2.84 (s, 3H), 7.36-7.43 (m, J=21.9, 12.9 Hz, 5H), 7.51 (d, J=6.5 Hz, 1H), 7.74 (t, J=12.6 Hz, 2H), 7.81-7.90 (m, 2H), 8.08 (d, J=7.6 Hz, 2H), 8.59 (s, 1H); 13C NMR (125 MHz, CDC13): 5 ppm 26.64, 26.78, 28.09, 85.57, 116.85, 121.50, 122.14, 122.73, 123.11, 123.75, 126.74, 127.71, 128.92, 130.88, 133.00, 133.35, 133.54, 137.17, 137.60, 137.73, 141.18, 147.02, 148.86, 149.44, 154.48, 168.50; rrilz (ESI+): 486.9 (M + H).
[0087]
Example 5: Synthesis of N-methy1-24(14(1-oxo-2,5,8,11-tetraoxadodec-1-y1)-L-valy1)-34(1E)-242-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide (compound a
Example 5: Synthesis of N-methy1-24(14(1-oxo-2,5,8,11-tetraoxadodec-1-y1)-L-valy1)-34(1E)-242-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide (compound a
[0088]
In a flask were added, subsequently, triethylene glycol monomethyl ether (500 mg, 3.045 mmol, 1.0 eq.), THF (10 mL), and triethylamine (616 mg, 6.09 mmol, 2.0 eq.). The mixture was cooled to 0 C (ice-water bath), followed by addition of a solution of p-nitrophenyl chloroformate in THF (675 mg in 10 mL THF, 3.350 mmol, 1.1 eq.) dropwise. The mixture was warmed to it, and stirred at it for 5 h, concentrated to remove most of the solvent. The residue was extracted between water and ethyl acetate (40 mL
each). The organic layer was separated and concentrated. The residual material was purified (silica-gel column; eluent, pet-ether and ethyl acetate, from 100:0 to 100:10), giving 1(3,6,9-trioxadecyl) 4-nitrophenyl carbonate (1.1 g, 99%): 1H NMR (500 MHz, CDC13): 6 ppm 3.36 (s, 3H), 3.51-3.58 (m, 2H), 3.66 (ddd, J=8.4, 6.8, 2.3 Hz, 6H), 3.80 (d, J=4.0 Hz, 2H), 4.39-4.48 (m, 2H), 7.37 (d, J=9.0 Hz, 2H), 8.26 (d, J=9.0 Hz, 2H).
In a flask were added, subsequently, triethylene glycol monomethyl ether (500 mg, 3.045 mmol, 1.0 eq.), THF (10 mL), and triethylamine (616 mg, 6.09 mmol, 2.0 eq.). The mixture was cooled to 0 C (ice-water bath), followed by addition of a solution of p-nitrophenyl chloroformate in THF (675 mg in 10 mL THF, 3.350 mmol, 1.1 eq.) dropwise. The mixture was warmed to it, and stirred at it for 5 h, concentrated to remove most of the solvent. The residue was extracted between water and ethyl acetate (40 mL
each). The organic layer was separated and concentrated. The residual material was purified (silica-gel column; eluent, pet-ether and ethyl acetate, from 100:0 to 100:10), giving 1(3,6,9-trioxadecyl) 4-nitrophenyl carbonate (1.1 g, 99%): 1H NMR (500 MHz, CDC13): 6 ppm 3.36 (s, 3H), 3.51-3.58 (m, 2H), 3.66 (ddd, J=8.4, 6.8, 2.3 Hz, 6H), 3.80 (d, J=4.0 Hz, 2H), 4.39-4.48 (m, 2H), 7.37 (d, J=9.0 Hz, 2H), 8.26 (d, J=9.0 Hz, 2H).
[0089]
In a flask were added, subsequently, axitinib (150 mg, 0.388 mmol, 1.0 eq.), DMF (4 mL), and triethylamine (79 mg, 0.776 mmol, 2.0 eq.). The mixture was stirred at it. To the stirred mixture was added 1-(3,6,9-trioxadecyl) 4-nitrophenyl carbonate (121 mg, 0.427 mmol, 1.1 eq.), and the resultant mixture was stirred at it overnight. After the starting material disappeared (TLC monitoring), the mixture was extracted between water (20 mL) and ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel;
eluent, DCM-methanol from 100:0 to 100:3), giving compound 5 (200 mg, 89%): 111 NMR
(500 MHz, CD30D): 6 ppm 2.85 (s, 3H), 3.26 (s, 3H), 3.43 (d, J=4.2 Hz, 2H), 3.57 et J=4.6 Hz, 2H), 3.64 (s, 2H), 3.69 (s, 2H), 3.86 (s, 2H), 4.63 (s, 2H), 7.35-7.40 (m, 5H), 7.52 (d, J=6.2 Hz, 1H), 7. 67-7.77 (m, 2H), 7.77-7.90 (m, 2H), 8.06 (d, J=8.2 Hz, 1H), 8.19 (s, 1H), 8.58 (s, 1H); 13C NMR (125 MHz, CDCI3): 5 ppm 26.78, 59.00, 66.79, 68.71, 70.55, 70.66, 71.88, 117.27, 121.63, 121.89 122.82, 123.86, 127.47, 128.70, 130.83, 132.45, 133.79, 134.14, 137.14, 137.51, 137.77, 141.37, 147.87, 149.53, 150.36, 154.32, 168.57; nth (ESI+): 576.9 (M + H).
In a flask were added, subsequently, axitinib (150 mg, 0.388 mmol, 1.0 eq.), DMF (4 mL), and triethylamine (79 mg, 0.776 mmol, 2.0 eq.). The mixture was stirred at it. To the stirred mixture was added 1-(3,6,9-trioxadecyl) 4-nitrophenyl carbonate (121 mg, 0.427 mmol, 1.1 eq.), and the resultant mixture was stirred at it overnight. After the starting material disappeared (TLC monitoring), the mixture was extracted between water (20 mL) and ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel;
eluent, DCM-methanol from 100:0 to 100:3), giving compound 5 (200 mg, 89%): 111 NMR
(500 MHz, CD30D): 6 ppm 2.85 (s, 3H), 3.26 (s, 3H), 3.43 (d, J=4.2 Hz, 2H), 3.57 et J=4.6 Hz, 2H), 3.64 (s, 2H), 3.69 (s, 2H), 3.86 (s, 2H), 4.63 (s, 2H), 7.35-7.40 (m, 5H), 7.52 (d, J=6.2 Hz, 1H), 7. 67-7.77 (m, 2H), 7.77-7.90 (m, 2H), 8.06 (d, J=8.2 Hz, 1H), 8.19 (s, 1H), 8.58 (s, 1H); 13C NMR (125 MHz, CDCI3): 5 ppm 26.78, 59.00, 66.79, 68.71, 70.55, 70.66, 71.88, 117.27, 121.63, 121.89 122.82, 123.86, 127.47, 128.70, 130.83, 132.45, 133.79, 134.14, 137.14, 137.51, 137.77, 141.37, 147.87, 149.53, 150.36, 154.32, 168.57; nth (ESI+): 576.9 (M + H).
[0090]
Example 6: Synthesis of N-methy1-24(1-(2,2,2-trifluoroethyloxycarbony1)-3-((lE)-2-(2-pyridinybetheny1)-1H-indazol-6-y1)thio)benzamide (compound 6).
Example 6: Synthesis of N-methy1-24(1-(2,2,2-trifluoroethyloxycarbony1)-3-((lE)-2-(2-pyridinybetheny1)-1H-indazol-6-y1)thio)benzamide (compound 6).
[0091]
Trifluoroethanol (500 mg, 4.98 mmol, 1.0 eq.), THE (10 mL), and triethylamine (1.1 g, 9.96 mmol, 2.0 eq.) were added subsequently into a flask. The mixture was cooled to 0 C (ice-water bath), followed by addition (to the mixture) of a solution of p-nitrophenyl chlorofonnate in THF (1.1 g in 10-mL THE, 5.48 mmol, 1.1 eq.). The reaction mixture was warmed to it and stirred at rt overnight, until the starting material disappeared (monitored by TLC). The mixture was concentrated to remove most of the solvent, followed by addition of water and ethyl acetate (40 mL each), and transferred into a separatory funnel. The organic layer was separated and concentrated.
The residual material was purified (silica-gel; eluent, pet-ether: ethyl acetate from 100:0 to 100:30), providing 4-nitrophenyl 2,2,2-trifluoroethyl carbonate (1.1 g, 75%): 1H NMR
(500 MHz, CDC13): 5 ppm 4.65 (q, J=8.0 Hz, 2H), 7.35-7.52 (m, 2H), 8.22-8.36 (m, 1H).
Trifluoroethanol (500 mg, 4.98 mmol, 1.0 eq.), THE (10 mL), and triethylamine (1.1 g, 9.96 mmol, 2.0 eq.) were added subsequently into a flask. The mixture was cooled to 0 C (ice-water bath), followed by addition (to the mixture) of a solution of p-nitrophenyl chlorofonnate in THF (1.1 g in 10-mL THE, 5.48 mmol, 1.1 eq.). The reaction mixture was warmed to it and stirred at rt overnight, until the starting material disappeared (monitored by TLC). The mixture was concentrated to remove most of the solvent, followed by addition of water and ethyl acetate (40 mL each), and transferred into a separatory funnel. The organic layer was separated and concentrated.
The residual material was purified (silica-gel; eluent, pet-ether: ethyl acetate from 100:0 to 100:30), providing 4-nitrophenyl 2,2,2-trifluoroethyl carbonate (1.1 g, 75%): 1H NMR
(500 MHz, CDC13): 5 ppm 4.65 (q, J=8.0 Hz, 2H), 7.35-7.52 (m, 2H), 8.22-8.36 (m, 1H).
[0092]
Into a flask were subsequently added axitinib (200 mg, 0.517 mmol, 1.0 eq.), DMF (4 mL), and triethylamine (104.7 mg, 1.03 mmol, 2.0 eq.). To the stirred mixture was added 4-nitrophenyl 2,2,2-trifluoroethyl carbonate (164.6 mg, 0.621 mmol, 1.2 eq.).
The reaction mixture was stirred at it overnight. After the starting material disappeared (monitored by TLC), water (20 mL) and ethyl acetate (30 mL) were added to the mixture.
The content of the flask was transferred into a separatory funnel. The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel; DCM-methanol from 100:0 to 100:5), giving compound 6 (200 mg, 75%): 1H NMR (500 MHz, DMSO-d6): 8 ppm 2.73 (d, J=4.3 Hz, 3H), 5.15 (q, J=8.8 Hz, 2H), 7.20 (d, J=6.1 Hz, 1H), 7.35 (d, J=4.5 Hz, 3H), 7.41 (d, J=8.1 Hz, 111), 7.50 (d, J=6.6 Hz, 1H), 7.79 (t, J=11.8 Hz, 2H), 7.85 (t, J=7.9 Hz, 1H), 7.91 (d, J=16.4 Hz, 111), 8.08 (s, 1H), 8.32 (d, J=8.2 Hz, 1H), 8.38 (d, J=3.9 Hz, 1H), 8.64 (d, J=4.5 Hz, 1H); 13C
NMR (125 MHz, DMSO-d6): 8 ppm 25.98, 62.40, 116.08, 120.73, 122.02, 122.46, 123.20, 123.52, 124.23, 127.22, 127.85, 127.96, 130.37, 131.57, 133.19, 134.91, 137.00, 138.32, 138.45, 140.97, 148.02, 148.48, 149.71, 153.68, 167.65; m/z (ESI+):
513.0 (M +
H).
Into a flask were subsequently added axitinib (200 mg, 0.517 mmol, 1.0 eq.), DMF (4 mL), and triethylamine (104.7 mg, 1.03 mmol, 2.0 eq.). To the stirred mixture was added 4-nitrophenyl 2,2,2-trifluoroethyl carbonate (164.6 mg, 0.621 mmol, 1.2 eq.).
The reaction mixture was stirred at it overnight. After the starting material disappeared (monitored by TLC), water (20 mL) and ethyl acetate (30 mL) were added to the mixture.
The content of the flask was transferred into a separatory funnel. The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel; DCM-methanol from 100:0 to 100:5), giving compound 6 (200 mg, 75%): 1H NMR (500 MHz, DMSO-d6): 8 ppm 2.73 (d, J=4.3 Hz, 3H), 5.15 (q, J=8.8 Hz, 2H), 7.20 (d, J=6.1 Hz, 1H), 7.35 (d, J=4.5 Hz, 3H), 7.41 (d, J=8.1 Hz, 111), 7.50 (d, J=6.6 Hz, 1H), 7.79 (t, J=11.8 Hz, 2H), 7.85 (t, J=7.9 Hz, 1H), 7.91 (d, J=16.4 Hz, 111), 8.08 (s, 1H), 8.32 (d, J=8.2 Hz, 1H), 8.38 (d, J=3.9 Hz, 1H), 8.64 (d, J=4.5 Hz, 1H); 13C
NMR (125 MHz, DMSO-d6): 8 ppm 25.98, 62.40, 116.08, 120.73, 122.02, 122.46, 123.20, 123.52, 124.23, 127.22, 127.85, 127.96, 130.37, 131.57, 133.19, 134.91, 137.00, 138.32, 138.45, 140.97, 148.02, 148.48, 149.71, 153.68, 167.65; m/z (ESI+):
513.0 (M +
H).
[0093] Example 7: Synthesis of N-methy1-241-((lS)- (1-methoxycarbonylethyfflamino)(phenoxy) phosphiny1-34(1E)-2-(2-pyridinyfletheny1)- 1 H-indazo1-6-yl)thio)benzamide (compound 7) .
[0094]
The reaction mixture of axitinib (200 mg, 0.517 mmol, 1.0 eq.), DMF (4 mL), N-(chloro(phenyloxy)phosphiny1)-L-alanine methyl ester (172.4 mg, 0.621 mmol, 1.2 eq.), and triethylamine (104.7 mg, 1.03 mmol, 2.0 eq.) in a flask was stirred overnight at it, until the starting material disappeared as monitored by TLC, followed by addition of water (20 mL) and ethyl acetate (30 mL). The organic layer was separated (separatory funnel), washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel; DCM-methanol from 100:0 to 100:5), giving compound 7 (130 mg, 40%): 1H NMR (500 MHz, CD30D): 8 ppm 1.40 (d, J=22.1 Hz, 3H), 2.82 (s, 3H), 3.49 (d, J=65.4 Hz, 3H), 4.29 (s, 1H), 7.35-6.99 (m, 10H), 7.45 (s, 1H), 7.73 (d, J=73.1 Hz, 4H), 8.00 (d, J=48.9 Hz, 2H), 8.32 (s, 1H), 8.53 (s, 111); 13C NMR (125 MHz, CD30D):
8 ppm 20.24, 26.76, 51.82, 52.73, 117.3, 121.56, 122.44, 123.51, 123.80, 123.91, 124.09, 124.40, 126.71, 128.03, 128.31, 129.09, 130.76, 131.68, 133.24, 133.73, 13552, 137.85, 138.71, 139.41, 146.56, 149.22, 150.40, 150.45, 151.10, 151.15, 155.97, 171.47, 174.94;
31P NMR (203 MHz, DMSO-d6): 8 ppm -1.82, -2.52; m/z (ESI+): 628.1 (M + H).
The reaction mixture of axitinib (200 mg, 0.517 mmol, 1.0 eq.), DMF (4 mL), N-(chloro(phenyloxy)phosphiny1)-L-alanine methyl ester (172.4 mg, 0.621 mmol, 1.2 eq.), and triethylamine (104.7 mg, 1.03 mmol, 2.0 eq.) in a flask was stirred overnight at it, until the starting material disappeared as monitored by TLC, followed by addition of water (20 mL) and ethyl acetate (30 mL). The organic layer was separated (separatory funnel), washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel; DCM-methanol from 100:0 to 100:5), giving compound 7 (130 mg, 40%): 1H NMR (500 MHz, CD30D): 8 ppm 1.40 (d, J=22.1 Hz, 3H), 2.82 (s, 3H), 3.49 (d, J=65.4 Hz, 3H), 4.29 (s, 1H), 7.35-6.99 (m, 10H), 7.45 (s, 1H), 7.73 (d, J=73.1 Hz, 4H), 8.00 (d, J=48.9 Hz, 2H), 8.32 (s, 1H), 8.53 (s, 111); 13C NMR (125 MHz, CD30D):
8 ppm 20.24, 26.76, 51.82, 52.73, 117.3, 121.56, 122.44, 123.51, 123.80, 123.91, 124.09, 124.40, 126.71, 128.03, 128.31, 129.09, 130.76, 131.68, 133.24, 133.73, 13552, 137.85, 138.71, 139.41, 146.56, 149.22, 150.40, 150.45, 151.10, 151.15, 155.97, 171.47, 174.94;
31P NMR (203 MHz, DMSO-d6): 8 ppm -1.82, -2.52; m/z (ESI+): 628.1 (M + H).
[0095]
Example 8: N-methyl-2((1-pivaloy1-3((1E)-2- (2-ppidinyl)etheny1)- 1H-indazol-6-yl)thio)benzamide (compound 8).
Example 8: N-methyl-2((1-pivaloy1-3((1E)-2- (2-ppidinyl)etheny1)- 1H-indazol-6-yl)thio)benzamide (compound 8).
[0096]
Under nitrogen atmosphere, axitinib (400 mg, 1.04 mmol, 1.0 eq.), DCM (35 mL), and triethylamine (315.1 mg, 3.12 mmol, 3.0 eq.) were added to a flask and the mixture was cooled with an ice-water bath, followed by addition of pivaloyl chloride (188 mg, 1.24 mmol, 1.2 eq.) dropwise. After the addition was completed, the cold bath was removed and the mixture was stirred at it overnight. The reaction was monitored by TLC until the starting material was completely consumed. The mixture was then concentrated directly, and the residual material was purified (silica-gel; DCM-methanol from100:0 to 100:5), giving compound 8 (400 mg, 81%): 1H NMR (500 MHz, CDC13):
ppm 1.58 (s, 9H), 2.95 (d, J=4.8 Hz, 3H), 6.38 (s, 1H), 7.23-7.26 (m, 1H), 7.28-7.38 (m, 4H), 7.52 (d, J=7.8 Hz, 1H), 7.60-7.72 (m, 2H), 7.76 (s, 1H), 7.93 (dd, J=24.1, 12.2 Hz, 2H), 8.56 (s, 111), 8.67 (s, 111); 13C NMR (125 MHz, CDC13): 6 ppm 26.85, 27.97, 42.16, 119.02, 121.13, 122.74, 122.99, 123.20, 123.42, 127.75, 127.88, 129.10, 130.94, 133.00, 133.36, 133.69, 137.17, 137.67, 142.23, 146.12, 149.70, 154.54, 168.57, 178.39;
Ink (ESI+): 471.0 (M + H).
Under nitrogen atmosphere, axitinib (400 mg, 1.04 mmol, 1.0 eq.), DCM (35 mL), and triethylamine (315.1 mg, 3.12 mmol, 3.0 eq.) were added to a flask and the mixture was cooled with an ice-water bath, followed by addition of pivaloyl chloride (188 mg, 1.24 mmol, 1.2 eq.) dropwise. After the addition was completed, the cold bath was removed and the mixture was stirred at it overnight. The reaction was monitored by TLC until the starting material was completely consumed. The mixture was then concentrated directly, and the residual material was purified (silica-gel; DCM-methanol from100:0 to 100:5), giving compound 8 (400 mg, 81%): 1H NMR (500 MHz, CDC13):
ppm 1.58 (s, 9H), 2.95 (d, J=4.8 Hz, 3H), 6.38 (s, 1H), 7.23-7.26 (m, 1H), 7.28-7.38 (m, 4H), 7.52 (d, J=7.8 Hz, 1H), 7.60-7.72 (m, 2H), 7.76 (s, 1H), 7.93 (dd, J=24.1, 12.2 Hz, 2H), 8.56 (s, 111), 8.67 (s, 111); 13C NMR (125 MHz, CDC13): 6 ppm 26.85, 27.97, 42.16, 119.02, 121.13, 122.74, 122.99, 123.20, 123.42, 127.75, 127.88, 129.10, 130.94, 133.00, 133.36, 133.69, 137.17, 137.67, 142.23, 146.12, 149.70, 154.54, 168.57, 178.39;
Ink (ESI+): 471.0 (M + H).
[0097] Example 9: N-methy1-24(1-((1S)-(1-methoxycarbonylethyrnamino)(1-naphthoxy)phosphiny1-34(1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide (compound 10).
[0098]
1-naphthol (720 mg, 4.99 mmol, 1.0 eq.) and diethyl ether (20 mL) were placed in a flask. Under nitrogen atmosphere, the system was cooled at -78 t, followed by addition of phosphorus oxychloride (765 mg, 4.99 mmol, 1.0 eq.) and triethylamine (504 mg, 4.99 mmol, 1.0 eq.) dropwise and subsequently. The mixture was stirred at -78 C for 1 h. The reaction temperature was raised to rt gradually, and the mixture stirred at it overnight. The insoluble material was removed by filtration; and the filtrate was concentrated, giving 1-naphthyl phosphorodichloridate (1.2 g, 92%): 1H NMR
(500 MHz, CDC13): 6 ppm 7.47 (t, J=8.0 Hz, 1H), 7.53-7.68 (m, 3H), 7.82 (d, J=8.0 Hz, 1H), 7.91 (d, J=7.7 Hz, 1H), 8.10 (d, J=7.9 Hz, 1H).
1-naphthol (720 mg, 4.99 mmol, 1.0 eq.) and diethyl ether (20 mL) were placed in a flask. Under nitrogen atmosphere, the system was cooled at -78 t, followed by addition of phosphorus oxychloride (765 mg, 4.99 mmol, 1.0 eq.) and triethylamine (504 mg, 4.99 mmol, 1.0 eq.) dropwise and subsequently. The mixture was stirred at -78 C for 1 h. The reaction temperature was raised to rt gradually, and the mixture stirred at it overnight. The insoluble material was removed by filtration; and the filtrate was concentrated, giving 1-naphthyl phosphorodichloridate (1.2 g, 92%): 1H NMR
(500 MHz, CDC13): 6 ppm 7.47 (t, J=8.0 Hz, 1H), 7.53-7.68 (m, 3H), 7.82 (d, J=8.0 Hz, 1H), 7.91 (d, J=7.7 Hz, 1H), 8.10 (d, J=7.9 Hz, 1H).
[0099] 1-Naphthyl phosphorodichloridate (1.1 g, 4.2 mmol, 1.0 eq.), dichloromethane (30 mL), and L-alanine methyl ester hydrochloride (586 mg, 4.2 mmol, 1.0 eq.) were placed in a flask. Under nitrogen protection, the reaction system was cooled to -78 C, followed by dropwise addition of triethylamine (848 mg, 8.4 mmol, 2.0 eq.) to the mixture. After the addition was completed, the mixture was stirred at -78 C for 1 h.
Then the reaction mixture was warmed to rt, and stirred at it for 1 h. The mixture was concentrated; and the residual material was purified (silica-gel; pet-ether :
ethyl acetate from 100:0 to 50:50), giving (1-naphthoxy)((1S)- (1-methoxycarbonylehtypamino)phosphinyl chloride (790 mg, 57%): 1H NMR (500 MHz, CDC13): 5 ppm 1.55 (dd, J=11.6, 7.2 Hz, 311), 3.78 (d, J=25.2 Hz, 311), 4.31 (s, 111), 4.50 (dd, J=34.5, 11.2 Hz, 1H), 7.43 (t, J=7.6 Hz, 111), 7.57 (dd, 1=18.4, 7.1 Hz, 311), 7.73 (d, J=7.7 Hz, 1H), 7.87 (d, J=6.9 Hz, 1H), 8.07 (t, 1=6.7 Hz, 1H).
Then the reaction mixture was warmed to rt, and stirred at it for 1 h. The mixture was concentrated; and the residual material was purified (silica-gel; pet-ether :
ethyl acetate from 100:0 to 50:50), giving (1-naphthoxy)((1S)- (1-methoxycarbonylehtypamino)phosphinyl chloride (790 mg, 57%): 1H NMR (500 MHz, CDC13): 5 ppm 1.55 (dd, J=11.6, 7.2 Hz, 311), 3.78 (d, J=25.2 Hz, 311), 4.31 (s, 111), 4.50 (dd, J=34.5, 11.2 Hz, 1H), 7.43 (t, J=7.6 Hz, 111), 7.57 (dd, 1=18.4, 7.1 Hz, 311), 7.73 (d, J=7.7 Hz, 1H), 7.87 (d, J=6.9 Hz, 1H), 8.07 (t, 1=6.7 Hz, 1H).
[00100]
In a flask were placed, subsequently, axitinib (200 mg, 0.517 mmol, 1.0 eq.), DMF (4 nth), (1-naphthoxy)((1S)-(1-methoxycarbonylehtyl)amino)phosphinyl chloride (186.5 mg, 0.569 mmol, 1.1 eq.), and triethylamine (131.9 mg, 1.29 mmol, 2.5 eq.). The mixture was stirred at rt for 5 h, followed by addition of water (20 mL) and ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified on a silica-gel column (DCM-methanol, from 100:0 to 100:5), giving compound 10 (126.1 mg, 34%): 1H NMR (500 MHz, DMSO-d6): 5 ppm 1.28-1.38 (d, 3H), 2.76 (s, 3H), 3.35-3.50 (s, 3H), 4.35 (s, 111), 6.90 (d, J=9.6 Hz, 1H), 7.23-7.43 (m, 7H), 7.48 (s, 1H), 7.60 (dd, 1=21.1, 14.3 Hz, 3H), 7.66-7.77 (m, 2H), 7.87 (dd, J=20.2, 11.4 Hz, 3H), 8.12-8.29 (m, 3H), 8.42 (s, 1H), 8.65 (s, 1H); 13C NMR (125 MHz, DMSO-d6): 5 ppm 19.11, 19.63, 26.04, 50.05, 51.79, 115.10, 117.02, 121.53, 121.71, 121.99, 122.44, 123.25, 125.10, 125.47, 126.72, 126.30, 126.84, 127.58, 127.83, 129.69, 129.85, 130.22, 132.50, 134.22, 134.83, 134.98, 135.24, 136.9, 137.26, 144.87, 145.52, 147.16, 149.47, 153.86, 167.72, 173.07; m/z (ES4):
678.2 (M +
H).
In a flask were placed, subsequently, axitinib (200 mg, 0.517 mmol, 1.0 eq.), DMF (4 nth), (1-naphthoxy)((1S)-(1-methoxycarbonylehtyl)amino)phosphinyl chloride (186.5 mg, 0.569 mmol, 1.1 eq.), and triethylamine (131.9 mg, 1.29 mmol, 2.5 eq.). The mixture was stirred at rt for 5 h, followed by addition of water (20 mL) and ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified on a silica-gel column (DCM-methanol, from 100:0 to 100:5), giving compound 10 (126.1 mg, 34%): 1H NMR (500 MHz, DMSO-d6): 5 ppm 1.28-1.38 (d, 3H), 2.76 (s, 3H), 3.35-3.50 (s, 3H), 4.35 (s, 111), 6.90 (d, J=9.6 Hz, 1H), 7.23-7.43 (m, 7H), 7.48 (s, 1H), 7.60 (dd, 1=21.1, 14.3 Hz, 3H), 7.66-7.77 (m, 2H), 7.87 (dd, J=20.2, 11.4 Hz, 3H), 8.12-8.29 (m, 3H), 8.42 (s, 1H), 8.65 (s, 1H); 13C NMR (125 MHz, DMSO-d6): 5 ppm 19.11, 19.63, 26.04, 50.05, 51.79, 115.10, 117.02, 121.53, 121.71, 121.99, 122.44, 123.25, 125.10, 125.47, 126.72, 126.30, 126.84, 127.58, 127.83, 129.69, 129.85, 130.22, 132.50, 134.22, 134.83, 134.98, 135.24, 136.9, 137.26, 144.87, 145.52, 147.16, 149.47, 153.86, 167.72, 173.07; m/z (ES4):
678.2 (M +
H).
[00101] Example 10: Synthesis of N-methy1-24(14(1S)-(1-isopropoxycarbonylethyMamino)(phenoxy)phosphiny1-3-((lE)-2-(2-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide (compound 11).
[00102]
In a flask were added phenol (470 mg, 4.99 mmol, 1.0 eq.) and diethyl ether (20 mL). The reaction system was cooled to -78 C, followed by addition of phosphorus oxychloride (765 mg, 4.99 mmol, 1.0 eq.) and triethylamine (504 mg, 4.99 mmol, 1.0 eq.), dropwise. The mixture was stirred at -78 C for 1 h, then at rt overnight. The insoluble material was removed by filtration, and the filtrate was concentrated, giving phenyl dichlorophosphate (900 mg, 85%).
In a flask were added phenol (470 mg, 4.99 mmol, 1.0 eq.) and diethyl ether (20 mL). The reaction system was cooled to -78 C, followed by addition of phosphorus oxychloride (765 mg, 4.99 mmol, 1.0 eq.) and triethylamine (504 mg, 4.99 mmol, 1.0 eq.), dropwise. The mixture was stirred at -78 C for 1 h, then at rt overnight. The insoluble material was removed by filtration, and the filtrate was concentrated, giving phenyl dichlorophosphate (900 mg, 85%).
[00103]
In a flask were placed phenyl dichlorophosphate (882 mg, 4.2 mmol, 1.0 eq.), DCM (30 mL), and L-alanine isopropyl ester hydrochloride (701.4 mg, 4.2 mmol, 1.0 eq.). The reaction system was protected under nitrogen atmosphere and cooled to -78 C, followed by addition of triethylamine (848 mg, 8.4 mmol, 2.0 eq.). The mixture was stirred at -78 C for 1 h, at rt for 1 h, and then concentrated. The residual material was purified on silica-gel column (eluent, pet ether and ethyl acetate from 100:0 to 50:50), giving (phenoxy)((1S)-(1-isopropoxyethypamino)phosphinyl chloride (720 mg, 57%).
In a flask were placed phenyl dichlorophosphate (882 mg, 4.2 mmol, 1.0 eq.), DCM (30 mL), and L-alanine isopropyl ester hydrochloride (701.4 mg, 4.2 mmol, 1.0 eq.). The reaction system was protected under nitrogen atmosphere and cooled to -78 C, followed by addition of triethylamine (848 mg, 8.4 mmol, 2.0 eq.). The mixture was stirred at -78 C for 1 h, at rt for 1 h, and then concentrated. The residual material was purified on silica-gel column (eluent, pet ether and ethyl acetate from 100:0 to 50:50), giving (phenoxy)((1S)-(1-isopropoxyethypamino)phosphinyl chloride (720 mg, 57%).
[00104]
Subsequently added to a flask were axitinib (200 mg, 0.517 mmol, 1.0 eq.), DMF (4 mL), (phenoxy)((1S)-(1-isopropoxyethyl)amino))phosphinyl chloride (173.9 mg, 0.569 mmol, 1.1 eq.), and triethylamine (131.9 mg, 1.29 mmol, 2.5 eq.). The mixture was stirred at rt overnight (TLC indicating completion of the reaction), followed by addition of water (20 mL) and ethyl acetated (30 mL). The mixture was transferred into a separatory funnel; and the organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel; eluent, DCM-methanol, from 100:0 to 100:5), giving compound 11 (128.7 mg, 38%): 1H NMR (500 MHz, DMSO-d6): 5 ppm 0.97 (ddd, J=29.3, 28.5, 5.8 Hz, 6H), 1.30 (dd, J=27.7, 6.4 Hz, 3H), 2.76 (d, J=1.9 Hz, 3H), 4.20 (m, 1H), 4.69 (m, 1H), 6.86-7.00 (m, 1H), 7.00-7.21 (m, 4H), 7.29 (s, 5H), 7.41 (s, 1H), 7.50 (d, J=5.1 Hz, 1H), 7.68-7.89 (m, 2H), 7.97 (dd, J=23.9, 16.1 Hz, 2H), 8.15 (s, 1H), 8.25 (d, J=8.3 Hz, 1H), 8.43 (s, 1H), 8.67 (s, 1H); 13C
NMR (125 MHz, CDC13): i5 ppm 21.06, 21.72, 26.72, 50.51, 50.92, 69.47, 115.62, 115.71, 120.60, 121.39, 122.82, 123.15, 123.68, 123.86, 125.60, 126.32, 127.81, 129.02, 130.78, 131.66, 133.22, 136.74, 137.99, 145.5, 148.09, 148.84, 149.81, 154.31, 168.71, 172.66; m/z (ESI+): 656.1 (M + H).
Subsequently added to a flask were axitinib (200 mg, 0.517 mmol, 1.0 eq.), DMF (4 mL), (phenoxy)((1S)-(1-isopropoxyethyl)amino))phosphinyl chloride (173.9 mg, 0.569 mmol, 1.1 eq.), and triethylamine (131.9 mg, 1.29 mmol, 2.5 eq.). The mixture was stirred at rt overnight (TLC indicating completion of the reaction), followed by addition of water (20 mL) and ethyl acetated (30 mL). The mixture was transferred into a separatory funnel; and the organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel; eluent, DCM-methanol, from 100:0 to 100:5), giving compound 11 (128.7 mg, 38%): 1H NMR (500 MHz, DMSO-d6): 5 ppm 0.97 (ddd, J=29.3, 28.5, 5.8 Hz, 6H), 1.30 (dd, J=27.7, 6.4 Hz, 3H), 2.76 (d, J=1.9 Hz, 3H), 4.20 (m, 1H), 4.69 (m, 1H), 6.86-7.00 (m, 1H), 7.00-7.21 (m, 4H), 7.29 (s, 5H), 7.41 (s, 1H), 7.50 (d, J=5.1 Hz, 1H), 7.68-7.89 (m, 2H), 7.97 (dd, J=23.9, 16.1 Hz, 2H), 8.15 (s, 1H), 8.25 (d, J=8.3 Hz, 1H), 8.43 (s, 1H), 8.67 (s, 1H); 13C
NMR (125 MHz, CDC13): i5 ppm 21.06, 21.72, 26.72, 50.51, 50.92, 69.47, 115.62, 115.71, 120.60, 121.39, 122.82, 123.15, 123.68, 123.86, 125.60, 126.32, 127.81, 129.02, 130.78, 131.66, 133.22, 136.74, 137.99, 145.5, 148.09, 148.84, 149.81, 154.31, 168.71, 172.66; m/z (ESI+): 656.1 (M + H).
[00105] Example 11: Synthesis of N-methy1-24(14(1S)-(1-isopropoxycarbonylethyl))amino)(1-naphthoxy)phosphiny1-3-((1E)-2-(2-pyridinylletheny1)-1H-indazol-6-yfithio)benzamide (compound 12).
[00106]
In a flask were placed 1-naphthol (720 mg, 4.99 mmol, 1.0 eq.) and diethyl ether (20 mL). Under nitrogen protection, the reaction system was cooled to -78 C, followed by dropwise addition of phosphorus oxychloride (765 mg, 4.99 mmol, 1.0 eq.) and triethylamine (504 mg, 4.99 mmol, 1.0 eq.). The mixture was stirred at -78 C for 1 h, warmed up to it, and stirred at it overnight. The insoluble material was removed by filtration. The filtrate was concentrated, giving 1-naphthyl dichlorophosphate (1.2 g, 92%): 1H NMR (500 MHz, CDC13): 6 ppm 7.47 (t, J=8.0 Hz, 1H), 7.53-7.68 (m, 3H), 7.82 (d, J=8.0 Hz, 1H), 7.91 (d, J=7.7 Hz, 1H), 8.10 (4, J=7.9 Hz, 1H).
In a flask were placed 1-naphthol (720 mg, 4.99 mmol, 1.0 eq.) and diethyl ether (20 mL). Under nitrogen protection, the reaction system was cooled to -78 C, followed by dropwise addition of phosphorus oxychloride (765 mg, 4.99 mmol, 1.0 eq.) and triethylamine (504 mg, 4.99 mmol, 1.0 eq.). The mixture was stirred at -78 C for 1 h, warmed up to it, and stirred at it overnight. The insoluble material was removed by filtration. The filtrate was concentrated, giving 1-naphthyl dichlorophosphate (1.2 g, 92%): 1H NMR (500 MHz, CDC13): 6 ppm 7.47 (t, J=8.0 Hz, 1H), 7.53-7.68 (m, 3H), 7.82 (d, J=8.0 Hz, 1H), 7.91 (d, J=7.7 Hz, 1H), 8.10 (4, J=7.9 Hz, 1H).
[00107]
In a flask were added 1-naphthyl dichlorophosphate (1.1 g, 4.2 mmol, 1.0 eq.), DCM (30 mL), and L-alanine isopropyl ester hydrochloride (701.4 mg, 4.2 mmol, 1.0 eq.). The reaction system was protected with nitrogen atmosphere, and cooled to -78 C. To this cold mixture was added dropwise triethylamine (848 mg, 8.4 mmol, 2.0 eq.).
The mixture was stirred at -78 C for 1 h, then warmed to rt, and stirred at it for 1 h. Then the mixture was concentrated; and the residual material was purified (silica-gel; eluent, pet-ether : ethyl acetate from 100:0 to 50:50), providing ((18)-(1-isopropoxycarbonyflethyDarnino)(1-naphthoxy)phosphinyl chloride (800 mg, 53%):
NMR (500 MHz, CDC13): 8 ppm 1.23-1.34 (m, 611), 1.54 (t, J=8.4 Hz, 311), 2.05 (s, 111), 4.24 (dt, J=17.3, 8.8 Hz, 1H), 4.48 (dt, J=39.8, 10.7 Hz, 1H), 5.08 (ddd, J=18.6, 12.4, 6.2 Hz, 111), 7.44 (t, J=7.9 Hz, 111), 7.67-7.51 (m, 3H), 7.73 (d, J=8.1 Hz, 111), 7.87 (d, J=7.4 Hz, 1H), 8.08 (t, J=8.4 Hz, 1H).
In a flask were added 1-naphthyl dichlorophosphate (1.1 g, 4.2 mmol, 1.0 eq.), DCM (30 mL), and L-alanine isopropyl ester hydrochloride (701.4 mg, 4.2 mmol, 1.0 eq.). The reaction system was protected with nitrogen atmosphere, and cooled to -78 C. To this cold mixture was added dropwise triethylamine (848 mg, 8.4 mmol, 2.0 eq.).
The mixture was stirred at -78 C for 1 h, then warmed to rt, and stirred at it for 1 h. Then the mixture was concentrated; and the residual material was purified (silica-gel; eluent, pet-ether : ethyl acetate from 100:0 to 50:50), providing ((18)-(1-isopropoxycarbonyflethyDarnino)(1-naphthoxy)phosphinyl chloride (800 mg, 53%):
NMR (500 MHz, CDC13): 8 ppm 1.23-1.34 (m, 611), 1.54 (t, J=8.4 Hz, 311), 2.05 (s, 111), 4.24 (dt, J=17.3, 8.8 Hz, 1H), 4.48 (dt, J=39.8, 10.7 Hz, 1H), 5.08 (ddd, J=18.6, 12.4, 6.2 Hz, 111), 7.44 (t, J=7.9 Hz, 111), 7.67-7.51 (m, 3H), 7.73 (d, J=8.1 Hz, 111), 7.87 (d, J=7.4 Hz, 1H), 8.08 (t, J=8.4 Hz, 1H).
[00108] Axitinib (200 mg, 0.517 mmol, 1.0 eq.), DMF (4 mL), ((1S)-(1-isopropoxycarbonyflethyDamino)(1-naphthoxy)phosphinyl chloride (201.9 mg, 0.569 mmol, 1.1 eq.), and triethylamine (131.9 mg, 1.29 mmol, 2.5 eq.) were mixed in a flask, and stirred at it overnight. After the reaction was completed, water (20 mL) and ethyl acetate (30 mL) were added to the mixture. The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel;
DCM-methanol, from 100:0 to 100:5), giving compound 12 (112 mg, 30%): 111 NMR
(500 MHz, DMSO-d6): 6 ppm 0.96 (ddd, J=48.9, 35.2, 6.2 Hz, 6H), 1.31 (dd, J=57.4, 6.9 Hz, 3H), 2.76 (d, J=4.0 Hz, 3H), 4.18-4.53 (m, 1H), 4.71 (dd, J=11.8, 5.8 Hz, 1H), 6.82-6.97 (m, 1H), 7.18-7.42 (m, 7H), 7.48 (s, 1H), 7.64 (dt, J=31.8, 17.2 Hz, 5H), 7.78-7.94 (m, 3H), 8.13-8.23 (m, 2H), 8.27 (d, J=8.0 Hz, 1H), 8.39 (s, 1H), 8.63 (s, 1H); 13C NMR
(125 MHz, CDC13): 6 ppm 21.10, 21.71, 26.68, 50.59, 50.94, 69.50, 115.69, 121.33, 121.97, 122.87, 122.98, 123.05, 123.28, 125.46, 126.33, 126.50, 126.58, 126.81, 127.76, 129.01, 130.76, 133.20, 134.81, 136.74, 137.47, 138.12, 145.51, 146.04, 148.25, 149.21, 154.52, 168.65, 172.64; 31P NMR (203 MHz, DMSO-d6): 6 ppm -1.77, -2.22; raiz (ESI+): 706.2 (M + H).
DCM-methanol, from 100:0 to 100:5), giving compound 12 (112 mg, 30%): 111 NMR
(500 MHz, DMSO-d6): 6 ppm 0.96 (ddd, J=48.9, 35.2, 6.2 Hz, 6H), 1.31 (dd, J=57.4, 6.9 Hz, 3H), 2.76 (d, J=4.0 Hz, 3H), 4.18-4.53 (m, 1H), 4.71 (dd, J=11.8, 5.8 Hz, 1H), 6.82-6.97 (m, 1H), 7.18-7.42 (m, 7H), 7.48 (s, 1H), 7.64 (dt, J=31.8, 17.2 Hz, 5H), 7.78-7.94 (m, 3H), 8.13-8.23 (m, 2H), 8.27 (d, J=8.0 Hz, 1H), 8.39 (s, 1H), 8.63 (s, 1H); 13C NMR
(125 MHz, CDC13): 6 ppm 21.10, 21.71, 26.68, 50.59, 50.94, 69.50, 115.69, 121.33, 121.97, 122.87, 122.98, 123.05, 123.28, 125.46, 126.33, 126.50, 126.58, 126.81, 127.76, 129.01, 130.76, 133.20, 134.81, 136.74, 137.47, 138.12, 145.51, 146.04, 148.25, 149.21, 154.52, 168.65, 172.64; 31P NMR (203 MHz, DMSO-d6): 6 ppm -1.77, -2.22; raiz (ESI+): 706.2 (M + H).
[00109]
Example 12: N-methyl-2-41-(N-(t-butoxycarbony1)-L-phenylalany1)-3-(( 1 E) -2- ( 2-p yrid in y 1) e th e n y 1) - 1H-indazol-6-yl)thio)benzamide (compound 13).
Example 12: N-methyl-2-41-(N-(t-butoxycarbony1)-L-phenylalany1)-3-(( 1 E) -2- ( 2-p yrid in y 1) e th e n y 1) - 1H-indazol-6-yl)thio)benzamide (compound 13).
[00110] To a flask were added axitinib (300 mg, 0.778 mmol, 1.0 eq.), DMF (4 mL), N-Boc-L-phenylalanine (247 mg, 0.934 mmol, 1.2 eq.), N,N-diisopropylethylamine (151 mg, 1.16 mmol, 1.5 eq.), and HATU (354 mg, 0.934 mmol, 1.2 eq). The mixture was stirred at it overnight, followed by addition of water (20 mL) and ethyl acetate (30 mL).
The mixture was transferred to a separatory funnel; and the organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel; eluent, DCM-methanol, from 100:0 to 100:3), giving compound 13 (300 mg, 60%): 1H NMR (500 MHz, CD30D): 6 ppm 1.29 (m, 9H), 2.83 (d, J=18.4 Hz, 3H), 2.19-3.09 (in, 111), 3.21 (s, 111), 5.76 (s, 111), 7.17 (d, J=7.4 Hz, 1H), 7.25 (1, J=7.3 Hz, 211), 7.31 (d, J=6.5 Hz, 211), 7.38 (d, J=12.5 Hz, 511), 7.50 (s, 111), 7.77 (d, J=16.1 Hz, 2H), 7.86 (d, J=16.5 Hz, 2H), 8.08 (d, J=8.1 Hz, 1H), 8.39(s, 1H), 8.61(s, 1H); 13C NMR
(125MHz, CDC13): 6 ppm 26.69, 26.96, 28.26, 39.12, 49.38, 54.41, 79.96, 117.37, 12137, 123.18, 123.24, 126.95, 127.88, 128.43, 128.99, 129.37, 130.83, 133.08, 133.34, 134.33, 136.12, 137.04, 138.33, 140.87, 147.99, 149.68, 154.18, 155.19, 168.36, 171.81;
nVz(ESI+): 634.2 (M+H).
The mixture was transferred to a separatory funnel; and the organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel; eluent, DCM-methanol, from 100:0 to 100:3), giving compound 13 (300 mg, 60%): 1H NMR (500 MHz, CD30D): 6 ppm 1.29 (m, 9H), 2.83 (d, J=18.4 Hz, 3H), 2.19-3.09 (in, 111), 3.21 (s, 111), 5.76 (s, 111), 7.17 (d, J=7.4 Hz, 1H), 7.25 (1, J=7.3 Hz, 211), 7.31 (d, J=6.5 Hz, 211), 7.38 (d, J=12.5 Hz, 511), 7.50 (s, 111), 7.77 (d, J=16.1 Hz, 2H), 7.86 (d, J=16.5 Hz, 2H), 8.08 (d, J=8.1 Hz, 1H), 8.39(s, 1H), 8.61(s, 1H); 13C NMR
(125MHz, CDC13): 6 ppm 26.69, 26.96, 28.26, 39.12, 49.38, 54.41, 79.96, 117.37, 12137, 123.18, 123.24, 126.95, 127.88, 128.43, 128.99, 129.37, 130.83, 133.08, 133.34, 134.33, 136.12, 137.04, 138.33, 140.87, 147.99, 149.68, 154.18, 155.19, 168.36, 171.81;
nVz(ESI+): 634.2 (M+H).
[00111]
Example 13: N-methy1-2-((1-(N-(t-butoxycarbony1)-L-histidy1)-3-((1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide (compound 14).
Example 13: N-methy1-2-((1-(N-(t-butoxycarbony1)-L-histidy1)-3-((1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide (compound 14).
[00112] To a flask were added axitinib (300 mg, 0.78 mmol, 1.0 eq.), DMF (6 mL), N(a)-(t-Boc)-L-histidine (219 mg, 0.86 mmol, 1.1 eq.), DPPA (234 mg, 0.86 mmol, 1.1 eq.), and triethylamine (95 mg, 0.94 mmol, 1.2 eq.). The mixture was stirred at it overnight, followed by addition of water (20 mL) and ethyl acetate (30 mL).
The mixture was transferred to a separatory funnel; and the organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel;
eluent, DCM-methanol, 10:1), giving compound 14 (195 mg, 40.1%): 1H NMR (500 MHz, CD30D): 6 ppm 1.30 (d, J=65.8 Hz, 9H), 2.76 (s, 311), 3.10 (s, 2H), 558 (s, 1H), 6.84 (s, 1H), 7.64-7.03 (m, 8H), 8.01-7.65 (m, 4H), 8.35 (dd, J=24.2, 15.7 Hz, 3H), 8.67 (s, 1H); 13C NMR (125 MHz, DMSO-d6): 6 ppm 26.50, 28.60, 29.22, 54.00, 55.32, 79.04, 117.76, 121.57, 122.85, 124.04, 127.52, 128.24, 128.45, 128.98, 130.84, 131.79, 134.22, 135.23, 135.32, 137.54, 138.49, 138.75, 14038, 147.65, 150.25, 154.28, 155.83, 168.19, 172.60; miz (ESI+): 624.4(M+H).
The mixture was transferred to a separatory funnel; and the organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel;
eluent, DCM-methanol, 10:1), giving compound 14 (195 mg, 40.1%): 1H NMR (500 MHz, CD30D): 6 ppm 1.30 (d, J=65.8 Hz, 9H), 2.76 (s, 311), 3.10 (s, 2H), 558 (s, 1H), 6.84 (s, 1H), 7.64-7.03 (m, 8H), 8.01-7.65 (m, 4H), 8.35 (dd, J=24.2, 15.7 Hz, 3H), 8.67 (s, 1H); 13C NMR (125 MHz, DMSO-d6): 6 ppm 26.50, 28.60, 29.22, 54.00, 55.32, 79.04, 117.76, 121.57, 122.85, 124.04, 127.52, 128.24, 128.45, 128.98, 130.84, 131.79, 134.22, 135.23, 135.32, 137.54, 138.49, 138.75, 14038, 147.65, 150.25, 154.28, 155.83, 168.19, 172.60; miz (ESI+): 624.4(M+H).
[00113] Example 14: Synthesis of N-methy1-2-((1-(4-fluorophenoxy)((lS)-(1-methoxycarbonylethyl))amino)phosphinyl-34(1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-ynthio)benzamide (compound 15).
[00114]
In a flask were placed 4-fluorophenol (4.3 g, 38.7 mmol, 1.0 eq.) and diethyl ether (20 mL). The reaction system was protected with nitrogen atmosphere and cooled to -78 C, followed by dropwise addition of phosphorus oxychloride (6 g, 38.7 mmol, 1.0 eq.) and triethylamine (3.92 g, 38.7 mmol, 1.0 eq.). The mixture was stirred for 1 h at -78 C. The temperature of the reaction was gradually raised to rt; and then the mixture was stirred at it for 1 h. The insoluble material was removed by filtration; and the filtrate was concentrated, giving 4-fluorophenyl phosphorodichloridate (8 g, 90%).
In a flask were placed 4-fluorophenol (4.3 g, 38.7 mmol, 1.0 eq.) and diethyl ether (20 mL). The reaction system was protected with nitrogen atmosphere and cooled to -78 C, followed by dropwise addition of phosphorus oxychloride (6 g, 38.7 mmol, 1.0 eq.) and triethylamine (3.92 g, 38.7 mmol, 1.0 eq.). The mixture was stirred for 1 h at -78 C. The temperature of the reaction was gradually raised to rt; and then the mixture was stirred at it for 1 h. The insoluble material was removed by filtration; and the filtrate was concentrated, giving 4-fluorophenyl phosphorodichloridate (8 g, 90%).
[00115] To a flask were added subsequently 4-fluorophenyl phosphorodichloridate (8 g, 35.2 mmol, 1.0 eq.), DCM (30 mL), and L-alanine methyl ester hydrochloride (3.20 g, 27.1 mmol, 0.8 eq.). The mixture, under nitrogen atmosphere, was cooled at -78 C, followed by dropwise addition of triethylamine (7.84 g, 77.4 mmol, 2.4 eq.).
The mixture was stirred for 1 h at -78 C. The temperature of the reaction was gradually raised to it and then the mixture was stirred at rt for 1 h. The mixture was then concentrated; and the residual material was purified (silica-gel; eluent: pet-ether and ethyl acetate, from 100:0 to 50:50), giving (4-fluorophenoxy)((1S)-(1-methoxycarbonylethyl))amino)phosphinyl chloride (3.0 g, 38%).
The mixture was stirred for 1 h at -78 C. The temperature of the reaction was gradually raised to it and then the mixture was stirred at rt for 1 h. The mixture was then concentrated; and the residual material was purified (silica-gel; eluent: pet-ether and ethyl acetate, from 100:0 to 50:50), giving (4-fluorophenoxy)((1S)-(1-methoxycarbonylethyl))amino)phosphinyl chloride (3.0 g, 38%).
[00116] To a flask were added axitinib (400 mg, 1.03 mmol, 1.0 eq.), N,N-dimethylformamide (6 mL), (4-fluorophenoxy)((lS)-(1-methoxycarbonylethyl))amino)phosphinyl chloride (678.5 mg, 2.30 mmol, 2.2 eq.), and triethylamine (260.5 mg, 2.6 mmol, 2.5 eq.). The mixture was stirred at it for 5 h, followed by addition of water (20 mL) and ethyl acetate (30 mL) for extraction. The organic layer was separated, washed with brine (3 x 30 mL), and concentrated.
The residual material was purified (silica-gel; DCM-methanol from 100:0 to 100:2), providing compound 15 (205 mg, 31.7 %): 111 NMR (500 MHz, CD30D): 81.42 (dd, J=16.2, 6.7 Hz, 31I), 2.84 (s, 31I), 3.54 (d, J=61.5 Hz, 3H), 4.32 (d, J=34.9 Hz, 1H), 6.98 (s, 2H), 7.15(d, J=23.4 Hz, 3H), 7.28-7.43 (m, 4H), 7.48 (s, 1H), 7.2 Hz, 2H), 7.72 (dd, J=16.5, 2H), 7.83 (d, J=16.3 Hz, 2H), 8.00-8.04(m, 2H), 8.59 (s, 1H); 13C NMR
(125 MHz, CD30D): 5 18.81, 25.33, 50.86, 115.80, 121.03, 121.91, 122.39, 122.57, 123.05, 126.66, 127.02, 127.74, 130.29, 132.22, 134.00, 136.70, 137.37, 138.23, 145.23, 145.67, 148.00, 149.03, 154.63, 159.05, 160.98, 170.14, 173.33; 31P NMR (203 MHz, CD30D):
-2.22, -1.77; m/z (ESL): 644.1 (M-H).
The residual material was purified (silica-gel; DCM-methanol from 100:0 to 100:2), providing compound 15 (205 mg, 31.7 %): 111 NMR (500 MHz, CD30D): 81.42 (dd, J=16.2, 6.7 Hz, 31I), 2.84 (s, 31I), 3.54 (d, J=61.5 Hz, 3H), 4.32 (d, J=34.9 Hz, 1H), 6.98 (s, 2H), 7.15(d, J=23.4 Hz, 3H), 7.28-7.43 (m, 4H), 7.48 (s, 1H), 7.2 Hz, 2H), 7.72 (dd, J=16.5, 2H), 7.83 (d, J=16.3 Hz, 2H), 8.00-8.04(m, 2H), 8.59 (s, 1H); 13C NMR
(125 MHz, CD30D): 5 18.81, 25.33, 50.86, 115.80, 121.03, 121.91, 122.39, 122.57, 123.05, 126.66, 127.02, 127.74, 130.29, 132.22, 134.00, 136.70, 137.37, 138.23, 145.23, 145.67, 148.00, 149.03, 154.63, 159.05, 160.98, 170.14, 173.33; 31P NMR (203 MHz, CD30D):
-2.22, -1.77; m/z (ESL): 644.1 (M-H).
[00117] Example 15: Synthesis of N-methy1-241-(( 1 S)-(1-methoxycarbonylethyfflarnino)(4-methylphenoxy)phosphiny1-34(1E1-2- (2-nvridinyl)etheny1)-1H-indazol-6-y1)thio)benzamide (compound 17).
[00118] To a flask were added 4-methylphenol (5 g, 46.2 mmol, 1.0 eq.) and diethyl ether (200 mL). The reaction system was protected with nitrogen atmosphere and cooled to -78 C, followed by dropwise addition of phosphorus oxychloride (7.1 g, 46.2 mmol, 1.0 eq.) and triethylamine (4.66 g, 46.2 mmol, 1.0 eq.). The mixture was stirred for 1 h at -78 C. The temperature of the reaction was gradually raised to it; and then the mixture was stirred at it for 1 h. The insoluble material was removed by filtration;
and the filtrate was concentrated, giving 4-methylphenyl phosphorodichloridate (9.0 g, 87%).
and the filtrate was concentrated, giving 4-methylphenyl phosphorodichloridate (9.0 g, 87%).
[00119] 4-methylphenyl phosphorodichloridate (7.29 g, 32.37 mmol, 1.0 eq.), DCM
(150 mL), and L-alanine methyl ester hydrochloride (4.52 g, 32.37 mmol, 1.0 eq.) were added in a flask. The reaction system was protected with nitrogen atmosphere and cooled to -78 C, followed by dropwise addition of triethylamine (6.54 g, 64.74 mmol, 2.0 eq.).
The mixture was stirred for 1 h at -78 C. The temperature of the reaction was gradually raised to rt; and then the mixture was stirred at it for 1 h. The mixture was concentrated;
and the residual material was purified (silica-gel; pet-ether and ethyl acetate, from 100:0 to 50:50), providing ((1S)-(1-methoxycarbonylethyDamino)(4-methylphenoxy)phosphinyl chloride (1.4 g, 30%): 1H NMR (500 MHz, CDC13): 5 ppm 1.51 (d, J=4.7 Hz, 3H), 2.32 (s, 3H), 3.78 (d, J=8.5 Hz, 3H), 4.18 (d, J=7.7 Hz, 1H), 4.42 (d, J=28.9 Hz, 1H), 7.11 (d, J=30.0 Hz, 4H).
(150 mL), and L-alanine methyl ester hydrochloride (4.52 g, 32.37 mmol, 1.0 eq.) were added in a flask. The reaction system was protected with nitrogen atmosphere and cooled to -78 C, followed by dropwise addition of triethylamine (6.54 g, 64.74 mmol, 2.0 eq.).
The mixture was stirred for 1 h at -78 C. The temperature of the reaction was gradually raised to rt; and then the mixture was stirred at it for 1 h. The mixture was concentrated;
and the residual material was purified (silica-gel; pet-ether and ethyl acetate, from 100:0 to 50:50), providing ((1S)-(1-methoxycarbonylethyDamino)(4-methylphenoxy)phosphinyl chloride (1.4 g, 30%): 1H NMR (500 MHz, CDC13): 5 ppm 1.51 (d, J=4.7 Hz, 3H), 2.32 (s, 3H), 3.78 (d, J=8.5 Hz, 3H), 4.18 (d, J=7.7 Hz, 1H), 4.42 (d, J=28.9 Hz, 1H), 7.11 (d, J=30.0 Hz, 4H).
[00120]
To a flask were added subsequently axitinib (450 mg, 1.16 mmol, 1.0 eq.), DMF (15 mL), ((1S-1-methoxycarbonylethyDamino)(4-methylphenoxy)phosphinyl chloride (1.37 g, 4.66 mmol, 4.0 eq.), and triethylamine (476 mg, 4.66 mmol, 4.0 eq.).
The mixture was stirred at it for 16 h, followed by addition of water and ethyl acetate (60 mL each). The organic layer was separated, washed with brine (3 x 60 mL), and concentrated. The residual material was purified on a silica-gel column (eluent, DCM-methanol, from 100:0 to 100:5, v/v), giving compound 17 (300 mg, 40%): 1H NMR
(500 MHz, DMSO-d6): ö ppm 1.31 (dd, J=20.8, 6.8 Hz, 3H), 2.76 (d, J=4.0 Hz, 3H), 3.43 (d, J=56.9 Hz, 3H), 4.25 (s, 1H), 7.14-6.91 (m, 6H), 7.32 (d, J=23.1 Hz, 4H), 7.49 (s, 1H), 7.72 (dd, J=20.0, 10.5 Hz, 2H), 8.00-7.82 (m, 2H), 8.12 (d, J=5.6 Hz, 1H), 8.25 (d, J=8.1 Hz, 111), 8.39 (s, 111), 8.64 (s, 111); 13C NMR (125 MHz, DMSO-d6): 5 ppm 19.34, 20.10, 25.98, 50.02, 51.66, 116.88, 119.91, 121.69, 121.96, 122.33, 123.11, 126.25, 12732, 127.80, 129.74, 129.91, 130.01, 130.15, 132.71, 134.46, 134.82, 135.11, 136.94, 137.07, 144.82, 147.05, 147.31, 149.64, 154.06, 167.66, 173.03; 31P NMR (203 MHz, DMSO-d6): 5 ppm -1.78, -2.54; m/z (ESI+): 642.1 (M + H).
To a flask were added subsequently axitinib (450 mg, 1.16 mmol, 1.0 eq.), DMF (15 mL), ((1S-1-methoxycarbonylethyDamino)(4-methylphenoxy)phosphinyl chloride (1.37 g, 4.66 mmol, 4.0 eq.), and triethylamine (476 mg, 4.66 mmol, 4.0 eq.).
The mixture was stirred at it for 16 h, followed by addition of water and ethyl acetate (60 mL each). The organic layer was separated, washed with brine (3 x 60 mL), and concentrated. The residual material was purified on a silica-gel column (eluent, DCM-methanol, from 100:0 to 100:5, v/v), giving compound 17 (300 mg, 40%): 1H NMR
(500 MHz, DMSO-d6): ö ppm 1.31 (dd, J=20.8, 6.8 Hz, 3H), 2.76 (d, J=4.0 Hz, 3H), 3.43 (d, J=56.9 Hz, 3H), 4.25 (s, 1H), 7.14-6.91 (m, 6H), 7.32 (d, J=23.1 Hz, 4H), 7.49 (s, 1H), 7.72 (dd, J=20.0, 10.5 Hz, 2H), 8.00-7.82 (m, 2H), 8.12 (d, J=5.6 Hz, 1H), 8.25 (d, J=8.1 Hz, 111), 8.39 (s, 111), 8.64 (s, 111); 13C NMR (125 MHz, DMSO-d6): 5 ppm 19.34, 20.10, 25.98, 50.02, 51.66, 116.88, 119.91, 121.69, 121.96, 122.33, 123.11, 126.25, 12732, 127.80, 129.74, 129.91, 130.01, 130.15, 132.71, 134.46, 134.82, 135.11, 136.94, 137.07, 144.82, 147.05, 147.31, 149.64, 154.06, 167.66, 173.03; 31P NMR (203 MHz, DMSO-d6): 5 ppm -1.78, -2.54; m/z (ESI+): 642.1 (M + H).
[00121] Example 16: Synthesis of N-methy1-24(1-(4-chlorophenoxy)((lS)-(1-methoxycarbonylethyl))amino)phosphinyl-34(1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide (compound 19).
[00122]
To a flask were added 4-chlorophenol (4.2 g, 38.7 mmol, 1.0 eq.) and diethyl ether (20 mL). The reaction system was protected with nitrogen atmosphere and cooled to -78 t, followed by dropwise addition of phosphorus oxychloride (6 g, 38.7 mmol, 1.0 eq.) and triethylamine (3.92 g, 38.7 mmol, 1.0 eq.). The mixture was stirred for 1 h at -78 C. The temperature of the reaction was gradually raised to rt; and then the mixture was stirred at it overnight. The insoluble material was removed by filtration; and the filtrate was concentrated, giving 4-chlorophenyl phosphorodichloridate (8.0 g, 85%).
To a flask were added 4-chlorophenol (4.2 g, 38.7 mmol, 1.0 eq.) and diethyl ether (20 mL). The reaction system was protected with nitrogen atmosphere and cooled to -78 t, followed by dropwise addition of phosphorus oxychloride (6 g, 38.7 mmol, 1.0 eq.) and triethylamine (3.92 g, 38.7 mmol, 1.0 eq.). The mixture was stirred for 1 h at -78 C. The temperature of the reaction was gradually raised to rt; and then the mixture was stirred at it overnight. The insoluble material was removed by filtration; and the filtrate was concentrated, giving 4-chlorophenyl phosphorodichloridate (8.0 g, 85%).
[00123]
In a flask were placed 4-chlorophenyl phosphorodichloridate (8.0 g, 32.9 mmol, 1.0 eq.), DCM (30 mL), and L-alanine methyl ester hydrochloride (3.20 g, 27.1 mmol, 0.8 eq.). The reaction system was protected with nitrogen atmosphere and cooled to -78 C, followed by dropwise addition of triethylamine (7.84 g, 77.4 mmol, 2.4 eq.).
The mixture was stirred for 1 h at -78 C. The temperature of the reaction was gradually raised to it; and then the mixture was stirred at it for 1 h. The mixture was concentrated;
and the residual material was purified (silica-gel; pet-ether and ethyl acetate, from 100:0 to 50:50), providing (4-chlorophenoxy)((1S-1-methoxycarbonylethyDamino)phosphinyl chloride (3.0 g, 42%).
In a flask were placed 4-chlorophenyl phosphorodichloridate (8.0 g, 32.9 mmol, 1.0 eq.), DCM (30 mL), and L-alanine methyl ester hydrochloride (3.20 g, 27.1 mmol, 0.8 eq.). The reaction system was protected with nitrogen atmosphere and cooled to -78 C, followed by dropwise addition of triethylamine (7.84 g, 77.4 mmol, 2.4 eq.).
The mixture was stirred for 1 h at -78 C. The temperature of the reaction was gradually raised to it; and then the mixture was stirred at it for 1 h. The mixture was concentrated;
and the residual material was purified (silica-gel; pet-ether and ethyl acetate, from 100:0 to 50:50), providing (4-chlorophenoxy)((1S-1-methoxycarbonylethyDamino)phosphinyl chloride (3.0 g, 42%).
[00124]
Axitinib (400 mg, 1.03 mmol, 1.0 eq.), DMF (6 mL), (4-chlorophenoxy)((1S-1-methoxycarbonylethyl)amino)phosphinyl chloride (702.5 mg, 2.30 mmol, 2.2 eq.), and triethylamine (260.5 mg, 2.6 mmol, 2.5 eq.) were subsequently placed in a flask. The mixture was stirred at it for 5 h, followed by addition of water (20 mL) and ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 nth), and concentrated. The residual material was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 100:2), giving compound 19 (210 mg, 30.8%): 111 NMR
(500 MHz, CD30D) 6 1.43 (s, 311), 2.84 (s, 311), 3.53 (d, J = 60.8 Hz, 311), 4.31 (d, J = 32.5 Hz, 1H), 7.22 (dd, J = 60.7, 41.0 Hz, 9H), 7.48 (s, 1H), 7.84 (s, 2H), 8.04 (s, 2H), 7.71 (s, 2H), 8.30 (s, 1H), 857 (s, 1H); 13C NMR (125 MHz, CD30D) 8 25.32, 50.24, 115.73, 121.84, 122.58, 123.08, 126.63, 127.08, 127.76, 129.35, 130.32, 130.69, 132.10, 132.47, 133.91, 136.85, 137.42, 138.33, 148.39, 149.02, 154.63, 170.16; 31P NMR (203 MHz, CD30D) 5-1.47, -0.88; nah(ESI-): 660.1 (M-H).
Axitinib (400 mg, 1.03 mmol, 1.0 eq.), DMF (6 mL), (4-chlorophenoxy)((1S-1-methoxycarbonylethyl)amino)phosphinyl chloride (702.5 mg, 2.30 mmol, 2.2 eq.), and triethylamine (260.5 mg, 2.6 mmol, 2.5 eq.) were subsequently placed in a flask. The mixture was stirred at it for 5 h, followed by addition of water (20 mL) and ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 nth), and concentrated. The residual material was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 100:2), giving compound 19 (210 mg, 30.8%): 111 NMR
(500 MHz, CD30D) 6 1.43 (s, 311), 2.84 (s, 311), 3.53 (d, J = 60.8 Hz, 311), 4.31 (d, J = 32.5 Hz, 1H), 7.22 (dd, J = 60.7, 41.0 Hz, 9H), 7.48 (s, 1H), 7.84 (s, 2H), 8.04 (s, 2H), 7.71 (s, 2H), 8.30 (s, 1H), 857 (s, 1H); 13C NMR (125 MHz, CD30D) 8 25.32, 50.24, 115.73, 121.84, 122.58, 123.08, 126.63, 127.08, 127.76, 129.35, 130.32, 130.69, 132.10, 132.47, 133.91, 136.85, 137.42, 138.33, 148.39, 149.02, 154.63, 170.16; 31P NMR (203 MHz, CD30D) 5-1.47, -0.88; nah(ESI-): 660.1 (M-H).
[00125]
Example 17: Synthesis of N-methy1-24(1-ethoxycaybony1-34(1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide (compound 22).
Example 17: Synthesis of N-methy1-24(1-ethoxycaybony1-34(1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide (compound 22).
[00126] To a flask were added ethanol (0.5g, 11.0 mmol, 1.0 eq.), THF (50 mL), and triethylamine (2.4 g, 23.9 mmol, 2.2 eq.). The reaction mixture was cooled to 0 C (ice-water bath), followed by addition to the mixture of a solution of p-nitrophenyl chloroformate (4.3 g, 21.7 mmol, 2.0 eq.) in THF (30 mL), dropwise. After completion of the addition, the reaction temperature was raised to it. The mixture was stirred at it for 4 h, and then concentrated. To the residual material were added water and ethyl acetate (40 mL each). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified on a silica-gel column (eluent, pet-ether and ethyl acetate from 100:0 to 95:5), giving ethyl p-nitrophenyl carbonate (1.5g, 65.2%).
[00127] To a flask were added axitinib (400 mg, 1.03 mmol, 1.0 eq.), DMF (12 mL), and triethylamine (312.1 mg, 3.09 mmol, 3.0 eq.). To the stirred mixture was added ethyl p-nitrophenyl carbonate (282.7mg, 1.34 mmol, 1.3 eq.). The mixture was further stirred at it overnight, followed by addition of water (50 mL) and ethyl acetate (90 mL). The organic layer was separated, washed with brine (3 x 70 mL), and concentrated.
The residual material was purified on a silica-gel column (eluent: DCM-methanol from 100:0 to 100:3), giving compound 22 (350 mg, 74.3%): 1H NMR (500 MHz, DMSO-d6): 6 ppm 1.36 (t, J = 7.1 Hz, 3H), 2.75 (d, J = 4.7 Hz, 3H), 4.48 (q, I = 7.0 Hz, 2H), 7.21 (d, J
= 7.4 Hz, 1H), 7.32-7.43 (m, 4H), 7.52 (d, J = 7.2 Hz, 1H), 7.79 (dd, J =
12.0, 8.2 Hz, 2H), 7.87 (t, J = 7.8 Hz, 1H), 7.93 (d, J = 16.4 Hz, 1H), 8.12 (s, 1H), 8.31 (d, J = 8.5 Hz, 1H), 8.40 (d, J = 4.6 Hz, 1H), 8.66 (d, J = 4.3 Hz, 1H);13C NMR (125 MHz, DMS0416):
appin 14.06, 26.03, 63.95, 116.34, 121.03, 122.20, 122.97, 123.45, 126.98, 127.28, 127.96, 130.40, 131.59, 133.38, 134.18, 137.02, 137.70, 138.47, 140.90, 146.90, 149.76, 153.84, 167.72; m/z(ESI-F): 459.2(M+H).
The residual material was purified on a silica-gel column (eluent: DCM-methanol from 100:0 to 100:3), giving compound 22 (350 mg, 74.3%): 1H NMR (500 MHz, DMSO-d6): 6 ppm 1.36 (t, J = 7.1 Hz, 3H), 2.75 (d, J = 4.7 Hz, 3H), 4.48 (q, I = 7.0 Hz, 2H), 7.21 (d, J
= 7.4 Hz, 1H), 7.32-7.43 (m, 4H), 7.52 (d, J = 7.2 Hz, 1H), 7.79 (dd, J =
12.0, 8.2 Hz, 2H), 7.87 (t, J = 7.8 Hz, 1H), 7.93 (d, J = 16.4 Hz, 1H), 8.12 (s, 1H), 8.31 (d, J = 8.5 Hz, 1H), 8.40 (d, J = 4.6 Hz, 1H), 8.66 (d, J = 4.3 Hz, 1H);13C NMR (125 MHz, DMS0416):
appin 14.06, 26.03, 63.95, 116.34, 121.03, 122.20, 122.97, 123.45, 126.98, 127.28, 127.96, 130.40, 131.59, 133.38, 134.18, 137.02, 137.70, 138.47, 140.90, 146.90, 149.76, 153.84, 167.72; m/z(ESI-F): 459.2(M+H).
[00128]
Example 18: Synthesis of N-methy1-24(1-dodecyloxycaybony1-34(1E)-2- (2-nridinyl)etheny1)-1H-indazol-6-yl)thio)benzamide (compound 25).
Example 18: Synthesis of N-methy1-24(1-dodecyloxycaybony1-34(1E)-2- (2-nridinyl)etheny1)-1H-indazol-6-yl)thio)benzamide (compound 25).
[00129]
1-Dodecanol (3 g, 16.1 mmol, 1.0 eq.), THE (50 mL), and triethylamine (4.88 g, 48.3 mmol, 3.0 eq.) were placed in a flask and cooled to 0 C (ice-water bath), followed by addition, dropwise, of a solution of p-nitrophenyl chloroformate (3.89 g, 19.32 mmol, 1.2 eq.) in THE (30 mL). After addition, the temperature of the reaction was raised to it; and the mixture was stirred at rt for 4 h, then concentrated to remove most of the solvent, followed by addition of water and ethyl acetate (40 mL each). The organic layer was separated and concentrated. The residue was purified (silica-gel column;
eluent, pet-ether to ethyl acetate from 100:0 to 95:5), providing 1-dodecyl p-nitrophenyl carbonate (4.1 g, 71.8%).
1-Dodecanol (3 g, 16.1 mmol, 1.0 eq.), THE (50 mL), and triethylamine (4.88 g, 48.3 mmol, 3.0 eq.) were placed in a flask and cooled to 0 C (ice-water bath), followed by addition, dropwise, of a solution of p-nitrophenyl chloroformate (3.89 g, 19.32 mmol, 1.2 eq.) in THE (30 mL). After addition, the temperature of the reaction was raised to it; and the mixture was stirred at rt for 4 h, then concentrated to remove most of the solvent, followed by addition of water and ethyl acetate (40 mL each). The organic layer was separated and concentrated. The residue was purified (silica-gel column;
eluent, pet-ether to ethyl acetate from 100:0 to 95:5), providing 1-dodecyl p-nitrophenyl carbonate (4.1 g, 71.8%).
[00130] To a flask were added axitinib (400 mg, 1.03 mmol, 1.0 eq.), DMF (12 mL), and triethylamine (312.1 mg, 3.09 mmol, 3.0 eq.). To the mixture under effective stirring was added 1-dodecyl p-nitrophenyl carbonate (472 mg, 1.34 mmol, 1.3 eq.). The latter mixture was stirred at rt for 3 h, followed by addition to the mixture of water (50 mL) and ethyl acetate (90 mL). The organic layer was separated, washed with brine (3 x 70 mL), and concentrated. The residual material was purified (silica-gel column;
eluent DCM-methanol from 100:0 to 100:3), giving compound 25 (512 mg, 82.3%): 1H NMR (500 MHz, CDC13) 6 ppm 0.87 (t, J=6.8 Hz, 3H), 1.26 (s, 14H), 1.34 (d, J=14.4 Hz, 2H), 1.39-1.50 (m, 2H), 1.78-1.93 (m, 2H), 2.95 (d, 1=4.9 Hz, 3H), 4.50 (t, J=7.0 Hz, 2H), 6.38 (s, 1H), 7.19-7.25 (m, 1H), 7.29-7.38 (m, 4H), 7.49 (d, J=7.7 Hz, 1H), 7.62-7.68 (m, 1H), 7.68-7.75 (m, 2H), 7.87 (d, .1=16.4 Hz, 1H), 7.97 (d, J=8.4 Hz, 1H), 8.23 (s, 1H), 8.65 (d, J=4.3 Hz, 1H); 13C NMR (125 MHz, CDC13) 6 ppm 14.15, 22.70, 25.71, 26.78, 28.66, 29.25, 29.36, 29.52, 29.59, 29.65, 31.92, 68.42, 116.89, 121.56, 121.70, 122.62, 123.74, 127.14, 127.68, 128.86, 130.84, 132.84, 133.41, 134.49, 136.75, 137.64, 137.82, 141.44, 147.70, 149.87, 150.57, 154.56, 168.47; raiz (ESI+): 599A (M + H).
eluent DCM-methanol from 100:0 to 100:3), giving compound 25 (512 mg, 82.3%): 1H NMR (500 MHz, CDC13) 6 ppm 0.87 (t, J=6.8 Hz, 3H), 1.26 (s, 14H), 1.34 (d, J=14.4 Hz, 2H), 1.39-1.50 (m, 2H), 1.78-1.93 (m, 2H), 2.95 (d, 1=4.9 Hz, 3H), 4.50 (t, J=7.0 Hz, 2H), 6.38 (s, 1H), 7.19-7.25 (m, 1H), 7.29-7.38 (m, 4H), 7.49 (d, J=7.7 Hz, 1H), 7.62-7.68 (m, 1H), 7.68-7.75 (m, 2H), 7.87 (d, .1=16.4 Hz, 1H), 7.97 (d, J=8.4 Hz, 1H), 8.23 (s, 1H), 8.65 (d, J=4.3 Hz, 1H); 13C NMR (125 MHz, CDC13) 6 ppm 14.15, 22.70, 25.71, 26.78, 28.66, 29.25, 29.36, 29.52, 29.59, 29.65, 31.92, 68.42, 116.89, 121.56, 121.70, 122.62, 123.74, 127.14, 127.68, 128.86, 130.84, 132.84, 133.41, 134.49, 136.75, 137.64, 137.82, 141.44, 147.70, 149.87, 150.57, 154.56, 168.47; raiz (ESI+): 599A (M + H).
[00131] Example 19: Synthesis of N-methy1-2-41-(2-oxo-4H-1,3,2-benzodioxaphosphorin-2-y1)-34(1E)-2-(2-pyridinybetheny1)-11/-indazol-6-yl)thio)benzamide (compound 27).
[00132] 2-Hydroxybenzyl alcohol (4 g, 32.23 mmol, 1.0 eq.) and DCM (120 mL) were mixed in a flask. Under nitrogen atmosphere, the mixture was cooled to -78 C, followed by dropwise addition of, to the mixture, phosphorus oxychloride (4.94 g, 32.23 mmol, 1.0 eq.) and triethylamine (6.5 g, 64.46 mmol, 2.0 eq.). The mixture was stirred at -78 C for 1 h; and the reaction temperature was then raised to a. The mixture was further stirred at rt for 3 h. At this point, pentafluorophenol (5.94 g, 32.23 mmol, 1.0 eq.) was introduced into the reaction mixture under nitrogen atmosphere. Under nitrogen protection, the reaction system was cooled to -78 C, followed by addition of triethylamine (3.26 g, 32.23 mmol, 2.0 eq.) dropwise. The resultant mixture was stirred at -78 C for 1 11, brought to it, and further stirred at rt for 1 h. The mixture was then concentrated; and the residual material was purified (silica-gel column;
eluent pet-ether to ethyl acetate from 100:0 to 50:50) to give 2-oxo-4H-2-pentafluorophenoxy-1,3,2-benzodioxaphosphorin (6.1 g, 53.7%).
eluent pet-ether to ethyl acetate from 100:0 to 50:50) to give 2-oxo-4H-2-pentafluorophenoxy-1,3,2-benzodioxaphosphorin (6.1 g, 53.7%).
[00133]
In a flask were added axitinib (300 mg, 0.776 mmol, 1.0 eq.), DMF (12 mL), and DBU (141.7 mg, 0.931 mmol, 1.2 eq.). The mixture was cooled to -20 C, followed by addition, dropwise, of 2-oxo-4H-2-pentafluorophenoxy-1,3,2-benzodioxaphosphorin (327.9 mg, 0.931 mmol, 1.2 eq.) in DMF (1 mL). The mixture was stirred at -20 C for 40 min, followed by addition of water (50 mL) and ethyl acetate (70 mL). The organic layer was separated, washed with brine (3 x 50 mL), and concentrated. The residue was purified on a silica-gel column (eluent, DCM-methanol from 100:0 to 97:3), giving compound 27 (243 mg, 56.5%): 1H NMR (500 MHz, DMSO-d6) 6 ppm: 2.77 (d, J=4.6 Hz, 3H), 538 (dd, J=18.6, 14.3 Hz, 1H), 5.88-5.98 (m, 1H), 7.16 (d, J=7.6 Hz, 1H), 7.22 (d, J=8.1 Hz, 1H), 7.29-7.41 (m, 5H), 7.44 (t, J=8.0 Hz, 2H), 7.52 (d, J=7.3 Hz, 1H), 7.67 (dd, J=20.4, 12.1 Hz, 2H), 7.82 (dd, J=16.8, 12.0 Hz, 2H), 8.07 (s, 1H), 8.33 (d, J=7.9 Hz, 1H), 8.41 (d, J=4.4 Hz, MX 8.60 (4, J=4.3 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) ppm: 26.11, 70.59, 115.53, 118.15, 121.12, 121.60, 122.40, 122.60, 123.49, 125.12, 126.35, 126.93, 127.77, 127.99, 130.20, 130.49, 131.00, 134.01, 134.13, 137.02, 137.10, 137.84, 144.58, 149.02, 149.60, 153.73, 167.79; 31P NMR (203 MHz, DMSO-d6): 6 ppm: -15.28; m/z (ESI+): 555.2 (M + H).
In a flask were added axitinib (300 mg, 0.776 mmol, 1.0 eq.), DMF (12 mL), and DBU (141.7 mg, 0.931 mmol, 1.2 eq.). The mixture was cooled to -20 C, followed by addition, dropwise, of 2-oxo-4H-2-pentafluorophenoxy-1,3,2-benzodioxaphosphorin (327.9 mg, 0.931 mmol, 1.2 eq.) in DMF (1 mL). The mixture was stirred at -20 C for 40 min, followed by addition of water (50 mL) and ethyl acetate (70 mL). The organic layer was separated, washed with brine (3 x 50 mL), and concentrated. The residue was purified on a silica-gel column (eluent, DCM-methanol from 100:0 to 97:3), giving compound 27 (243 mg, 56.5%): 1H NMR (500 MHz, DMSO-d6) 6 ppm: 2.77 (d, J=4.6 Hz, 3H), 538 (dd, J=18.6, 14.3 Hz, 1H), 5.88-5.98 (m, 1H), 7.16 (d, J=7.6 Hz, 1H), 7.22 (d, J=8.1 Hz, 1H), 7.29-7.41 (m, 5H), 7.44 (t, J=8.0 Hz, 2H), 7.52 (d, J=7.3 Hz, 1H), 7.67 (dd, J=20.4, 12.1 Hz, 2H), 7.82 (dd, J=16.8, 12.0 Hz, 2H), 8.07 (s, 1H), 8.33 (d, J=7.9 Hz, 1H), 8.41 (d, J=4.4 Hz, MX 8.60 (4, J=4.3 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) ppm: 26.11, 70.59, 115.53, 118.15, 121.12, 121.60, 122.40, 122.60, 123.49, 125.12, 126.35, 126.93, 127.77, 127.99, 130.20, 130.49, 131.00, 134.01, 134.13, 137.02, 137.10, 137.84, 144.58, 149.02, 149.60, 153.73, 167.79; 31P NMR (203 MHz, DMSO-d6): 6 ppm: -15.28; m/z (ESI+): 555.2 (M + H).
[00134] Example 20: Synthesis of N-methy1-2-01-(P(S)-((lS)-(1-isopropoxycarbonylethyl))amino)(phenoxy)phosphinyl(-3-((lE)-2-(2-pyridinyflethenyl)-1H-indazol-6-ynthio)benzamide (compound 39).
[00135] A flask loaded with WISH-isopropoxycarbomylethyl)amino)(phenoxy)phosphinyl chloride (8.7 g, 28.4 mmol, 1.0 eq.) and DCM (100 mL) was protected under nitrogen atmosphere and cooled to 0 C. To this cold mixture was added TEA (2.9 g, 31.2 mmol, 1.1 eq.) and a solution of pentafluorophenol (5.2 g, 28.4 mmol, 1.0 eq.) in DCM (20 mL). The resulting mixture was stirred at 0 C for 4 h, and then concentrated to a residue. The residual material was treated with methyl t-butyl ether (100 mL). Insoluble material was removed by filtration;
and the filtrate was concentrated to dryness. The solid material thus obtained was stirred in a mixture of ethyl acetate and hexane (20 to 80, v/v; total 50 mL) overnight. The white solid was collected, giving N-(P(S)-(phenoxy)(pentafluorophenoxy)phosphiny1)-L-alanine isopropyl ester (5.8 g, 45.1%).
and the filtrate was concentrated to dryness. The solid material thus obtained was stirred in a mixture of ethyl acetate and hexane (20 to 80, v/v; total 50 mL) overnight. The white solid was collected, giving N-(P(S)-(phenoxy)(pentafluorophenoxy)phosphiny1)-L-alanine isopropyl ester (5.8 g, 45.1%).
[00136] To a flask were added axitinib (500 mg, 1.3 mmol, 1.0 eq.), DMF (13 mL), and N-(P(S)-(phenoxy)(pentafluorophenoxy)phosphiny1)-L-alanine isopropyl ester (704 mg, 1.6 mmol, 1.2 eq.). The mixture was cooled to -50 C, followed by addition of DBU
(208 mg, 1.4 mmol, 1.1 eq.); and the mixture was stirred at -50 C for 1 h.
The reaction was quenched by addition of 4 mL of 0.5 M HCl solution. The mixture was then extracted with ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified on a silica-gel column (eluent, DCM-methanol from 100:0 to 100:2, v/v), giving compound 39 (280 mg, 32.8%): 1H NMR (500 MHz, DMSO-d6): 8 ppm 1.02 (d, J=6.2 Hz, 3H), 1.09 (d, J=6.3 Hz, 3H), 1.31 (d, J=7.2 Hz, 3H), 2.79 (d, J=4.6 Hz, 3H), 4.24 (d, 1=7.3 Hz, 1H), 4.66-4.84 (m, 1H), 6.94-7.00 (m, 1H), 7.06 (dd, J=13.8, 10.3 Hz, 1H), 7.15-7.24 (m, 3H), 7.28-7.41 (m, 6H), 7.49-7.55 (m, 1H), 7.68-7.77 (m, 2H), 7.97-7.85 (m, 2H), 8.16 (s, 1H), 8.27 (d, J=8.3 Hz, 1H), 8.42 (d, J=4.5 Hz, 1H), 8.66 (d, J=4.1 Hz, 111);
(125 MHz, DMSO-d6): 6 ppm 20.25, 21.71, 26.56, 50.74, 68.46, 117.54, 120.78, 122.36, 122.63, 122.88, 123.65, 123.73, 125.84, 126.70, 128.04, 128.33, 130.26, 130.76, 133.20, 135.28, 135.88, 137.28, 137.47, 145.19, 145.28, 147.56, 147.65, 150.12, 154.54, 168.22, 172.64; 31P NMR (203 MHz, DMSO-d6): 5ppm -2.69; tnk (ESI+): 656.2 (M+H).
(208 mg, 1.4 mmol, 1.1 eq.); and the mixture was stirred at -50 C for 1 h.
The reaction was quenched by addition of 4 mL of 0.5 M HCl solution. The mixture was then extracted with ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified on a silica-gel column (eluent, DCM-methanol from 100:0 to 100:2, v/v), giving compound 39 (280 mg, 32.8%): 1H NMR (500 MHz, DMSO-d6): 8 ppm 1.02 (d, J=6.2 Hz, 3H), 1.09 (d, J=6.3 Hz, 3H), 1.31 (d, J=7.2 Hz, 3H), 2.79 (d, J=4.6 Hz, 3H), 4.24 (d, 1=7.3 Hz, 1H), 4.66-4.84 (m, 1H), 6.94-7.00 (m, 1H), 7.06 (dd, J=13.8, 10.3 Hz, 1H), 7.15-7.24 (m, 3H), 7.28-7.41 (m, 6H), 7.49-7.55 (m, 1H), 7.68-7.77 (m, 2H), 7.97-7.85 (m, 2H), 8.16 (s, 1H), 8.27 (d, J=8.3 Hz, 1H), 8.42 (d, J=4.5 Hz, 1H), 8.66 (d, J=4.1 Hz, 111);
(125 MHz, DMSO-d6): 6 ppm 20.25, 21.71, 26.56, 50.74, 68.46, 117.54, 120.78, 122.36, 122.63, 122.88, 123.65, 123.73, 125.84, 126.70, 128.04, 128.33, 130.26, 130.76, 133.20, 135.28, 135.88, 137.28, 137.47, 145.19, 145.28, 147.56, 147.65, 150.12, 154.54, 168.22, 172.64; 31P NMR (203 MHz, DMSO-d6): 5ppm -2.69; tnk (ESI+): 656.2 (M+H).
[00137]
Example 21: Synthesis of N-methy1-24(140-L-asparaginy1)-34(1E)-242-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide bis(trifluoroacetate) (compound 40).
Example 21: Synthesis of N-methy1-24(140-L-asparaginy1)-34(1E)-242-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide bis(trifluoroacetate) (compound 40).
[00138]
In a flask were mixed axitinib (500 mg, 1.3 mmol, 1.0 eq.), DMF (10 mL), N-(t-Boc)-L-aspartic acid 14-butyl ester (413 mg, 1.4 mmol, 1.1 eq.), and TEA
(328 mg, 3.3 mmol, 2.5 eq.), followed by addition of DPPA (716 mg, 2.6 mmol, 2 eq.) dropwise.
The mixture was stirred at rt for 4 h, and then to the mixture were added water (50 mL) and ethyl acetate (200 mL). The organic layer was separated, washed with brine (3 x 50 mL), and concentrated. The residual material was purified on a silica-gel column (eluent, DCM-methanol, 10:1), providing Boc-protected intermediate (800 mg, 93.6%).
This intermediate (800 mg) was taken in DCM (20 mL) in a flask, followed by addition of TFA (10 mL) dropwise. The mixture was stirred at rt for 2.5 h, and then concentrated.
The crude product thus obtained was stirred in methanol-ethyl acetate (5:95, v/v; total 10 mL); and the solid material was collected by filtration and dried, providing compound 40 (380 mg, 52.0%): 1H NMR (500 MHz, DM5046): 5 ppm 2.78 (s, 3H), 3.81 (s, 1H), 3.92 (d, J=17.3 Hz, 1H), 4.52 (s, 1H), 7.24 (s, 1H), 7.41 (s, 3H), 7.53 (d, J=17.2 Hz, 2H), 7.91 (dd, J=40.1, 22.8 Hz, 4H), 8.33 (s, 1H), 8.41 (s, 4H), 8.70 (s, 1H); 13C
NMR (125 MHz, DMSO-d6): 8 ppm 26.33, 39.63, 48.56, 117.38, 121.42, 123.01, 124.04, 124.20, 127.73, 128.51, 128.51, 130.93, 132.01, 133.90, 135.29, 137.80, 138.88,
In a flask were mixed axitinib (500 mg, 1.3 mmol, 1.0 eq.), DMF (10 mL), N-(t-Boc)-L-aspartic acid 14-butyl ester (413 mg, 1.4 mmol, 1.1 eq.), and TEA
(328 mg, 3.3 mmol, 2.5 eq.), followed by addition of DPPA (716 mg, 2.6 mmol, 2 eq.) dropwise.
The mixture was stirred at rt for 4 h, and then to the mixture were added water (50 mL) and ethyl acetate (200 mL). The organic layer was separated, washed with brine (3 x 50 mL), and concentrated. The residual material was purified on a silica-gel column (eluent, DCM-methanol, 10:1), providing Boc-protected intermediate (800 mg, 93.6%).
This intermediate (800 mg) was taken in DCM (20 mL) in a flask, followed by addition of TFA (10 mL) dropwise. The mixture was stirred at rt for 2.5 h, and then concentrated.
The crude product thus obtained was stirred in methanol-ethyl acetate (5:95, v/v; total 10 mL); and the solid material was collected by filtration and dried, providing compound 40 (380 mg, 52.0%): 1H NMR (500 MHz, DM5046): 5 ppm 2.78 (s, 3H), 3.81 (s, 1H), 3.92 (d, J=17.3 Hz, 1H), 4.52 (s, 1H), 7.24 (s, 1H), 7.41 (s, 3H), 7.53 (d, J=17.2 Hz, 2H), 7.91 (dd, J=40.1, 22.8 Hz, 4H), 8.33 (s, 1H), 8.41 (s, 4H), 8.70 (s, 1H); 13C
NMR (125 MHz, DMSO-d6): 8 ppm 26.33, 39.63, 48.56, 117.38, 121.42, 123.01, 124.04, 124.20, 127.73, 128.51, 128.51, 130.93, 132.01, 133.90, 135.29, 137.80, 138.88,
139.08, 140.61, 147.98, 150.10, 153.99, 158.72, 168.18, 169.82, 170.36; ink (ESI+): 502.0 (M+H).
[00139]
Example 22: N-methy1-24(14P(S)-(1S)-(1-methoxycarbonylethyl))amino)(1-naphthoxy)phosphinyl-34(1E)-242-pyridinyflethenyl)-1H-indazol-6-y1)thioThenzamide (compound 41).
[00139]
Example 22: N-methy1-24(14P(S)-(1S)-(1-methoxycarbonylethyl))amino)(1-naphthoxy)phosphinyl-34(1E)-242-pyridinyflethenyl)-1H-indazol-6-y1)thioThenzamide (compound 41).
[00140] (18)-(1-Methox ycarbonylethyl))amino)(1-naphthoxy)phosphinyl chloride (8.4 g, 17.7 mmol, 1.0 eq.) and DCM (100 mL) were placed in a flask. The system was protected with nitrogen atmosphere, and cooled to 0 C, followed by addition of TEA
(2.0 g, 19.5 mmol, 1.1 eq.) dropwise. Then to the mixture was added a solution of pentafluorophenol (3.2 g, 17.7 mmol, 1.0 eq.) in DCM (20 mL). The mixture was stirred at 0 C for 4 h, and then concentrated. The residual material was dissolved in methyl t-butyl ether (100 mL) and filtered. The filtrate was concentrated to dryness, providing a solid. The material was stirred in a mixture of ethyl acetate and hexane (20:80, v/v; total 50 mL) overnight. The white solid was collected and dried, giving N-(P(S)-(1-naphthoxy)(pentafluorophenoxy)phosphiny1)-L-alanine methyl ester (6.0 g, 71.3%).
(2.0 g, 19.5 mmol, 1.1 eq.) dropwise. Then to the mixture was added a solution of pentafluorophenol (3.2 g, 17.7 mmol, 1.0 eq.) in DCM (20 mL). The mixture was stirred at 0 C for 4 h, and then concentrated. The residual material was dissolved in methyl t-butyl ether (100 mL) and filtered. The filtrate was concentrated to dryness, providing a solid. The material was stirred in a mixture of ethyl acetate and hexane (20:80, v/v; total 50 mL) overnight. The white solid was collected and dried, giving N-(P(S)-(1-naphthoxy)(pentafluorophenoxy)phosphiny1)-L-alanine methyl ester (6.0 g, 71.3%).
[00141] Axitinib (500 mg, 1.3 mmol, 1.0 eq.) and N-(P(S)-(1-naphthoxy)(pentafluorophenoxy)phosphiny1)-L-alanine methyl ester (741 mg, 1.6 mmol, 1.2 eq.) were mixed in DMF (13 mL) in a flask and cooled to -50 C, followed by addition of DBU (208 mg, 1.4 mmol, 1.1 eq.) dropwise. The mixture was stirred at -50 C for 1 h, and then the reaction was quenched by addition of 0.5 M HC1 (4 mL).
The mixture was extracted with ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified on a silica-gel column (eluent: DCM-methanol, from 100:0 to 100:2), giving compound (201 mg, 22.8%): 111 NMR (500 MHz, DMSO-d6): 5 ppm 1.28 (d, J=7.2 Hz, 311), 2.76 (d, J=4.6 Hz, 311), 3.50 (s, 311), 4.27 - 4.40 (m, 111), 6.90 (d, J=7.3 Hz, 111), 7.23 - 7.41 (m, 7H), 7.49 (d, J=6.7 Hz, 1H), 7.53 - 7.66 (m, 3H), 7.70 (dd, J=17.7, 7.3 Hz, 2H), 7.84 (dd, J=15.7, 7.7 Hz, 2H), 7.91 (d, J=8.1 Hz, 1H), 8.13 (s, 1H), 8.19 (d, J=8.3 Hz, 1H), 8.25 (d, J=8.4 Hz, 1H), 8.41 (d, 3=4.6 Hz, 1H), 8.57-8.72 (m, 1H); 13C NMR
(125 MHz, DMSO-d6): 8 ppm 20.16, 26.55, 50.63, 52.33, 115.69, 117.47, 121.78, 122.00, 122.55, 123.01, 123.70, 125.62, 130.22, 130.77, 133.22, 134.69, 135.82, 137.27, 137.51, 145.32, 145.91, 145.96, 147.60, 147.69, 150.20, 154.46, 168.21, 173.69; 31P NMR (203 MHz, DMSO-d6): 5ppm -2.12; rn/z (ESI+): 678.3 (M+H).
The mixture was extracted with ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified on a silica-gel column (eluent: DCM-methanol, from 100:0 to 100:2), giving compound (201 mg, 22.8%): 111 NMR (500 MHz, DMSO-d6): 5 ppm 1.28 (d, J=7.2 Hz, 311), 2.76 (d, J=4.6 Hz, 311), 3.50 (s, 311), 4.27 - 4.40 (m, 111), 6.90 (d, J=7.3 Hz, 111), 7.23 - 7.41 (m, 7H), 7.49 (d, J=6.7 Hz, 1H), 7.53 - 7.66 (m, 3H), 7.70 (dd, J=17.7, 7.3 Hz, 2H), 7.84 (dd, J=15.7, 7.7 Hz, 2H), 7.91 (d, J=8.1 Hz, 1H), 8.13 (s, 1H), 8.19 (d, J=8.3 Hz, 1H), 8.25 (d, J=8.4 Hz, 1H), 8.41 (d, 3=4.6 Hz, 1H), 8.57-8.72 (m, 1H); 13C NMR
(125 MHz, DMSO-d6): 8 ppm 20.16, 26.55, 50.63, 52.33, 115.69, 117.47, 121.78, 122.00, 122.55, 123.01, 123.70, 125.62, 130.22, 130.77, 133.22, 134.69, 135.82, 137.27, 137.51, 145.32, 145.91, 145.96, 147.60, 147.69, 150.20, 154.46, 168.21, 173.69; 31P NMR (203 MHz, DMSO-d6): 5ppm -2.12; rn/z (ESI+): 678.3 (M+H).
[00142] Example 23: Synthesis of N-methy1-2-((l-nicotinoy1-34(1E)-2-(2-pyridinynetheny1)-11/-indazol-6-yOthio)benzamide (compound 42).
[00143]
In a flask were placed axitinib (300 mg, 0.778 mmol, 1.0 eq.), DMF (5mL), nicotinic acid (116 mg, 0.945 mmol, 1.2 eq.), N,N-diisopropylethylamine (151 mg, 1.16 mmol, 1.5 eq.), and HATU (354 mg, 0.934 mmol, 1.2 eq). The mixture was stirred at rt overnight, followed by addition of water (20 mL) and ethyl acetate (30 mL).
The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 100:3), giving compound 42 (240 mg, 63 %): 1H NMR (500 MHz, CD30D): 8 ppm 2.86 (s, 3H), 7.32 (s, 111), 7.41 (s, 4H), 7.51 (s, 1H), 7.62 (d, J=26.9 Hz, 3H), 7.77 (d, J=46.4 Hz, 2H), 8.03 (s, 1H), 8.41-8.58 (m, 3H), 8.73 (s, 1H), 9.19 (s, 1H); 13C NMR (125 MHz, CDC13): 6 ppm 26.69, 117.73, 121.35, 123.19, 123.98, 128.09, 128.87, 129.11, 130.78, 132.80, 133.37, 134.68, 136.74, 138.25, 138.71, 138.94, 141.63, 148.31, 149.81, 151.94, 152.45, 154.17, 165.87, 168.51; tn/z(ESI+): 492.1 (M+H).
In a flask were placed axitinib (300 mg, 0.778 mmol, 1.0 eq.), DMF (5mL), nicotinic acid (116 mg, 0.945 mmol, 1.2 eq.), N,N-diisopropylethylamine (151 mg, 1.16 mmol, 1.5 eq.), and HATU (354 mg, 0.934 mmol, 1.2 eq). The mixture was stirred at rt overnight, followed by addition of water (20 mL) and ethyl acetate (30 mL).
The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 100:3), giving compound 42 (240 mg, 63 %): 1H NMR (500 MHz, CD30D): 8 ppm 2.86 (s, 3H), 7.32 (s, 111), 7.41 (s, 4H), 7.51 (s, 1H), 7.62 (d, J=26.9 Hz, 3H), 7.77 (d, J=46.4 Hz, 2H), 8.03 (s, 1H), 8.41-8.58 (m, 3H), 8.73 (s, 1H), 9.19 (s, 1H); 13C NMR (125 MHz, CDC13): 6 ppm 26.69, 117.73, 121.35, 123.19, 123.98, 128.09, 128.87, 129.11, 130.78, 132.80, 133.37, 134.68, 136.74, 138.25, 138.71, 138.94, 141.63, 148.31, 149.81, 151.94, 152.45, 154.17, 165.87, 168.51; tn/z(ESI+): 492.1 (M+H).
[00144] Example 24: Synthesis of N-acetyl-N-methy1-241-acety1-34(1E)-2-(2-pyridinynetheny1)-1H-indazol-6-yOthio)benzamide (compound 43).
[00145] p-Nitrophenol (9.7 g, 63.86 mmol, 1.0 eq.), DCM
(50 mL), and triethylamine (12.9 g, 127.6 mmol, 2.0 eq.) were mixed in a flask. The reaction system was protected under nitrogen atmosphere and cooled in an ice-water bath. Acetyl chloride (5 g, 70.24 mmol, 1.1 eq.) was added dropwise into the above reaction system. After completion of the addition, the cold bath was removed. The mixture was stirred at it for 3 h, and then concentrated. The residue was purified (silica-gel column; eluent, pet ether to ethyl acetate from 100:0 to 90:10), providing p-nitrophenyl acetate (10 g, 86.4%).
(50 mL), and triethylamine (12.9 g, 127.6 mmol, 2.0 eq.) were mixed in a flask. The reaction system was protected under nitrogen atmosphere and cooled in an ice-water bath. Acetyl chloride (5 g, 70.24 mmol, 1.1 eq.) was added dropwise into the above reaction system. After completion of the addition, the cold bath was removed. The mixture was stirred at it for 3 h, and then concentrated. The residue was purified (silica-gel column; eluent, pet ether to ethyl acetate from 100:0 to 90:10), providing p-nitrophenyl acetate (10 g, 86.4%).
[00146] Axitinib (1 g, 2.59 mmol, 1.0 eq.), DCM (50 mL), and triethylarnine (784.7 mg, 7.77 mmol, 3.0 eq.) were mixed in a flask, and cooled in an ice-water bath under nitrogen atmosphere. To the cold mixture was added dropwise acetyl chloride (405 mg, 5.18 mmol, 2.0 eq.). The cold bath was then removed; and the mixture was stirred at it for 16 11, followed by addition of water (60 mL). The organic layer was separated, washed with brine (60 mL), and concentrated. The residue was purified (silica-gel column;
eluent, DCM-methanol from 100:0 to 100:3), giving N-methy1-24(1-acety1-3-01E)-2-(2-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide (1.1 g, 99%).
eluent, DCM-methanol from 100:0 to 100:3), giving N-methy1-24(1-acety1-3-01E)-2-(2-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide (1.1 g, 99%).
[00147] N-methy1-24(1-acety1-3-((lE)-2-(2-pyridinypetheny1)-1H-indazol-6-y1)thio)benzamide (1.1 g, 2.58 mmol, 1.0 eq.) and THF (35 mL) were placed in a flask.
Under nitrogen atmosphere, the mixture was cooled in an ice-water bath, followed by addition to the mixture of Lithium bis(trimethylsilyflamide (LiHMDS, 1.0 M
solution in THF; 7.74 nth, 7.74 mmol, 3.0 eq.). The mixture was stirred in the cold bath for 30 min., followed by addition of a solution of p-nitrophenyl acetate (1.4 g) in THF (10 mL), and continued being stirred for 2 h in the cold bath and for 1 h at it afterwards.
After addition of water (40 mL) and ethyl acetate (70 mL), the organic layer was separated and concentrated. The residue was purified on a silica-gel column (eluent: pet-ether and ethyl acetate, from 100:0 to 60:40), giving compound 43 (200 mg, 16.4%): 1H NMR (500 MHz, CDC13): 6 ppm 2.41 (s, 3H), 2.78 (s, 3H), 3.11 (s, 3H), 7.27-7.30 (m, 1H), 7.32 (dd, J=8.4, 1.5 Hz, 1H), 7.41 (d, J=2.7 Hz, 4H), 7.53 (d, J=7.6 Hz, 1H), 7.73 (d, J=16.3 Hz, 1H), 7.78 (t, J=7.6 Hz, 1H), 7.90 (d, J=16.2 Hz, 1H), 7.96 (d, J=8.3 Hz, 1H), 8.45 (d, J=0.8 Hz, 1H), 8.67 (d, J=4.9 Hz, 1H); 13C NMR (126 MHz, CDC13): 5 ppm 22.98, 26.46, 33.11, 117.35, 121.20, 121.67, 122.78, 124.08, 127.07, 127.53, 128.36, 130.90, 131.70, 133.59, 133.91, 136.91, 136.81, 137.23, 139.14, 140.44, 147.00, 149.69, 154.20, 170.92, 171.71, 173.16; rn/z (ESI+): 471 (M + H).
Under nitrogen atmosphere, the mixture was cooled in an ice-water bath, followed by addition to the mixture of Lithium bis(trimethylsilyflamide (LiHMDS, 1.0 M
solution in THF; 7.74 nth, 7.74 mmol, 3.0 eq.). The mixture was stirred in the cold bath for 30 min., followed by addition of a solution of p-nitrophenyl acetate (1.4 g) in THF (10 mL), and continued being stirred for 2 h in the cold bath and for 1 h at it afterwards.
After addition of water (40 mL) and ethyl acetate (70 mL), the organic layer was separated and concentrated. The residue was purified on a silica-gel column (eluent: pet-ether and ethyl acetate, from 100:0 to 60:40), giving compound 43 (200 mg, 16.4%): 1H NMR (500 MHz, CDC13): 6 ppm 2.41 (s, 3H), 2.78 (s, 3H), 3.11 (s, 3H), 7.27-7.30 (m, 1H), 7.32 (dd, J=8.4, 1.5 Hz, 1H), 7.41 (d, J=2.7 Hz, 4H), 7.53 (d, J=7.6 Hz, 1H), 7.73 (d, J=16.3 Hz, 1H), 7.78 (t, J=7.6 Hz, 1H), 7.90 (d, J=16.2 Hz, 1H), 7.96 (d, J=8.3 Hz, 1H), 8.45 (d, J=0.8 Hz, 1H), 8.67 (d, J=4.9 Hz, 1H); 13C NMR (126 MHz, CDC13): 5 ppm 22.98, 26.46, 33.11, 117.35, 121.20, 121.67, 122.78, 124.08, 127.07, 127.53, 128.36, 130.90, 131.70, 133.59, 133.91, 136.91, 136.81, 137.23, 139.14, 140.44, 147.00, 149.69, 154.20, 170.92, 171.71, 173.16; rn/z (ESI+): 471 (M + H).
[00148] Example 25: Synthesis of N-methy1-24(1-(2-methoxyethoxycarbony1)-3-((lE)-2-(2-pyridinybetheny1)-11-1-indazol-6-y1)thio)benzamide (compound 44).
[00149] A mixture of 2-methoxyethanol (4 g, 52.56 mmol, 1.0 eq.), THF (50 mL), and triethylamine (10.62 g, 105.12 mmol, 2.0 eq.) was cooled in an ice-water bath, followed by addition of a solution of p-nitrophenyl chloroformate (13,7 g, 68.34 mmol, 1.3 eq.) in THF (50 mL). Temperature was then raised to rt; and the mixture was stirred at it for 4 h.
After concentration, the residue was extracted between water (100 mL) and ethyl acetate (100 mL). The organic layer was separated and concentrated. The residual material was purified (silica-gel column; eluent, pet-ether and ethyl acetate from 100:0 to 90:10), providing 2-methoxyethyl p-nitrophenyl carbonate (7.2 g, 56.8%).
After concentration, the residue was extracted between water (100 mL) and ethyl acetate (100 mL). The organic layer was separated and concentrated. The residual material was purified (silica-gel column; eluent, pet-ether and ethyl acetate from 100:0 to 90:10), providing 2-methoxyethyl p-nitrophenyl carbonate (7.2 g, 56.8%).
[00150]
Axitinib (450 mg, 1.16 mmol, 1.0 eq.), DMF (12 mL), and triethylamine (351.48 mg, 3.48 mmol, 3.0 eq.) were mixed and stirred in a flask, followed by addition of 2-methoxyethyl p-nitrophenyl carbonate (337.1 mg, 1.39 mmol, 1.2 eq.). The mixture was stirred at it for 3 h, followed by addition of water (100 mL) and ethyl acetate (120 mL). The organic layer was separated, washed with brine (3 x 70 mL), and concentrated.
The residue was purified on a silica-gel column (eluent: DCM-methanol, from 100:0 to 100:3), giving compound 44 (452 mg, 79.8%): 1H NMR (500 MHz, CDC13) 6 ppm 2.94 (d, J=4.9 Hz, 3H), 343 (s, 3H), 3.72-3.85 (m, 2H), 4.59-4.69 (m, 2H), 6.39 (s, 1H), 7.23 (dd, J=7.0, 5.2 Hz, 1H), 7.31-7.38 (m, 4H), 7.49 (d, J=7.8 Hz, 1H), 7.61-7.68 (m, 1H), 7.73 (dd, J=14.9, 5.9 Hz, 2H), 7.87 (d, 1=16.4 Hz, 1H), 7.96 (d, 1=8.4 Hz, 1H), 8.22 (s, 1H), 8,65 (d, J=4,2 Hz, 1H); 13C NMR (125 MHz, CDC13) 5 ppm 26.77, 59.02, 66.56, 70.01, 116.94, 121.52, 122.70, 123.10, 123.77, 127.25, 127.62, 128.69, 130.82, 132.82, 133.47, 134.58, 136.78, 137.76, 138.00, 141.40, 147.93, 149.86, 150.40, 154.48, 168.57;
miz (ESI+): 489.1 (M + H).
Axitinib (450 mg, 1.16 mmol, 1.0 eq.), DMF (12 mL), and triethylamine (351.48 mg, 3.48 mmol, 3.0 eq.) were mixed and stirred in a flask, followed by addition of 2-methoxyethyl p-nitrophenyl carbonate (337.1 mg, 1.39 mmol, 1.2 eq.). The mixture was stirred at it for 3 h, followed by addition of water (100 mL) and ethyl acetate (120 mL). The organic layer was separated, washed with brine (3 x 70 mL), and concentrated.
The residue was purified on a silica-gel column (eluent: DCM-methanol, from 100:0 to 100:3), giving compound 44 (452 mg, 79.8%): 1H NMR (500 MHz, CDC13) 6 ppm 2.94 (d, J=4.9 Hz, 3H), 343 (s, 3H), 3.72-3.85 (m, 2H), 4.59-4.69 (m, 2H), 6.39 (s, 1H), 7.23 (dd, J=7.0, 5.2 Hz, 1H), 7.31-7.38 (m, 4H), 7.49 (d, J=7.8 Hz, 1H), 7.61-7.68 (m, 1H), 7.73 (dd, J=14.9, 5.9 Hz, 2H), 7.87 (d, 1=16.4 Hz, 1H), 7.96 (d, 1=8.4 Hz, 1H), 8.22 (s, 1H), 8,65 (d, J=4,2 Hz, 1H); 13C NMR (125 MHz, CDC13) 5 ppm 26.77, 59.02, 66.56, 70.01, 116.94, 121.52, 122.70, 123.10, 123.77, 127.25, 127.62, 128.69, 130.82, 132.82, 133.47, 134.58, 136.78, 137.76, 138.00, 141.40, 147.93, 149.86, 150.40, 154.48, 168.57;
miz (ESI+): 489.1 (M + H).
[00151]
Example 26: Synthesis of N-methyl-24(141-oxo-2,5,8-trioxanany1)-34(1E)-242-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide (compound 45).
Example 26: Synthesis of N-methyl-24(141-oxo-2,5,8-trioxanany1)-34(1E)-242-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide (compound 45).
[00152]
2-(2-Methyloxyethoxy)ethanol (6.3g, 52.56 mmol, 1.0 eq.), THF (50 mL), and triethylamine (10.62 g, 105.12 mmol, 2.0 eq.) were mixed in a flask and cooled to 0 C in an ice-water bath, followed by addition of a solution of p-nitrophenyl chloroformate (13.7 g, 68.34 mmol, 1.3 eq) in THF (50 mL). The temperature was raised to it; and the mixture was stirred at It for 4 h. Solvent was removed on a rotary evaporator; and the residual material was treated with ethyl acetate and water (100 mL
each). The organic layer was separated and concentrated. The residue was purified (silica-gel column; eluent, pet-ether and ethyl acetate from 100:0 to 90:10), providing 2-(2-methoxyethoxy)ethyl p-nitrophenyl carbonate (8.0g, 53.7%).
2-(2-Methyloxyethoxy)ethanol (6.3g, 52.56 mmol, 1.0 eq.), THF (50 mL), and triethylamine (10.62 g, 105.12 mmol, 2.0 eq.) were mixed in a flask and cooled to 0 C in an ice-water bath, followed by addition of a solution of p-nitrophenyl chloroformate (13.7 g, 68.34 mmol, 1.3 eq) in THF (50 mL). The temperature was raised to it; and the mixture was stirred at It for 4 h. Solvent was removed on a rotary evaporator; and the residual material was treated with ethyl acetate and water (100 mL
each). The organic layer was separated and concentrated. The residue was purified (silica-gel column; eluent, pet-ether and ethyl acetate from 100:0 to 90:10), providing 2-(2-methoxyethoxy)ethyl p-nitrophenyl carbonate (8.0g, 53.7%).
[00153]
Axitinib (450 mg, 1.16 mmol, 1.0 eq.), DMF (12 mL), and triethylamine (351.48 mg, 3.48 mmol, 3.0 eq.) were mixed and stirred at it, followed by addition of 2-(2-methoxyethoxy)ethyl p-nitrophenyl carbonate (396.2 mg, 1.39 mmol, 1.2 eq.).
The mixture was stirred at it for 3 h, followed by addition of water (100 mL) and ethyl acetate (120 mL). The organic layer was separated, washed with brine (3 x 70 mL), and concentrated. The residual material was purified on a silica-gel column (eluent: DCM-methanol, from 100:0 to 100:3), giving compound 45 (500 mg, 80.6%): 1H NMR
(500 MHz, DMSO-d6): 6 ppm 2.76 (d, J = 4.6 Hz, 3H), 3.21 (s, 3H), 3.46 (dd, J =
5.6, 3.9 Hz, 2H), 3.60 (dd, J = 5.6, 3.9 Hz, 2H), 3.74-3.83 (m, 2H), 4.52-4.61 (m, 2H), 7.13-7.19 (m, 1H), 7.32-7.43 (m, 4H), 7.53 (dd, J=7.2, 1.9 Hz, 1H), 7.79 (t, J=12.1 Hz, 2H), 7.87 (td, J=7.7, 1.7 Hz, 1H), 7.94 (d, J=16.3 Hz, 1H), 8.20 (s, 1H), 8.36 (dd, J=37.4, 6.6 Hz, 2H), 8.66 (d, J=4.6 Hz, 1H);13C NMR (125 MHz, CDC13): a ppm 26.78, 59.06, 66.76, 68.74, 70.60, 71.91, 117.20, 121.56, 122.75, 123.12, 123.87, 127.50, 128.74, 130.83, 132.59, 133.67, 134.59, 136.80, 137.59, 137.78, 141.39, 147.95, 149.88, 150.39,
Axitinib (450 mg, 1.16 mmol, 1.0 eq.), DMF (12 mL), and triethylamine (351.48 mg, 3.48 mmol, 3.0 eq.) were mixed and stirred at it, followed by addition of 2-(2-methoxyethoxy)ethyl p-nitrophenyl carbonate (396.2 mg, 1.39 mmol, 1.2 eq.).
The mixture was stirred at it for 3 h, followed by addition of water (100 mL) and ethyl acetate (120 mL). The organic layer was separated, washed with brine (3 x 70 mL), and concentrated. The residual material was purified on a silica-gel column (eluent: DCM-methanol, from 100:0 to 100:3), giving compound 45 (500 mg, 80.6%): 1H NMR
(500 MHz, DMSO-d6): 6 ppm 2.76 (d, J = 4.6 Hz, 3H), 3.21 (s, 3H), 3.46 (dd, J =
5.6, 3.9 Hz, 2H), 3.60 (dd, J = 5.6, 3.9 Hz, 2H), 3.74-3.83 (m, 2H), 4.52-4.61 (m, 2H), 7.13-7.19 (m, 1H), 7.32-7.43 (m, 4H), 7.53 (dd, J=7.2, 1.9 Hz, 1H), 7.79 (t, J=12.1 Hz, 2H), 7.87 (td, J=7.7, 1.7 Hz, 1H), 7.94 (d, J=16.3 Hz, 1H), 8.20 (s, 1H), 8.36 (dd, J=37.4, 6.6 Hz, 2H), 8.66 (d, J=4.6 Hz, 1H);13C NMR (125 MHz, CDC13): a ppm 26.78, 59.06, 66.76, 68.74, 70.60, 71.91, 117.20, 121.56, 122.75, 123.12, 123.87, 127.50, 128.74, 130.83, 132.59, 133.67, 134.59, 136.80, 137.59, 137.78, 141.39, 147.95, 149.88, 150.39,
154.51, 168.55;
m/z(ESI-E): 533.2(M-EH).
[00154] Example 27: Synthesis of N-methy1-24(1-(1-oxo-2,5,8,11,14-pentaoxapentadecy1)-34(1E1-242-pridinyfietheny1)-1H-indazol-6-yfithioThenzamide (compound 46).
m/z(ESI-E): 533.2(M-EH).
[00154] Example 27: Synthesis of N-methy1-24(1-(1-oxo-2,5,8,11,14-pentaoxapentadecy1)-34(1E1-242-pridinyfietheny1)-1H-indazol-6-yfithioThenzamide (compound 46).
[00155]
3,6,9,12-Tetraoxatride,can-1-ol (4 g, 19.2 mmol, 1.0 eq.), THF (50 mL), and triethylamine (5.8 g, 57.69 mmol, 3.0 eq.) were mixed in a flask and cooled to 0 C in an ice-water bath, followed by addition of a solution of p-nitrophenyl chloroformate (3.87 g, 19.23 mmol, 1.0 eq.) in THE (20 mL). The temperature was raised to rt after completion of addition. Then the mixture was stirred at it for 4 h, concentrated to remove most of the solvent, followed by addition of water and ethyl acetate (100 mL each). The organic layer was separated and concentrated. The residual material was purified (silica-gel column;
eluent, pet-ether and ethyl acetate from 80:20 to 50:50), giving p-nitrophenyl 3,6,9,12-tetraoxatridecyl carbonate (5.3 g, 73.9%).
3,6,9,12-Tetraoxatride,can-1-ol (4 g, 19.2 mmol, 1.0 eq.), THF (50 mL), and triethylamine (5.8 g, 57.69 mmol, 3.0 eq.) were mixed in a flask and cooled to 0 C in an ice-water bath, followed by addition of a solution of p-nitrophenyl chloroformate (3.87 g, 19.23 mmol, 1.0 eq.) in THE (20 mL). The temperature was raised to rt after completion of addition. Then the mixture was stirred at it for 4 h, concentrated to remove most of the solvent, followed by addition of water and ethyl acetate (100 mL each). The organic layer was separated and concentrated. The residual material was purified (silica-gel column;
eluent, pet-ether and ethyl acetate from 80:20 to 50:50), giving p-nitrophenyl 3,6,9,12-tetraoxatridecyl carbonate (5.3 g, 73.9%).
[00156]
Axitinib (400 mg, 1.03 mmol, 1.0 eq.), DMF (12 mL), and triethylamine (313.6 mg, 3.1 mmol, 3.0 eq.) were mixed and stirred in a flask, followed by addition of p-nitrophenyl 3,6,9,12-tetraoxatridecyl carbonate (462.9 mg, 1.24 mmol, 1.2 eq.). The mixture was stirred at it overnight. Water (100 mL) and ethyl acetate (120 mL) were added to the reaction mixture. The organic layer was separated, washed with brine (3 x 70 nth), and concentrated. The residue was purified (silica-gel column;
eluent, DCM-methanol from 100:0 to 100:3), giving compound 46 (456 mg, 71.32%): 111 NMR
(500 MHz, CDC13) 8 ppm 2.95 (d, J=4.9 Hz, 3H), 3.37 (d, J=16.9 Hz, 3H), 3.53 (dt, J=6.2, 4.6 Hz, 2H), 3.59-3.62 (m, 4H), 3.62-3.67 (m, 4H), 3.68-3.75 (m, 2H), 3.84-3.92 (m, 2H), 4.61-4.68 (m, 2H), 6.51 (s, 1H), 7.23 (dd, J=7.0, 5.2 Hz, 1H), 7.28-7.39 (m, 4H), 7.49 (d, J=7.9 Hz, 1H), 7.60-7.67 (m, 1H), 7.69-7.79 (m, 2H), 7.87 (d, 1=16.4 Hz, 1H), 7.98 (d, J=8.4 Hz, 1H), 8.24 (s, 1H), 8.65 (d, J=4.3 Hz, 1H); 13C NMR (125 MHz, CDC13) 8 ppm 26.74, 58.95, 66.76, 68.68, 70.41, 70.50, 70.55, 70.60, 71.84, 117.23, 121.49, 121.56, 122.74, 123.12, 123.82, 127.42, 127.54, 128.66, 130.77, 132.39, 133.82, 134.55, 136.80, 137.49, 137.78, 141.34, 147.91, 149.83, 150.33, 154.44, 168.57; m/z (ESI-F):
621.3 (M +
II).
Axitinib (400 mg, 1.03 mmol, 1.0 eq.), DMF (12 mL), and triethylamine (313.6 mg, 3.1 mmol, 3.0 eq.) were mixed and stirred in a flask, followed by addition of p-nitrophenyl 3,6,9,12-tetraoxatridecyl carbonate (462.9 mg, 1.24 mmol, 1.2 eq.). The mixture was stirred at it overnight. Water (100 mL) and ethyl acetate (120 mL) were added to the reaction mixture. The organic layer was separated, washed with brine (3 x 70 nth), and concentrated. The residue was purified (silica-gel column;
eluent, DCM-methanol from 100:0 to 100:3), giving compound 46 (456 mg, 71.32%): 111 NMR
(500 MHz, CDC13) 8 ppm 2.95 (d, J=4.9 Hz, 3H), 3.37 (d, J=16.9 Hz, 3H), 3.53 (dt, J=6.2, 4.6 Hz, 2H), 3.59-3.62 (m, 4H), 3.62-3.67 (m, 4H), 3.68-3.75 (m, 2H), 3.84-3.92 (m, 2H), 4.61-4.68 (m, 2H), 6.51 (s, 1H), 7.23 (dd, J=7.0, 5.2 Hz, 1H), 7.28-7.39 (m, 4H), 7.49 (d, J=7.9 Hz, 1H), 7.60-7.67 (m, 1H), 7.69-7.79 (m, 2H), 7.87 (d, 1=16.4 Hz, 1H), 7.98 (d, J=8.4 Hz, 1H), 8.24 (s, 1H), 8.65 (d, J=4.3 Hz, 1H); 13C NMR (125 MHz, CDC13) 8 ppm 26.74, 58.95, 66.76, 68.68, 70.41, 70.50, 70.55, 70.60, 71.84, 117.23, 121.49, 121.56, 122.74, 123.12, 123.82, 127.42, 127.54, 128.66, 130.77, 132.39, 133.82, 134.55, 136.80, 137.49, 137.78, 141.34, 147.91, 149.83, 150.33, 154.44, 168.57; m/z (ESI-F):
621.3 (M +
II).
[00157] Example 28: Synthesis of N-methy1-241-(2-(2-hydroxyethoxy)ethoxycarbony1)-3-01E)-2-(2-pyridinyl)etheny1)-1H-indazol-6-yl)thio)benzamide hydrochloride (compound 49).
[00158]
In a flask were subsequently added diethylene glycol (3.5 g, 33.0 mmol, 5.0 eq.), DCM (10 mL), DMAP (0.16 g, 1.3 mmol, 0.2 eq.), TEA (0.67 g, 6.6 mmol, 1.0 eq.), and DCM (10 mL). The mixture was cooled to 0 C, followed by addition of a solution of TBSC1 (1.0 g, 6.6 mmol, 1.0 eq.) in DCM (2.5 mL). The reaction temperature was raised to rt; and the reaction continued at it for 3 h, followed by washing the reaction mixture with saturated ammonium chloride solution (30 mL) and brine (30 mL) subsequently.
The organic layer was concentrated, providing diethylene glycol mono-(tert-butyldimethylsily1) ether (1.3 g, 89.4%).
In a flask were subsequently added diethylene glycol (3.5 g, 33.0 mmol, 5.0 eq.), DCM (10 mL), DMAP (0.16 g, 1.3 mmol, 0.2 eq.), TEA (0.67 g, 6.6 mmol, 1.0 eq.), and DCM (10 mL). The mixture was cooled to 0 C, followed by addition of a solution of TBSC1 (1.0 g, 6.6 mmol, 1.0 eq.) in DCM (2.5 mL). The reaction temperature was raised to rt; and the reaction continued at it for 3 h, followed by washing the reaction mixture with saturated ammonium chloride solution (30 mL) and brine (30 mL) subsequently.
The organic layer was concentrated, providing diethylene glycol mono-(tert-butyldimethylsily1) ether (1.3 g, 89.4%).
[00159]
Diethylene glycol mono-(tert-butyldimethylsily1) ether (1.3 g, 5.9 mmol, 1.0 eq.), DCM (15 mL), and TEA (0.66 g, 6.5 mmol, 1.1 eq.) were mixed in a flask.
The mixture was cooled to 0 C, followed by dropwise addition of a solution of p-nitrophenyl chloroformate (1.1 g, 5.3 mmol, 0.9 eq.) in DCM (6 mL). The reaction temperature was raised to it; and the reaction continued at it for 3 h. The mixture was soaked on silica gel and loaded on a silica-gel column for purification (eluent: pet-ether and ethyl acetate, from 100:0 to 100:20), giving 2-(2-(tert-butyldimethylsilyloxy)ethoxy)ethyl p-nitrophenyl carbonate (1.6 g, 78.3%).
Diethylene glycol mono-(tert-butyldimethylsily1) ether (1.3 g, 5.9 mmol, 1.0 eq.), DCM (15 mL), and TEA (0.66 g, 6.5 mmol, 1.1 eq.) were mixed in a flask.
The mixture was cooled to 0 C, followed by dropwise addition of a solution of p-nitrophenyl chloroformate (1.1 g, 5.3 mmol, 0.9 eq.) in DCM (6 mL). The reaction temperature was raised to it; and the reaction continued at it for 3 h. The mixture was soaked on silica gel and loaded on a silica-gel column for purification (eluent: pet-ether and ethyl acetate, from 100:0 to 100:20), giving 2-(2-(tert-butyldimethylsilyloxy)ethoxy)ethyl p-nitrophenyl carbonate (1.6 g, 78.3%).
[00160]
In a flask were placed axitinib (835 mg, 2.2 mmol, 1.0 eq.), DMF (21 mL), TEA (556 mg, 5.5 mmol, 2.5 eq.), and a solution of 2-(tert-butyldimethylsilyloxyethoxy)ethyl p-nitrophenyl carbonate (1.0 g, 2.6 mmol, 1.2 eq.) in DMF (5 mL). At room temperature the mixture was stirred overnight, followed by addition of water (60 mL) and ethyl acetate (90 mL). The organic layer was separated, washed with brine (3 x 50 mL), and concentrated. The residual material was purified on a silica-gel column (eluent: DCM-methanol, from 100:0 to 100:3), giving N-methy1-24(1-(2-(2-(ter-butyldimethysilyloxy)ethoxy)ethoxycarbony1)-341E)-2-(2-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide (1.7 g, 81.0%). The above obtained product (1.0 g) was stirred in a solution of 1% hydrochloric acid in ethanol (60 mL) at it for 2 h. The mixture was then concentrated to dryness, giving compound 49 (780 mg, 87.8%): 1H NMR
(500 MHz, D20): 6 ppm 2.71 (s, 311), 3.56-3.65 (m, 211), 3.65-3.73 (m, 211), 3.80 (s, 211), 4.46 (s, 211), 6.90 (d, J=8.4 Hz, HI), 7.20 (t, J=11.3 Hz, 211), 7.32 (d, J=7.7 Hz, 111), 7.42 (dq, J=18.9, 7.6 Hz, 5H), 7.89 (t, J-6.8 Hz, 1H), 8.17 (d, J=8.2 Hz, 1H), 8.45 (d, J=8.1 Hz, 1H), 8.60 (d, J=5.8 Hz, 1H); 13C NMR (125 MHz, D20): 8 ppm 26.24, 60.34, 67.51, 67.79, 71.82, 114.51, 120.76, 121.52, 123.10, 124.11, 126.28, 126.76, 127.79, 128.27, 130.94, 131.41, 132.70, 137.40, 139.10, 139.51, 141.11, 144.71, 146.69, 147.49, 149.14, 170.21; ink (ESI+): 519.2 (M+H).
In a flask were placed axitinib (835 mg, 2.2 mmol, 1.0 eq.), DMF (21 mL), TEA (556 mg, 5.5 mmol, 2.5 eq.), and a solution of 2-(tert-butyldimethylsilyloxyethoxy)ethyl p-nitrophenyl carbonate (1.0 g, 2.6 mmol, 1.2 eq.) in DMF (5 mL). At room temperature the mixture was stirred overnight, followed by addition of water (60 mL) and ethyl acetate (90 mL). The organic layer was separated, washed with brine (3 x 50 mL), and concentrated. The residual material was purified on a silica-gel column (eluent: DCM-methanol, from 100:0 to 100:3), giving N-methy1-24(1-(2-(2-(ter-butyldimethysilyloxy)ethoxy)ethoxycarbony1)-341E)-2-(2-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide (1.7 g, 81.0%). The above obtained product (1.0 g) was stirred in a solution of 1% hydrochloric acid in ethanol (60 mL) at it for 2 h. The mixture was then concentrated to dryness, giving compound 49 (780 mg, 87.8%): 1H NMR
(500 MHz, D20): 6 ppm 2.71 (s, 311), 3.56-3.65 (m, 211), 3.65-3.73 (m, 211), 3.80 (s, 211), 4.46 (s, 211), 6.90 (d, J=8.4 Hz, HI), 7.20 (t, J=11.3 Hz, 211), 7.32 (d, J=7.7 Hz, 111), 7.42 (dq, J=18.9, 7.6 Hz, 5H), 7.89 (t, J-6.8 Hz, 1H), 8.17 (d, J=8.2 Hz, 1H), 8.45 (d, J=8.1 Hz, 1H), 8.60 (d, J=5.8 Hz, 1H); 13C NMR (125 MHz, D20): 8 ppm 26.24, 60.34, 67.51, 67.79, 71.82, 114.51, 120.76, 121.52, 123.10, 124.11, 126.28, 126.76, 127.79, 128.27, 130.94, 131.41, 132.70, 137.40, 139.10, 139.51, 141.11, 144.71, 146.69, 147.49, 149.14, 170.21; ink (ESI+): 519.2 (M+H).
[00161] Example 29: Synthesis of N-methy1-2-((1-(2-(2- (2-hydrox yethoxy)ethoxy)ethoxycarbon y1)-34(1E)-2-(2-pyridin yfletheny1)-1H-indazol-6-yl)thio)benzamide hydrochloride (compound 50).
[00162]
In a flask were added triethylene glycol (5.0 g, 33.0 mmol, 5.0 eq.), DCM (10 mL), DMAP (0.16 g, 1.3 mmol, 0.2 eq.), TEA (0.67 g, 6.6 mmol, 1.0 eq.), and DCM (10 mL). The mixture was cooled to 0 C, followed by dropwise addition of a solution of TBSC1 (1.0 g, 6.6 mmol, 1.0 eq.) in DCM (2.5 mL). The reaction temperature was raised to rt; and the mixture was stirred at it for 4 h. The mixture was then washed with saturated ammonium chloride solution (30 mL) and with brine (30 mL), subsequently.
The organic layer was concentrated to dryness, providing 10,10,11,11-tetramethy1-3,6,9-trioxa-10-siladodecan-l-ol (1.4 g, 80.2%).
In a flask were added triethylene glycol (5.0 g, 33.0 mmol, 5.0 eq.), DCM (10 mL), DMAP (0.16 g, 1.3 mmol, 0.2 eq.), TEA (0.67 g, 6.6 mmol, 1.0 eq.), and DCM (10 mL). The mixture was cooled to 0 C, followed by dropwise addition of a solution of TBSC1 (1.0 g, 6.6 mmol, 1.0 eq.) in DCM (2.5 mL). The reaction temperature was raised to rt; and the mixture was stirred at it for 4 h. The mixture was then washed with saturated ammonium chloride solution (30 mL) and with brine (30 mL), subsequently.
The organic layer was concentrated to dryness, providing 10,10,11,11-tetramethy1-3,6,9-trioxa-10-siladodecan-l-ol (1.4 g, 80.2%).
[00163]
10,10,11,11-Tetramethy1-3,6,9-trioxa-10-siladodecan-1-ol (1.4 g, 5.3 mmol, 1.0 eq.), DCM (15 nth), and TEA (0.64 g, 6.4 mmol, 1.2 eq.) were mixed in a flask and cooled to 0 C, followed by addition of p-nitrophenyl chloroformate (1.2 g, 5.8 mmol, 1.1 eq.; dissolved in DCM, 6 mL) dropwise. The reaction temperature was raised to it; and the mixture was stirred at it for 3 h. The mixture was absorbed on silica-gel, loaded onto a silica-gel column, and purified with eluent of a mixture pet-ether and ethyl acetate (from 100:0 to 100:20), giving p-nitrophenyl 10,10,11,11-tetramethy1-3,6,9-trioxa-10-siladodec-1-y1 carbonate (1.6 g, 70.3%).
10,10,11,11-Tetramethy1-3,6,9-trioxa-10-siladodecan-1-ol (1.4 g, 5.3 mmol, 1.0 eq.), DCM (15 nth), and TEA (0.64 g, 6.4 mmol, 1.2 eq.) were mixed in a flask and cooled to 0 C, followed by addition of p-nitrophenyl chloroformate (1.2 g, 5.8 mmol, 1.1 eq.; dissolved in DCM, 6 mL) dropwise. The reaction temperature was raised to it; and the mixture was stirred at it for 3 h. The mixture was absorbed on silica-gel, loaded onto a silica-gel column, and purified with eluent of a mixture pet-ether and ethyl acetate (from 100:0 to 100:20), giving p-nitrophenyl 10,10,11,11-tetramethy1-3,6,9-trioxa-10-siladodec-1-y1 carbonate (1.6 g, 70.3%).
[00164]
Axitinib (1.2 g, 3.1 mmol, 1.0 eq.), DMF (30 mL), TEA (783 mg, 7.75 mmol, 2.5 eq.), and a solution of the carbonate obtained from the reaction above (1.6 g, 3.7 mmol, 1.2 eq.) in DMF (6 mL) were mixed in a flask. The mixture was stirred overnight, followed by addition of water (60 mL) and ethyl acetate (90 mL). The organic layer was separated, washed with brine (3 x 50 mL), and concentrated. The residual material was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 100:3), providing the shy-protected intermediate (1.7 g, 81.0%). This intermediate (677 mg) was taken into a solution of 1% hydrochloric acid in ethanol (50 nth); and the mixture was stirred at it for 2 h, and then concentrated to dryness, giving compound 50 (478 mg, 79.8%): 1H
NMR
(500 MHz, D20): 5 ppm 2.73 (s, 3H), 3.50 (s, 2H), 3.59 (d, J=11.1 Hz, 6H), 3.74 (s, 2H), 4.36 (s, 211), 6.77 (s, 111), 7.01 (d, J=15.6 Hz, 211), 7.13-7.34 (m, 511), 7.41 (s, 111), 7.76 (s, 111), 7.99 (d, J=7.3 Hz, 111), 8.30 (s, 111), 8.47 (s, 111); 13C NMR (125 MHz, D20): 5 ppm 26.24, 60.34, 67.39, 67.96, 69.44, 69.84, 71.75, 114.85, 120.83, 121.70, 124.06, 126.06, 126.96, 127.17, 128.31, 131.01, 131.71, 132.54, 137.27, 138.90, 139.58, 141.83, 144.99, 145.92, 148.01, 149.22, 170.30; ink (ESI+): 563.2 (M+H).
Axitinib (1.2 g, 3.1 mmol, 1.0 eq.), DMF (30 mL), TEA (783 mg, 7.75 mmol, 2.5 eq.), and a solution of the carbonate obtained from the reaction above (1.6 g, 3.7 mmol, 1.2 eq.) in DMF (6 mL) were mixed in a flask. The mixture was stirred overnight, followed by addition of water (60 mL) and ethyl acetate (90 mL). The organic layer was separated, washed with brine (3 x 50 mL), and concentrated. The residual material was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 100:3), providing the shy-protected intermediate (1.7 g, 81.0%). This intermediate (677 mg) was taken into a solution of 1% hydrochloric acid in ethanol (50 nth); and the mixture was stirred at it for 2 h, and then concentrated to dryness, giving compound 50 (478 mg, 79.8%): 1H
NMR
(500 MHz, D20): 5 ppm 2.73 (s, 3H), 3.50 (s, 2H), 3.59 (d, J=11.1 Hz, 6H), 3.74 (s, 2H), 4.36 (s, 211), 6.77 (s, 111), 7.01 (d, J=15.6 Hz, 211), 7.13-7.34 (m, 511), 7.41 (s, 111), 7.76 (s, 111), 7.99 (d, J=7.3 Hz, 111), 8.30 (s, 111), 8.47 (s, 111); 13C NMR (125 MHz, D20): 5 ppm 26.24, 60.34, 67.39, 67.96, 69.44, 69.84, 71.75, 114.85, 120.83, 121.70, 124.06, 126.06, 126.96, 127.17, 128.31, 131.01, 131.71, 132.54, 137.27, 138.90, 139.58, 141.83, 144.99, 145.92, 148.01, 149.22, 170.30; ink (ESI+): 563.2 (M+H).
[00165] Example 30: Synthesis of N-methy1-2-((1-(13-hydroxy-1-oxo-2,5,8,11-tetraoxatridec-1-y1)-3-((1E)-2-(2-pridinyfletheny1)-1H-indazol-6-y1)thio)benzamide hydrochloride (compound 51).
[00166] Tetraethylene glycol (8 g, 41.18 mmol, 5.0 eq.), DCM (25 mL), DMAP
(201 mg, 8.24 mmol, 0.2 eq.), and triethylamine (833.1 mg, 8.24 mmol, 1.0 eq.) were mixed in a flask and cooled to 0 C in an ice-water bath, followed by addition of a solution of TBSC1 (1.24 g, 8.24 mmol, 1.0 eq.) in DCM (5 mL). The temperature of the reaction was raised to it; and the mixture was stirred at it for 5 h. The mixture was washed with saturated ammonium chloride aqueous solution (2 x 30 mL); and the organic layer was separated and concentrated to dryness, providing 13,13,14,14-tetramethy1-3,6,9,12-tetraoxa-13-silapentadecan-l-ol (2.1 g, 82.6%).
(201 mg, 8.24 mmol, 0.2 eq.), and triethylamine (833.1 mg, 8.24 mmol, 1.0 eq.) were mixed in a flask and cooled to 0 C in an ice-water bath, followed by addition of a solution of TBSC1 (1.24 g, 8.24 mmol, 1.0 eq.) in DCM (5 mL). The temperature of the reaction was raised to it; and the mixture was stirred at it for 5 h. The mixture was washed with saturated ammonium chloride aqueous solution (2 x 30 mL); and the organic layer was separated and concentrated to dryness, providing 13,13,14,14-tetramethy1-3,6,9,12-tetraoxa-13-silapentadecan-l-ol (2.1 g, 82.6%).
[00167]
13,13,14,14-Tetramethy1-3,6,9,12-tetraoxa-13-silapentadecan-1-ol (2.1 g, 6.8 mmol, 1.0 eq.), DCM (30 mL), and triethylamine (826.6 mg, 8.16mmol, 1.2 eq.) were mixed in a flask, and cooled to 0 C in an ice-water bath, followed by dropwise addition of p-nitrophenyl chloroformate (1.4 g dissolved in 10 mL DCM, 6.8 mmol, 1.0 eq.). The temperature of the reaction was raised to it; and the mixture was stirred at it for 5 h. The reaction mixture was then concentrated to dryness, and the residue was extracted with ethyl acetate and water (40 mL each). The organic layer was separated and concentrated.
The residue was purified (silica-gel column; eluent, pet-ether and ethyl acetated from 100:0 to 100:10), providing p-nitrophenyl 13,13,14,14-tetramehty1-3,6,9,12-trtraoxa-13-silapentadec-1-y1 carbonate (1.6 g, 49.7%).
13,13,14,14-Tetramethy1-3,6,9,12-tetraoxa-13-silapentadecan-1-ol (2.1 g, 6.8 mmol, 1.0 eq.), DCM (30 mL), and triethylamine (826.6 mg, 8.16mmol, 1.2 eq.) were mixed in a flask, and cooled to 0 C in an ice-water bath, followed by dropwise addition of p-nitrophenyl chloroformate (1.4 g dissolved in 10 mL DCM, 6.8 mmol, 1.0 eq.). The temperature of the reaction was raised to it; and the mixture was stirred at it for 5 h. The reaction mixture was then concentrated to dryness, and the residue was extracted with ethyl acetate and water (40 mL each). The organic layer was separated and concentrated.
The residue was purified (silica-gel column; eluent, pet-ether and ethyl acetated from 100:0 to 100:10), providing p-nitrophenyl 13,13,14,14-tetramehty1-3,6,9,12-trtraoxa-13-silapentadec-1-y1 carbonate (1.6 g, 49.7%).
[00168]
A mixture of axitinib (550 mg, 1.42 mmol, 1.0 eq.), DMF (10 mL), and triethylamine (368 mg, 3.63 mmol, 2.5 eq.) was stirred in a flask, followed by addition of the above prepared carbonate (800 mg, 1.75 mmol, 1.2 eq.). The mixture was stirred at it overnight, followed by addition of water (40 mL) and ethyl acetate (60 mL) for extraction. The organic layer was separated, washed with brine (3 x 40 mL), and concentrated. The residual material was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 100:3), providing N-methy1-24(1-(13,13,14,14-tetramehtyl-3,6,9,12-trtraoxa-13-silapentadec-1-y1)-34(1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide (850 mg, 83.1 %), which was treated, under stirring, in a solution of hydrochloric acid in ethanol (1 mL conc. HC1 in 99 nil, ethanol) for 3 h (TLC
indicating completion of the reaction at this point). The latter mixture was concentrated to dryness, giving compound 51 (723 mg, 95.3%): 1H NMR (500 MHz, CD30D) 6 ppm: 2.86 (s, 3H), 3.44-3.51 (m, 2H), 3.51-3.57 (m, 2H), 3.57-3.64 (m, 4H), 3.64-3.75 (m, 4H), 3.87 (s, 211), 4.64 (s, 211), 7.34 (d, J=8.6 Hz, 111), 7.39 (s, 111), 7.43 (d, J=3.5 Hz, 211), 7.55 (dd, J=5.7, 3.3 Hz, 111), 7.87 (d, J=16.7 Hz, 111), 7.99 (d, J=6.3 Hz, 111), 8.07-8.22 (m, 3H), 8.55 (d, J=8.3 Hz, 1H), 8.63 (t, J=7.3 Hz, 1H), 8.80 (d, J=4.7 Hz, 1H);
(125 MHz, D20) 6 ppm: 26.06, 60.00, 67.07, 67.59, 68.99, 69.18, 69.28, 69.37, 71.25, 114.57, 120.68, 121.34, 122.79, 123.95, 125.99, 126.65, 127.99, 130.73, 131.37, 132.19, 13631, 138.50, 139.24, 140.69, 144.52, 146.47, 147.16, 148.87, 169.84; tn/z.
(ESI+):
607.3 (M + 11).
A mixture of axitinib (550 mg, 1.42 mmol, 1.0 eq.), DMF (10 mL), and triethylamine (368 mg, 3.63 mmol, 2.5 eq.) was stirred in a flask, followed by addition of the above prepared carbonate (800 mg, 1.75 mmol, 1.2 eq.). The mixture was stirred at it overnight, followed by addition of water (40 mL) and ethyl acetate (60 mL) for extraction. The organic layer was separated, washed with brine (3 x 40 mL), and concentrated. The residual material was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 100:3), providing N-methy1-24(1-(13,13,14,14-tetramehtyl-3,6,9,12-trtraoxa-13-silapentadec-1-y1)-34(1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide (850 mg, 83.1 %), which was treated, under stirring, in a solution of hydrochloric acid in ethanol (1 mL conc. HC1 in 99 nil, ethanol) for 3 h (TLC
indicating completion of the reaction at this point). The latter mixture was concentrated to dryness, giving compound 51 (723 mg, 95.3%): 1H NMR (500 MHz, CD30D) 6 ppm: 2.86 (s, 3H), 3.44-3.51 (m, 2H), 3.51-3.57 (m, 2H), 3.57-3.64 (m, 4H), 3.64-3.75 (m, 4H), 3.87 (s, 211), 4.64 (s, 211), 7.34 (d, J=8.6 Hz, 111), 7.39 (s, 111), 7.43 (d, J=3.5 Hz, 211), 7.55 (dd, J=5.7, 3.3 Hz, 111), 7.87 (d, J=16.7 Hz, 111), 7.99 (d, J=6.3 Hz, 111), 8.07-8.22 (m, 3H), 8.55 (d, J=8.3 Hz, 1H), 8.63 (t, J=7.3 Hz, 1H), 8.80 (d, J=4.7 Hz, 1H);
(125 MHz, D20) 6 ppm: 26.06, 60.00, 67.07, 67.59, 68.99, 69.18, 69.28, 69.37, 71.25, 114.57, 120.68, 121.34, 122.79, 123.95, 125.99, 126.65, 127.99, 130.73, 131.37, 132.19, 13631, 138.50, 139.24, 140.69, 144.52, 146.47, 147.16, 148.87, 169.84; tn/z.
(ESI+):
607.3 (M + 11).
[00169] Example 31. Synthesis of N-methy1-241-(indol-4-oxy)((lS)-1-methoxycarbonylethyfflamino)phosphinyl-34(1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-ynthio)benzamide (compound 61).
[00170]
Under nitrogen atmosphere, 1H-indo1-4-ol (6 g, 45.06 mmol, 1.0 eq.) and DCM (200 mL) were placed in a flask, and cooled to -78 C, followed by addition dropwise of phosphorus oxychloride (6.91 g, 45.06 mmol, 1.0 eq.) and triethylamine (4.55 g, 45.06 mmol, 1.0 eq.), subsequently. The mixture was stirred at -78 C
for 1 h.
The reaction temperature was raised gradually to it; and the mixture was stirred at it overnight. To the mixture was added L-alanine methyl ester hydrochloride (6.29 g, 45.06 mmol, 1.0 eq.), followed by cooling the mixture to -78 C under nitrogen atmosphere.
Triethylamine (9.1 g, 90.12 mmol, 2.0 eq.) was then added dropwise to the cold mixture.
The resulting mixture was stirred at -78 C for 1 h. The temperature was raised gradually to it; and the mixture was stirred at it for 1 more hour, and then concentrated. The residue was purified (silica-gel column; eluent, pet-ether and ethyl acetate from 100:0 to 50:50), providing N-(chloro(indo1-4-oxy)phosphiny1)-L-alanine methyl ester (9.2 g, 64.4%).
Under nitrogen atmosphere, 1H-indo1-4-ol (6 g, 45.06 mmol, 1.0 eq.) and DCM (200 mL) were placed in a flask, and cooled to -78 C, followed by addition dropwise of phosphorus oxychloride (6.91 g, 45.06 mmol, 1.0 eq.) and triethylamine (4.55 g, 45.06 mmol, 1.0 eq.), subsequently. The mixture was stirred at -78 C
for 1 h.
The reaction temperature was raised gradually to it; and the mixture was stirred at it overnight. To the mixture was added L-alanine methyl ester hydrochloride (6.29 g, 45.06 mmol, 1.0 eq.), followed by cooling the mixture to -78 C under nitrogen atmosphere.
Triethylamine (9.1 g, 90.12 mmol, 2.0 eq.) was then added dropwise to the cold mixture.
The resulting mixture was stirred at -78 C for 1 h. The temperature was raised gradually to it; and the mixture was stirred at it for 1 more hour, and then concentrated. The residue was purified (silica-gel column; eluent, pet-ether and ethyl acetate from 100:0 to 50:50), providing N-(chloro(indo1-4-oxy)phosphiny1)-L-alanine methyl ester (9.2 g, 64.4%).
[00171]
Axitinib (400 mg, 1.03 mmol, 1.0 eq.), DMF (12 mL), and N-(chloro(indo1-4-oxy)phosphiny1)-L-alanine methyl ester (1.47 g, 4.65 mmol, 4.5 eq.), and triethylamine (0.575 g, 5.69 mmol, 5.5 eq.) were mixed in a flask and stirred at it for 5 h.
To the mixture were added water (50 mL) and ethyl acetate (70 mL) for extraction. The organic layer was separated, washed with brine (3 x 50 mL), and concentrated. The residue was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 97:3), giving compound 61(210 mg, 30.4%): 1H NMR (500 MHz, DMSO-d6) 5 ppm: 1.31 (dd, J=60.5, 7.2 Hz, 3H), 2.76 (d, J=4.4 Hz, 3H), 3.46 (d, J=41.4 Hz, 3H), 4.37 (dt, J=17.5, 8.7 Hz, 1H), 6.49 (d, J=15.3 Hz, 1H), 6.75 (dd, J=34.7, 7.8 Hz, 1H), 6.88 (ddd, J=18.8, 13.3, 8.4 Hz, 211), 7.07 (dt, J=25.2, 12.7 Hz, 111), 7.15 (dd, J=14.2, 8.2 Hz, HI), 7.30 (ddd, J=19.9, 14.5, 8.0 Hz, 5H), 748 (d, J=7.0 Hz, 111), 7.68 (ddd, J=20.2, 14.7, 5.6 Hz, 2H), 7.81-7.94 (m, 2H), 8.11-8.25 (m, 2H), 8.39 (d, J=4.7 Hz, 1H), 8.64 (s, 1H), 11.22 (d, J=13.2 Hz, 1H); 13C NMR (125 MHz, DMS0416) 5 ppm: 19.98, 20.62, 50.85, 52.32, 9830, 109.51, 117.99, 120.92, 121.50, 122.15, 122.39, 122.55, 122.94, 123.77, 125.96, 126.62, 128.11, 128.35, 130.03, 130.81, 133.15, 134.90, 136.14, 137.14, 137.60, 138.41, 142.76, 145.46, 147.43, 150.25, 154.64, 168.30, 173.86; 31P NMR (203 MHz, DMSO-d6): 6 ppm: -2.83, -2.39; ink (ESI+): 667.4 (M + H).
Axitinib (400 mg, 1.03 mmol, 1.0 eq.), DMF (12 mL), and N-(chloro(indo1-4-oxy)phosphiny1)-L-alanine methyl ester (1.47 g, 4.65 mmol, 4.5 eq.), and triethylamine (0.575 g, 5.69 mmol, 5.5 eq.) were mixed in a flask and stirred at it for 5 h.
To the mixture were added water (50 mL) and ethyl acetate (70 mL) for extraction. The organic layer was separated, washed with brine (3 x 50 mL), and concentrated. The residue was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 97:3), giving compound 61(210 mg, 30.4%): 1H NMR (500 MHz, DMSO-d6) 5 ppm: 1.31 (dd, J=60.5, 7.2 Hz, 3H), 2.76 (d, J=4.4 Hz, 3H), 3.46 (d, J=41.4 Hz, 3H), 4.37 (dt, J=17.5, 8.7 Hz, 1H), 6.49 (d, J=15.3 Hz, 1H), 6.75 (dd, J=34.7, 7.8 Hz, 1H), 6.88 (ddd, J=18.8, 13.3, 8.4 Hz, 211), 7.07 (dt, J=25.2, 12.7 Hz, 111), 7.15 (dd, J=14.2, 8.2 Hz, HI), 7.30 (ddd, J=19.9, 14.5, 8.0 Hz, 5H), 748 (d, J=7.0 Hz, 111), 7.68 (ddd, J=20.2, 14.7, 5.6 Hz, 2H), 7.81-7.94 (m, 2H), 8.11-8.25 (m, 2H), 8.39 (d, J=4.7 Hz, 1H), 8.64 (s, 1H), 11.22 (d, J=13.2 Hz, 1H); 13C NMR (125 MHz, DMS0416) 5 ppm: 19.98, 20.62, 50.85, 52.32, 9830, 109.51, 117.99, 120.92, 121.50, 122.15, 122.39, 122.55, 122.94, 123.77, 125.96, 126.62, 128.11, 128.35, 130.03, 130.81, 133.15, 134.90, 136.14, 137.14, 137.60, 138.41, 142.76, 145.46, 147.43, 150.25, 154.64, 168.30, 173.86; 31P NMR (203 MHz, DMSO-d6): 6 ppm: -2.83, -2.39; ink (ESI+): 667.4 (M + H).
[00172] Example 32: Synthesis of N-methy1-24(141S)-(9H-carbazol-4-oxy)(1-methoxycarbonylethyfflanriino)phosphinyl-3-((lE)-2-(2-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide (compound 66).
[00173] 4-Hydroxycarbazole (5 g, 27.29 mmol, 1.0 eq.) and DCM (200 mL), under protection of nitrogen atmosphere, were mixed in a flask and cooled to -78 C, followed by addition dropwise of phosphorus oxychloride (4.2 g, 27.29 mmol, 1.0 eq.) and triethylamine (2.76 g, 27.29 mmol, 1.0 eq.), subsequently. The mixture was stirred at -78 C for 1 h; the temperature was gradually raised to it The mixture was further stirred at it for 1 h. To the mixture at this point was added L-alanine methyl ester hydrochloride (3.81 g, 27.29 mmol, 1.0 eq.). The mixture was then cooled, under nitrogen atmosphere, to -78 C, followed by addition dropwise of triethylamine (5.51 g, 54.58 mmol, 2.0 eq.), and continued to be stirred at -78 C for 1 h. The reaction temperature was raised gradually to it. The mixture was stirred at it for 1 h, and then concentrated. The residue was purified on a silica-gel column (eluent: pet-ether and ethyl acetate from 100:0 to 50:50), providing (4-carbazol-4-oxy)((1S)-(1-methoxycarbonylethyDarnino)phosphinyl chloride (4.1 g, 40.9%).
[00174]
Axitinib (400 mg, 1.03 mmol, 1.0 eq.), DMF (12 mL), (4-carbazol-4-oxy)((lS)-(1-methoxycarbonylethyDamino)phosphinyl chloride (1.89 g, 5.18 mmol, 5.0 eq.), and triethylamine (0.63 g, 6.18 mmol, 6.0 eq.) were mixed in a flask and stirred at it for 5 h, followed by addition of water (50 nth) and ethyl acetate (70 nth).
The organic layer was separated, washed with brine (3 x 50 EEL), and concentrated. The residual material was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 97:3), giving compound 67 (330 mg, 44.7%): 111 NMR (500 MHz, CDC13) 6 ppm: 1.31 (dd, J=87.4, 7.0 Hz, 311), 2.81 (d, J=4.9 Hz, 311), 3.54 (d, J=75.1 Hz, 311), 4.20-4.59 (m, 211), 6.39 (s, 1H), 7.07-7.25 (m, 9H), 7.37 (dd, J=21.4, 7.9 Hz, 3H), 7.49-7.62 (m, 2H), 7.71 (t, J=7.6 Hz, 1H), 7.81-7.89 (m, 2H), 8.14 (s, 1H), 8.39 (dd, J=11.8, 7.8 Hz, 1H), 8.48 (d, J=7.6 Hz, 1H), 8.66 (s, 1H); 13C NMR (125 MHz, CDC13) 6 ppm: 20.85, 26.68, 50.62, 52.49, 108.22, 109.78, 110.66, 115.68, 119.71, 120.95, 121.21, 121.71, 122.02, 122.97, 123.21, 125.99, 126.35, 127.54, 128.61, 130.67, 132.85, 133.30, 136.76, 136.89, 137.83, 139.53, 141.59, 145.26, 148.37, 149.83, 154.78, 168.92, 173.63; 31P NMR (203 MHz, CDC13): 6 ppm: -1.70, -2.50; adz (ESI+): 717.3 (M + H).
Axitinib (400 mg, 1.03 mmol, 1.0 eq.), DMF (12 mL), (4-carbazol-4-oxy)((lS)-(1-methoxycarbonylethyDamino)phosphinyl chloride (1.89 g, 5.18 mmol, 5.0 eq.), and triethylamine (0.63 g, 6.18 mmol, 6.0 eq.) were mixed in a flask and stirred at it for 5 h, followed by addition of water (50 nth) and ethyl acetate (70 nth).
The organic layer was separated, washed with brine (3 x 50 EEL), and concentrated. The residual material was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 97:3), giving compound 67 (330 mg, 44.7%): 111 NMR (500 MHz, CDC13) 6 ppm: 1.31 (dd, J=87.4, 7.0 Hz, 311), 2.81 (d, J=4.9 Hz, 311), 3.54 (d, J=75.1 Hz, 311), 4.20-4.59 (m, 211), 6.39 (s, 1H), 7.07-7.25 (m, 9H), 7.37 (dd, J=21.4, 7.9 Hz, 3H), 7.49-7.62 (m, 2H), 7.71 (t, J=7.6 Hz, 1H), 7.81-7.89 (m, 2H), 8.14 (s, 1H), 8.39 (dd, J=11.8, 7.8 Hz, 1H), 8.48 (d, J=7.6 Hz, 1H), 8.66 (s, 1H); 13C NMR (125 MHz, CDC13) 6 ppm: 20.85, 26.68, 50.62, 52.49, 108.22, 109.78, 110.66, 115.68, 119.71, 120.95, 121.21, 121.71, 122.02, 122.97, 123.21, 125.99, 126.35, 127.54, 128.61, 130.67, 132.85, 133.30, 136.76, 136.89, 137.83, 139.53, 141.59, 145.26, 148.37, 149.83, 154.78, 168.92, 173.63; 31P NMR (203 MHz, CDC13): 6 ppm: -1.70, -2.50; adz (ESI+): 717.3 (M + H).
[00175] Example 33: Synthesis of N-methy1-24(14(1S)-(naphth-2-oxy)(1-methoxycarbonylethyMarnino)phosphiny1-34(1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide (compound 90).
[00176]
Under nitrogen protection, 2-naphthol (720 mg, 4.99 mmol, 1.0 eq.) and diethyl ether (20 nth) were mixed in a flask and cooled to -78 C, followed by addition of phosphorus oxychloride (765 mg, 4.99 mmol, 1.0 eq.) and triethylamine (504 mg, 4.99 mmol, 1.0 eq.) dropwise and subsequently. The stirred mixture was kept at -78 C for 1 h, raising the reaction temperature gradually to rt, and kept at rt overnight.
Insoluble material was removed by filtration; and the filtrate was concentrated to give naphth-2-y1 dichlorophosphate (1.2 g, 92%).
Under nitrogen protection, 2-naphthol (720 mg, 4.99 mmol, 1.0 eq.) and diethyl ether (20 nth) were mixed in a flask and cooled to -78 C, followed by addition of phosphorus oxychloride (765 mg, 4.99 mmol, 1.0 eq.) and triethylamine (504 mg, 4.99 mmol, 1.0 eq.) dropwise and subsequently. The stirred mixture was kept at -78 C for 1 h, raising the reaction temperature gradually to rt, and kept at rt overnight.
Insoluble material was removed by filtration; and the filtrate was concentrated to give naphth-2-y1 dichlorophosphate (1.2 g, 92%).
[00177]
Naphth-2-y1 dichlorophosphate (1.1 g, 4.2 mmol, 1.0 eq.), DCM (30 mL), and L-alanine methyl ester hydrochloride (586 mg, 4.2 mmol, 1.0 eq.) were mixed in a flask.
Under nitrogen atmosphere, the mixture was cooled to -78 C, followed by addition of triethylamine (848 mg, 8.4 mmol, 2.0 eq.) dropwise. The mixture was stirred at for 1 h, and at it for 1 h (after the reaction temperature was slowly raised to rt.). The mixture was concentrated; and the residual material was purified (silica-gel column;
eluent, pet-ether and ethyl acetate from 100:0 to 50:50), providing N4chloro(naphth-2-yflphosphiny1)-L-alanine methyl ester (790 mg, 57%).
Naphth-2-y1 dichlorophosphate (1.1 g, 4.2 mmol, 1.0 eq.), DCM (30 mL), and L-alanine methyl ester hydrochloride (586 mg, 4.2 mmol, 1.0 eq.) were mixed in a flask.
Under nitrogen atmosphere, the mixture was cooled to -78 C, followed by addition of triethylamine (848 mg, 8.4 mmol, 2.0 eq.) dropwise. The mixture was stirred at for 1 h, and at it for 1 h (after the reaction temperature was slowly raised to rt.). The mixture was concentrated; and the residual material was purified (silica-gel column;
eluent, pet-ether and ethyl acetate from 100:0 to 50:50), providing N4chloro(naphth-2-yflphosphiny1)-L-alanine methyl ester (790 mg, 57%).
[00178]
Axitinib (200 mg, 0.518 mmol, 1.0 eq.), DMF (4 mL), N4chloro(naphth-2-yflphosphiny1)-L-alanine methyl ester (186.5 mg, 0.569 mmol, 1.1 eq.), and triethylamine (131.9 mg, 1.29 mmol, 2.5 eq.) were mixed in a flask and stirred at rt for 5 h. To the mixture were added water (20 mL) and ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. Purification of the residual material on a silica-gel column (eluent, DCM-methanol from 100:0 to 100:5) gave compound 90 (126.1 mg, 34%): 1H NMR (500 MHz, CDC13): 6 1.48 (dd, J=41.1, 6.6 Hz, 3H), 2.72-2.92 (m, 3H), 3.65 (dd, J=72.4, 1.6 Hz, 3H), 4.28-4.78 (m, 2H), 6.53 (s, 1H), 7.25 (ddd, J=26.1, 11.7, 4.9 Hz, 6H), 745 (t, J=8.0 Hz, 2H), 7.56 (s, 1H), 7.59-7.66 (m, 2H), 7.66-7.74 (m, 3H), 7,79 (dd, J=16.1, 8.2 Hz, 2H), 7.85-7.99 (m, 2H), 8.11 (d, J=6.9 Hz, 1H), 8.69 (s, 1H);13C NMR (125 MHz, CDC13): 8 21.00, 26.66, 50.66, 52.65, 11533, 117.40, 120.22, 121.32, 122.83, 123.20, 125.82, 126.26, 126.85, 127.75, 128.97, 129.95, 130.80, 131.13, 132.31, 133.04, 133.24, 133.70, 136.78, 137.74, 137.92, 138.11, 145.44, 147.37, 148.22, 149.23, 149.40, 154.51, 168.73, 173.71; 31P NMR (203 MHz, CDC13): 8 -2.75, -1.99; m/z(ESI-F):678.2(M-FH).
Axitinib (200 mg, 0.518 mmol, 1.0 eq.), DMF (4 mL), N4chloro(naphth-2-yflphosphiny1)-L-alanine methyl ester (186.5 mg, 0.569 mmol, 1.1 eq.), and triethylamine (131.9 mg, 1.29 mmol, 2.5 eq.) were mixed in a flask and stirred at rt for 5 h. To the mixture were added water (20 mL) and ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. Purification of the residual material on a silica-gel column (eluent, DCM-methanol from 100:0 to 100:5) gave compound 90 (126.1 mg, 34%): 1H NMR (500 MHz, CDC13): 6 1.48 (dd, J=41.1, 6.6 Hz, 3H), 2.72-2.92 (m, 3H), 3.65 (dd, J=72.4, 1.6 Hz, 3H), 4.28-4.78 (m, 2H), 6.53 (s, 1H), 7.25 (ddd, J=26.1, 11.7, 4.9 Hz, 6H), 745 (t, J=8.0 Hz, 2H), 7.56 (s, 1H), 7.59-7.66 (m, 2H), 7.66-7.74 (m, 3H), 7,79 (dd, J=16.1, 8.2 Hz, 2H), 7.85-7.99 (m, 2H), 8.11 (d, J=6.9 Hz, 1H), 8.69 (s, 1H);13C NMR (125 MHz, CDC13): 8 21.00, 26.66, 50.66, 52.65, 11533, 117.40, 120.22, 121.32, 122.83, 123.20, 125.82, 126.26, 126.85, 127.75, 128.97, 129.95, 130.80, 131.13, 132.31, 133.04, 133.24, 133.70, 136.78, 137.74, 137.92, 138.11, 145.44, 147.37, 148.22, 149.23, 149.40, 154.51, 168.73, 173.71; 31P NMR (203 MHz, CDC13): 8 -2.75, -1.99; m/z(ESI-F):678.2(M-FH).
[00179] Example 34: Synthesis of N-methy1-24(141-oxo-2,5,8,11,14,17,20,23-octaoxatetracos-1-y1)-34(1E)-242-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide (compound 94).
[00180] Heptaethylene glycol monomethyl ether (400 mg, 1.17 mmol, 1.0 eq.), THF
(5 mL), and triethylamine (177.59 g, 1.76 mmol, 1.5 eq.) were mixed in a flask and cooled to 0 C in an ice water bath, followed by addition of a solution of p-nitrophenyl chloroformate (258.69 mg, 1.29 mmol, 1.1 eq.) in THF (5mL) dropwise. The reaction temperature was raised to it the mixture was stirred at it for 4 h, and then concentrated.
The residual material was purified on a silica-gel column (eluent: pet-ether and ethyl acetate from 100:0 to 70:30), giving 3,6,9,12,15,18,21-heptaoxadocos-1-y1 p-nitrophenyl carbonate (400 mg, 67.8%).
(5 mL), and triethylamine (177.59 g, 1.76 mmol, 1.5 eq.) were mixed in a flask and cooled to 0 C in an ice water bath, followed by addition of a solution of p-nitrophenyl chloroformate (258.69 mg, 1.29 mmol, 1.1 eq.) in THF (5mL) dropwise. The reaction temperature was raised to it the mixture was stirred at it for 4 h, and then concentrated.
The residual material was purified on a silica-gel column (eluent: pet-ether and ethyl acetate from 100:0 to 70:30), giving 3,6,9,12,15,18,21-heptaoxadocos-1-y1 p-nitrophenyl carbonate (400 mg, 67.8%).
[00181]
In a flask were mixed axitinib (280 mg, 0.72 mmol, 1.0 eq.), DMF (10 mL), and triethylamine (145.44 mg, 1.44 mmol, 2.0 eq.). The mixture was stirred at it while 3,6,9,12,15,18,21-heptaoxadocos-1-y1 p-nitrophenyl carbonate (400.0 mg, 0.79 mmol, 1.1 eq.) was added. The mixture was stirred at it for 16 h, followed by addition of water (100 mL) and ethyl acetate (120 mL). The organic layer was separated, washed with brine (3 x 70 nth), and concentrated. The residual material was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 100:3), giving compound 94 (310 mg, 57%): 1H NMR
(500 MHz, DMS0-4:16): 5 2.76 (4, J=4.6 Hz, 3H), 3.21 (s, 3H), 3.38-3.49 (m, 20H), 3.50-3.56 (m, 2H), 3.57-3.64 (m, 2H), 3.75-3.88 (m, 2H), 4.46-4.65 (m, 2H), 7.16 (d, J=7.3 Hz, HI), 7.37 (ddd, J=16.0, 14.5, 7.9 Hz, 4H), 7.52 (dd, J=7.1, 1.6 Hz, 111), 7.74-7.82(m, 211), 7.85 (dt, J=7.6, 3.8 Hz, 111), 7.92 (d, J=16.4 Hz, 111), 8.19 (s, 111), 8.31 (d, J=8.4 Hz, 1H), 8.38 (d, J=4.5 Hz, 1H), 8.65 (d, J=4.3 Hz, 1H);13C NMR (125 MHz, DMS0-46): 8 26.52, 58.47, 67.32, 68.50, 70.17, 71.71, 117.50, 121.50, 122.81, 123.62, 123.97, 127.38, 12841, 130.89, 131.51, 134.54, 134.76, 137.51, 137.85, 138.33, 147.57, 150.25, 154.30, 168.18;m/z(ESI-F): 753.6(M-FH).
In a flask were mixed axitinib (280 mg, 0.72 mmol, 1.0 eq.), DMF (10 mL), and triethylamine (145.44 mg, 1.44 mmol, 2.0 eq.). The mixture was stirred at it while 3,6,9,12,15,18,21-heptaoxadocos-1-y1 p-nitrophenyl carbonate (400.0 mg, 0.79 mmol, 1.1 eq.) was added. The mixture was stirred at it for 16 h, followed by addition of water (100 mL) and ethyl acetate (120 mL). The organic layer was separated, washed with brine (3 x 70 nth), and concentrated. The residual material was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 100:3), giving compound 94 (310 mg, 57%): 1H NMR
(500 MHz, DMS0-4:16): 5 2.76 (4, J=4.6 Hz, 3H), 3.21 (s, 3H), 3.38-3.49 (m, 20H), 3.50-3.56 (m, 2H), 3.57-3.64 (m, 2H), 3.75-3.88 (m, 2H), 4.46-4.65 (m, 2H), 7.16 (d, J=7.3 Hz, HI), 7.37 (ddd, J=16.0, 14.5, 7.9 Hz, 4H), 7.52 (dd, J=7.1, 1.6 Hz, 111), 7.74-7.82(m, 211), 7.85 (dt, J=7.6, 3.8 Hz, 111), 7.92 (d, J=16.4 Hz, 111), 8.19 (s, 111), 8.31 (d, J=8.4 Hz, 1H), 8.38 (d, J=4.5 Hz, 1H), 8.65 (d, J=4.3 Hz, 1H);13C NMR (125 MHz, DMS0-46): 8 26.52, 58.47, 67.32, 68.50, 70.17, 71.71, 117.50, 121.50, 122.81, 123.62, 123.97, 127.38, 12841, 130.89, 131.51, 134.54, 134.76, 137.51, 137.85, 138.33, 147.57, 150.25, 154.30, 168.18;m/z(ESI-F): 753.6(M-FH).
[00182]
Example 35: Synthesis of N-methy1-241-alS)-(2-methylbenzyloxy)(1-methoxycarbonylethyl))amino)phosphinyl-34(1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide (compound 95).
Example 35: Synthesis of N-methy1-241-alS)-(2-methylbenzyloxy)(1-methoxycarbonylethyl))amino)phosphinyl-34(1E)-2-(2-pyridinyfletheny1)-1H-indazol-6-y1)thio)benzamide (compound 95).
[00183]
Under nitrogen protection, phosphorus oxychloride (1.9 g, 12.3 mmol, 1.0 eq.) and DCM (50 mL) were placed in a flask and cooled to -78 C, followed by addition, to the cold mixture, of 2-methylbenzyl alcohol (1.5 g, 12.3 mmol, 1.0 eq.) and a solution of triethylamine (1.2 g, 12.3 mmol, 1.0 eq.) in DCM (20 mL). The mixture was stirred at -78 C for 3 h, followed by addition of L-alanine methyl ester hydrochloride (1.5 g, 11.1 mmol, 0.9 eq.) under nitrogen atmosphere at -78 C, and by addition dropwise of triethylamine (2.5 g, 24.6 mmol, 2.0 eq.). The mixture was stirred at -78 C
for 1.5 h.
Then reaction temperature was raised slowly to rt, and the mixture was stirred for one more hour at n. The mixture was cooled to 0 C, followed by addition of pentafluorophenol (1.6 g, 8.88 mmol, 0.8 eq.) and triethylamine (1.1 g, 11.1 mmol, 1.0 eq.). This mixture was stirred at it for 1 h, and then treated with brine (30 mL). The organic layer was separated, filtered, and concentrated. The residual material was purified on a silica-gel column (eluent: pet-ether and ethyl acetate, from 100:0 to 35:65), giving N-02-methylbenzyloxy)(pentefluorophenoxy)phosphiny1)-L-alanine methyl ester (2.8 g, 71.9%).
Under nitrogen protection, phosphorus oxychloride (1.9 g, 12.3 mmol, 1.0 eq.) and DCM (50 mL) were placed in a flask and cooled to -78 C, followed by addition, to the cold mixture, of 2-methylbenzyl alcohol (1.5 g, 12.3 mmol, 1.0 eq.) and a solution of triethylamine (1.2 g, 12.3 mmol, 1.0 eq.) in DCM (20 mL). The mixture was stirred at -78 C for 3 h, followed by addition of L-alanine methyl ester hydrochloride (1.5 g, 11.1 mmol, 0.9 eq.) under nitrogen atmosphere at -78 C, and by addition dropwise of triethylamine (2.5 g, 24.6 mmol, 2.0 eq.). The mixture was stirred at -78 C
for 1.5 h.
Then reaction temperature was raised slowly to rt, and the mixture was stirred for one more hour at n. The mixture was cooled to 0 C, followed by addition of pentafluorophenol (1.6 g, 8.88 mmol, 0.8 eq.) and triethylamine (1.1 g, 11.1 mmol, 1.0 eq.). This mixture was stirred at it for 1 h, and then treated with brine (30 mL). The organic layer was separated, filtered, and concentrated. The residual material was purified on a silica-gel column (eluent: pet-ether and ethyl acetate, from 100:0 to 35:65), giving N-02-methylbenzyloxy)(pentefluorophenoxy)phosphiny1)-L-alanine methyl ester (2.8 g, 71.9%).
[00184]
In a flask were added axitinib (400 mg, 1.0 mmol, 1.0 eq.), DMF (15 mL), and N-42-methylbenzyloxy)(pentefluorophenoxy)phosphiny1)-L-alanine methyl ester (563 mg, 1.2 mmol, 1.2 eq.), followed by addition dropwise of DBU (183 mg, 1.2 mmol, 1.2 eq.). The mixture was stirred at it for 0.5 h, and then treated with water (10 nth) and ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 10 mL), and concentrated. The residual material was purified using a silica-gel column (eluent:
DCM-methanol, from 100:0 to 97:3), giving compound 95 (328 mg, 50.0%): 111 NMR
(500 MHz, CDC13): 6 ppm 1.27-1.43 (m, 311), 2.31 (d, J=2.7, 311), 2.91 (t, J=4.5, 311), 3.58 (d, 1=66.0, 3H), 3.96-4.39 (m, 2H), 4.97 (td, 1=12.2, 7.0, 1H), 5.07-5.26 (m, 1H), 6.53 (s, 1H), 7.09 (dd, J=16.9, 8.9, 2H), 7.14-7.26 (m, 4H), 7.32 (d, J=2.5, 3H), 7.47 (d, J=7.7, 1H), 7.54-7.67 (m, 211), 7.73 (t, 1=7.4, 111), 7.79-7.98 (m, 211), 8.13 (d, J=18.3, 111), 8.65 (d, 1=4.1, 111); 13C NMR (125 MHz, CDC13): 6 ppm 18.8, 20.81, 26.67, 50.22, 52.40, 67.59, 116.03, 121.16, 122.57, 122.85, 125.93, 126.38, 127.42, 127.46, 128.78, 128.93, 129.29, 130.33, 132.65, 132.90, 132.95, 133.65, 133.77, 136.18, 136.78, 137.04, 137.74, 145.05, 147.84, 149.80, 154.74, 168.70, 173.81; 31P NMR (203 MHz, CDC13): 6 ppm 1.43, 2.03; m/z (ESI+): 656.2 (M+H).
In a flask were added axitinib (400 mg, 1.0 mmol, 1.0 eq.), DMF (15 mL), and N-42-methylbenzyloxy)(pentefluorophenoxy)phosphiny1)-L-alanine methyl ester (563 mg, 1.2 mmol, 1.2 eq.), followed by addition dropwise of DBU (183 mg, 1.2 mmol, 1.2 eq.). The mixture was stirred at it for 0.5 h, and then treated with water (10 nth) and ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 10 mL), and concentrated. The residual material was purified using a silica-gel column (eluent:
DCM-methanol, from 100:0 to 97:3), giving compound 95 (328 mg, 50.0%): 111 NMR
(500 MHz, CDC13): 6 ppm 1.27-1.43 (m, 311), 2.31 (d, J=2.7, 311), 2.91 (t, J=4.5, 311), 3.58 (d, 1=66.0, 3H), 3.96-4.39 (m, 2H), 4.97 (td, 1=12.2, 7.0, 1H), 5.07-5.26 (m, 1H), 6.53 (s, 1H), 7.09 (dd, J=16.9, 8.9, 2H), 7.14-7.26 (m, 4H), 7.32 (d, J=2.5, 3H), 7.47 (d, J=7.7, 1H), 7.54-7.67 (m, 211), 7.73 (t, 1=7.4, 111), 7.79-7.98 (m, 211), 8.13 (d, J=18.3, 111), 8.65 (d, 1=4.1, 111); 13C NMR (125 MHz, CDC13): 6 ppm 18.8, 20.81, 26.67, 50.22, 52.40, 67.59, 116.03, 121.16, 122.57, 122.85, 125.93, 126.38, 127.42, 127.46, 128.78, 128.93, 129.29, 130.33, 132.65, 132.90, 132.95, 133.65, 133.77, 136.18, 136.78, 137.04, 137.74, 145.05, 147.84, 149.80, 154.74, 168.70, 173.81; 31P NMR (203 MHz, CDC13): 6 ppm 1.43, 2.03; m/z (ESI+): 656.2 (M+H).
[00185] Example 36: Synthesis of N-methy1-2-((1-((lS)-(naphthoxy)(1-(1S-1-phenylethoxycarbonyl)lethyl))amino)phosphinyl-34(1E)-2-(2-pyridinyfletheny1)-indazol-6-y1)thio)benzamide (compound 96).
[00186]
In a flask were placed N-(t-Boc)-L-alanine (2 g, 10.57 mmol, 1.0 eq.), DDC
(2.61 g, 12.69 mmol, 1.2 eq.), DMAP (1.29 g, 10.57 mmol, 1.0 eq.), and acetonitrile (20 mL); and the mixture was stirred at it for 20 min., followed by addition of (S)-(-)-1-phenylethanol (1.29 g, 10.57 mmol, 1.0 eq.) dropwise. The mixture was stirred overnight at rt, and filtered to remove insoluble material. The filtrate was concentrated; and the residue was purified on a silica-gel column (eluent: pet-ether and ethyl acetate, from 100:0 to 20:80), providing N-(tert-butoxycarbony1)-L-alanine (S)-1-phenylethyl ester (2.8 g, 90.2%). This ester (2.8 g, 9.54 mmol, 1.0 eq.) was treated in a solution of 4M HCl in dioxane (15 mL, 6.3 eq.) diluted with dioxane (10 mL) by stirring at it for 3 h.
Concentration of the reaction solution gave L-alanine (S)-1-phenylethyl ester hydrochloride salt (2.1 g, 95.8%).
In a flask were placed N-(t-Boc)-L-alanine (2 g, 10.57 mmol, 1.0 eq.), DDC
(2.61 g, 12.69 mmol, 1.2 eq.), DMAP (1.29 g, 10.57 mmol, 1.0 eq.), and acetonitrile (20 mL); and the mixture was stirred at it for 20 min., followed by addition of (S)-(-)-1-phenylethanol (1.29 g, 10.57 mmol, 1.0 eq.) dropwise. The mixture was stirred overnight at rt, and filtered to remove insoluble material. The filtrate was concentrated; and the residue was purified on a silica-gel column (eluent: pet-ether and ethyl acetate, from 100:0 to 20:80), providing N-(tert-butoxycarbony1)-L-alanine (S)-1-phenylethyl ester (2.8 g, 90.2%). This ester (2.8 g, 9.54 mmol, 1.0 eq.) was treated in a solution of 4M HCl in dioxane (15 mL, 6.3 eq.) diluted with dioxane (10 mL) by stirring at it for 3 h.
Concentration of the reaction solution gave L-alanine (S)-1-phenylethyl ester hydrochloride salt (2.1 g, 95.8%).
[00187] Naphthol (313.7 mg, 2.18 mmol, 1.0 eq.) and DCM (30 mL) were loaded in a flask, cooled to -78 C under nitrogen atmosphere, followed by addition of phosphorus oxychloride (334 mg, 2.176 mmol, 1.0 eq.) and triethylamine (220 mg, 2.176 mmol, 1.0 eq.) subsequently and dropwise. The mixture was stirred at -78 C for 1 h; and the temperature of the reaction was raised to it. The mixture was further stirred at it overnight, followed by addition of (S)-1-phenylethyl ester hydrochloride salt (499.8 mg, 2.176 mmol, 1.0 eq.) under nitrogen protection. After the mixture was cooled to -78 C, triethylamine (437.25 mg, 4.352 mmol, 2.0 eq.) was introduced dropwise. The mixture was stirred at -78 C for 1 h; and the temperature of the reaction was raised to it. The mixture was further stirred at it for 1 h, followed by addition of pentafluorophenol (400 mg, 2.176 mmol, 1.0 eq.). Under nitrogen atmosphere, the reaction mixture was cooled to -78 C; and triethylamine (220 mg, 2.176 mmol, 1.0 eq.) was added dropwise.
The resultant mixture was stirred at -78 C for 1 h, warmed to it gradually, and stirred at it for 1 h, and then concentrated. The residual material was purified (silica-gel column; eluent, pet-ether and ethyl acetate from 100:0 to 80:20), giving N-chloro(naphth- 1-yloxy)(pentafluorophenoxy)phosphonyl-L-alartine (S)-1-phenylethyl ester (450 mg, 36.6%).
The resultant mixture was stirred at -78 C for 1 h, warmed to it gradually, and stirred at it for 1 h, and then concentrated. The residual material was purified (silica-gel column; eluent, pet-ether and ethyl acetate from 100:0 to 80:20), giving N-chloro(naphth- 1-yloxy)(pentafluorophenoxy)phosphonyl-L-alartine (S)-1-phenylethyl ester (450 mg, 36.6%).
[00188]
Axitinib (256.3 mg, 0.663 mmol, 1.0 eq.), DMF (12 mL), and DBU (121.2 mg, 0.796 mmol, 1.2 eq.) were mixed in a flask and cooled to -20 C, followed by addition a solution of N-chloro(naphth-l-yloxy)(pentafluorophenoxy)phosphonyl-L-alartine (S)-1-phenylethyl ester (450 mg, 0.796 mmol, 1.2 eq.) in DMF (1 mL).
The mixture was stirred at -20 C for 40 min, followed by addition of water (50 mL) and ethyl acetate (70 mL). The organic layer was separated, washed with brine (3 x 50 mL), and concentrated. The residue was purified (silica-gel column; eluent, DCM and methanol from 100:0 to 97:3), giving compound 96 (300 mg, 58.9%): 1H NMR (500 MHz, DMSO-d6) 8 ppm: 1.14-1.40 (m, 6H), 2.76 (4, J = 4.3 Hz, 3H), 4.30-4.52 (m, 1H), 5.56-5.72 (m, 1H), 6.83-6.94 (m, 1H), 7.15-7.43 (m, 12H), 7.49 (d, J = 4.9 Hz, 1H), 7.53-7.74 (m, 5H), 7.80-7.96 (m, 3H), 8.12-8.24 (m, 2H), 8.24-8.30 (m, 1H), 8.40 (s, 1H), 8.63 (s, 1H); 13C NMR (125 MHz, DMS0-46) a ppm:19.41, 22.01, 26.13, 50.22, 72.56, 115.12, 117.15, 121.59, 121.77, 122.15, 122.47, 123.25, 125.16, 125.54, 125.76, 126.24, 126.36, 126.52, 126.92, 127.60, 127.88, 128.27, 128.34, 129.71, 130.29, 132.81, 134.28, 134.89, 135.44, 136.83, 137.06, 141.42, 144.90, 145.58, 147.33, 149.74, 154.03, 167.79, 171.91;
31P NMR (203 MHz, DMSO-d6): 6 ppm: -2.26, -1.76; m/z (ESI+): 768.5 (M + H).
Axitinib (256.3 mg, 0.663 mmol, 1.0 eq.), DMF (12 mL), and DBU (121.2 mg, 0.796 mmol, 1.2 eq.) were mixed in a flask and cooled to -20 C, followed by addition a solution of N-chloro(naphth-l-yloxy)(pentafluorophenoxy)phosphonyl-L-alartine (S)-1-phenylethyl ester (450 mg, 0.796 mmol, 1.2 eq.) in DMF (1 mL).
The mixture was stirred at -20 C for 40 min, followed by addition of water (50 mL) and ethyl acetate (70 mL). The organic layer was separated, washed with brine (3 x 50 mL), and concentrated. The residue was purified (silica-gel column; eluent, DCM and methanol from 100:0 to 97:3), giving compound 96 (300 mg, 58.9%): 1H NMR (500 MHz, DMSO-d6) 8 ppm: 1.14-1.40 (m, 6H), 2.76 (4, J = 4.3 Hz, 3H), 4.30-4.52 (m, 1H), 5.56-5.72 (m, 1H), 6.83-6.94 (m, 1H), 7.15-7.43 (m, 12H), 7.49 (d, J = 4.9 Hz, 1H), 7.53-7.74 (m, 5H), 7.80-7.96 (m, 3H), 8.12-8.24 (m, 2H), 8.24-8.30 (m, 1H), 8.40 (s, 1H), 8.63 (s, 1H); 13C NMR (125 MHz, DMS0-46) a ppm:19.41, 22.01, 26.13, 50.22, 72.56, 115.12, 117.15, 121.59, 121.77, 122.15, 122.47, 123.25, 125.16, 125.54, 125.76, 126.24, 126.36, 126.52, 126.92, 127.60, 127.88, 128.27, 128.34, 129.71, 130.29, 132.81, 134.28, 134.89, 135.44, 136.83, 137.06, 141.42, 144.90, 145.58, 147.33, 149.74, 154.03, 167.79, 171.91;
31P NMR (203 MHz, DMSO-d6): 6 ppm: -2.26, -1.76; m/z (ESI+): 768.5 (M + H).
[00189]
Example 37: Synthesis of N-methy1-24(1-((5-methy1-2-oxo-1,3-dioxo1-4-y1)methoxycabony1)-341E)-2-(2-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide (compound 97).
Example 37: Synthesis of N-methy1-24(1-((5-methy1-2-oxo-1,3-dioxo1-4-y1)methoxycabony1)-341E)-2-(2-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide (compound 97).
[00190]
(5-Methyl-2-oxo-1,3-dioxo1-4-yOmethanol (500 mg, 3.84 mmol, 1.0 eq.), DCM (10 mL), and triethylamine (0.78 g, 7.68 mmol, 2.0 eq.) were mixed in a flask and the mixture was cooled to 0 C in an ice-water bath. To the cold mixture was added a solution of p-nitrophenyl chloroformate (0.78 g, 7.68 mmol, 1.5 eq.) in DCM
(10 mL) dropwise. The mixture was warmed to rt, stirred at it for 16 h, and then concentrated to remove most of the solvent. The residue was purified (silica-gel column;
eluent, pet-ether and ethyl acetate from 100:0 to 50:50), providing 5-methyl-2-oxo-1,3-dioxo1-4-yOmethyl p-nitrophenyl carbonate (600 mg, 54%).
(5-Methyl-2-oxo-1,3-dioxo1-4-yOmethanol (500 mg, 3.84 mmol, 1.0 eq.), DCM (10 mL), and triethylamine (0.78 g, 7.68 mmol, 2.0 eq.) were mixed in a flask and the mixture was cooled to 0 C in an ice-water bath. To the cold mixture was added a solution of p-nitrophenyl chloroformate (0.78 g, 7.68 mmol, 1.5 eq.) in DCM
(10 mL) dropwise. The mixture was warmed to rt, stirred at it for 16 h, and then concentrated to remove most of the solvent. The residue was purified (silica-gel column;
eluent, pet-ether and ethyl acetate from 100:0 to 50:50), providing 5-methyl-2-oxo-1,3-dioxo1-4-yOmethyl p-nitrophenyl carbonate (600 mg, 54%).
[00191]
Axitinib (400 mg, 1.04 mmol, 1.0 eq.), DMF (6 mL), and triethylamine (157 mg, 1.56 mmol, 1.5 eq.) were stirred in a flask, followed by addition of 5-methy1-2-oxo-1,3-dioxo1-4-yemethyl p-nitrophenyl carbonate (366 mg, 1.24 mmol, 1.2 eq.).
The mixture was stirred at rt for 16 h, followed by addition of water (20 mL) and ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified on a silica-gel column (eluent, DCM-methanol from 100:0 to 100:3), giving compound 97 (355 mg, 54%): 1H NMR (500 MHz, DMSO-d6): a 2.25 (s, 3H), 2.76 (d, J=4.3 Hz, 3H), 5.40 (s, 2H), 7.19 (s, 1H), 7.37 (s, 3H), 7.42 (d, J=8.2 Hz, 1H), 7.51 (s, 1H), 7.75-7.84 (m, 2H), 7.87 (s, 1H), 7.93 (d, J=16.0 Hz, 1H), 8.16 (s, 1H), 8.32 (d, J=8.2 Hz, 1H), 8.40 (s, 1H), 8.66 (s, 1H);13C NMR
(125MHz, DMSO-d6): 6 9.47, 26.53, 57.47, 117.08, 121.27, 122.89,123.63, 124.40, 124.11, 127.55, 128.44, 130.89, 131.75, 133.08, 134.17, 134.98, 137.55, 138.20, 138.60, 141.46, 141.66, 147.83, 149.92, 150.23, 152.24, 154.21, 168.18; nVz(ESI+):
543.0 (M+H).
Axitinib (400 mg, 1.04 mmol, 1.0 eq.), DMF (6 mL), and triethylamine (157 mg, 1.56 mmol, 1.5 eq.) were stirred in a flask, followed by addition of 5-methy1-2-oxo-1,3-dioxo1-4-yemethyl p-nitrophenyl carbonate (366 mg, 1.24 mmol, 1.2 eq.).
The mixture was stirred at rt for 16 h, followed by addition of water (20 mL) and ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified on a silica-gel column (eluent, DCM-methanol from 100:0 to 100:3), giving compound 97 (355 mg, 54%): 1H NMR (500 MHz, DMSO-d6): a 2.25 (s, 3H), 2.76 (d, J=4.3 Hz, 3H), 5.40 (s, 2H), 7.19 (s, 1H), 7.37 (s, 3H), 7.42 (d, J=8.2 Hz, 1H), 7.51 (s, 1H), 7.75-7.84 (m, 2H), 7.87 (s, 1H), 7.93 (d, J=16.0 Hz, 1H), 8.16 (s, 1H), 8.32 (d, J=8.2 Hz, 1H), 8.40 (s, 1H), 8.66 (s, 1H);13C NMR
(125MHz, DMSO-d6): 6 9.47, 26.53, 57.47, 117.08, 121.27, 122.89,123.63, 124.40, 124.11, 127.55, 128.44, 130.89, 131.75, 133.08, 134.17, 134.98, 137.55, 138.20, 138.60, 141.46, 141.66, 147.83, 149.92, 150.23, 152.24, 154.21, 168.18; nVz(ESI+):
543.0 (M+H).
[00192]
Example 38: Synthesis of N-methy1-24(1-(2-hydroxyethoxycabony1)-34(1E)-2-(2-pyridinynetheny1)-1H-indazol-6-yl)thio)benzamide (compound 48) and its hydrochloride (compound 98).
Example 38: Synthesis of N-methy1-24(1-(2-hydroxyethoxycabony1)-34(1E)-2-(2-pyridinynetheny1)-1H-indazol-6-yl)thio)benzamide (compound 48) and its hydrochloride (compound 98).
[00193]
A mixture of ethylene glycol (4.2 g, 71.7 mmol, 5.0 eq.), DCM (40 mL), triethylamine (1.15 g, 11.3 mmol, 2.0 eq.), tert-butyldimethylsily1 chloride (2 g, 13.3 mmol, 1.0 eq), and 4-dimethylaminopyridine (322 mg, 2.66 mmol, 0.2 eq) was stirred at it for 16 h, and concentrated to remove the solvent. The residual material was purified on a silica-gel column (eluent: per-ether and ethyl acetate from 100:0 to 80:20), providing 2-(tert-butyldimethylsilyloxy)ethanol (1.93 g, 82%).
A mixture of ethylene glycol (4.2 g, 71.7 mmol, 5.0 eq.), DCM (40 mL), triethylamine (1.15 g, 11.3 mmol, 2.0 eq.), tert-butyldimethylsily1 chloride (2 g, 13.3 mmol, 1.0 eq), and 4-dimethylaminopyridine (322 mg, 2.66 mmol, 0.2 eq) was stirred at it for 16 h, and concentrated to remove the solvent. The residual material was purified on a silica-gel column (eluent: per-ether and ethyl acetate from 100:0 to 80:20), providing 2-(tert-butyldimethylsilyloxy)ethanol (1.93 g, 82%).
[00194]
2-(tert-Butyldimethylsilyloxy)ethanol (1.93 g, 11.0 mmol, 1.0 eq.) was mixed with DCM (10 mL) and triethylamine (2.22 g, 22.0 mmol, 2.0 eq.) in a flask and cooled to 0 t in an ice-water bath. To the cold mixture was added a solution of p-nitrophenyl chloroformate (2.65 g, 13.2 mmol, 1.2 eq.) in DCM (10 nth) dropwise. After the reaction temperature was raised to it, the mixture was stirred at it for 16 h. The mixture was concentrated; and the residual material was extracted between ethyl acetate and water (40 mL each). The organic layer was separated and concentrated to a residue. The residual material was purified (silica-gel column; eluent, pet-ether and ethyl acetate from 100:0 to 80:20), giving 2-(tert-butyldimethylsilyloxy)ethyl p-nitrophenyl carbonate (3 g, 81%).
Axitinib (400 mg, 1.04 mmol, 1.0 eq.), DMF (6 mL), and triethylamine (79 mg, 2.08 mmol, 2.0 eq.) were mixed in a flask and stirred, followed by addition of 2-(tert-butyldimethylsilyloxy)ethyl p-nitrophenyl carbonate (424 mg, 1.25 mmol, 1.2 eq.). The mixture was stirred at rt for 16 h, followed by addition of water (20 mL) and ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 100:3), giving N-methyl-2-((1-(2-(tert-butyldimetylsilyoxyethoxycabony1)-3-01E)-2-(2-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide (600 mg, 98%) as silyl-protected intermediate. The intermediate (600 mg) was stirred in ethanol (10 mL) containing concentrated HC1 (0.1 mL) at a for 3 h.
The solid material was collected by filtration, dissolved in water, and freeze-dried, giving compound 98 (290 mg, 56%): 111NMR (500 MHz, DMSO-d6): 6 2.75 (d, J=4.4 Hz, 3H), 3.55-3.88 (m, 2H), 4.36-4.64 (m, 2H), 7.21 (d, J=7.1 Hz, 111), 7.38 (dd, J=10.2, 5.5 Hz, 311), 7.53 (d, J=7.1 Hz, 1H), 7.73-7.86 (m, 1H), 8.01 (d, J=16.7 Hz, 111), 8.13 (s, 1H), 8.25-8.35 (m, 211), 8.43 (dd, J=22.1, 3.9 Hz, 311), 8.80 (d, J=5.2 Hz, 1H);13C
NMR (125 MHz, DMSO-d6): 326.54, 59.24, 70.07, 116.96, 122.47, 123.24, 124.78, 125.72, 127.14, 127.74, 128.12, 128.48, 130.94, 132.13, 133.77, 138.57, 138.91, 141.39, 143.95, 144.19, 146.31, 150.35, 168.28; m/z(ESI+): 475.1(M+H).
2-(tert-Butyldimethylsilyloxy)ethanol (1.93 g, 11.0 mmol, 1.0 eq.) was mixed with DCM (10 mL) and triethylamine (2.22 g, 22.0 mmol, 2.0 eq.) in a flask and cooled to 0 t in an ice-water bath. To the cold mixture was added a solution of p-nitrophenyl chloroformate (2.65 g, 13.2 mmol, 1.2 eq.) in DCM (10 nth) dropwise. After the reaction temperature was raised to it, the mixture was stirred at it for 16 h. The mixture was concentrated; and the residual material was extracted between ethyl acetate and water (40 mL each). The organic layer was separated and concentrated to a residue. The residual material was purified (silica-gel column; eluent, pet-ether and ethyl acetate from 100:0 to 80:20), giving 2-(tert-butyldimethylsilyloxy)ethyl p-nitrophenyl carbonate (3 g, 81%).
Axitinib (400 mg, 1.04 mmol, 1.0 eq.), DMF (6 mL), and triethylamine (79 mg, 2.08 mmol, 2.0 eq.) were mixed in a flask and stirred, followed by addition of 2-(tert-butyldimethylsilyloxy)ethyl p-nitrophenyl carbonate (424 mg, 1.25 mmol, 1.2 eq.). The mixture was stirred at rt for 16 h, followed by addition of water (20 mL) and ethyl acetate (30 mL). The organic layer was separated, washed with brine (3 x 30 mL), and concentrated. The residual material was purified (silica-gel column; eluent, DCM-methanol from 100:0 to 100:3), giving N-methyl-2-((1-(2-(tert-butyldimetylsilyoxyethoxycabony1)-3-01E)-2-(2-pyridinyfletheny1)-1H-indazol-6-yl)thio)benzamide (600 mg, 98%) as silyl-protected intermediate. The intermediate (600 mg) was stirred in ethanol (10 mL) containing concentrated HC1 (0.1 mL) at a for 3 h.
The solid material was collected by filtration, dissolved in water, and freeze-dried, giving compound 98 (290 mg, 56%): 111NMR (500 MHz, DMSO-d6): 6 2.75 (d, J=4.4 Hz, 3H), 3.55-3.88 (m, 2H), 4.36-4.64 (m, 2H), 7.21 (d, J=7.1 Hz, 111), 7.38 (dd, J=10.2, 5.5 Hz, 311), 7.53 (d, J=7.1 Hz, 1H), 7.73-7.86 (m, 1H), 8.01 (d, J=16.7 Hz, 111), 8.13 (s, 1H), 8.25-8.35 (m, 211), 8.43 (dd, J=22.1, 3.9 Hz, 311), 8.80 (d, J=5.2 Hz, 1H);13C
NMR (125 MHz, DMSO-d6): 326.54, 59.24, 70.07, 116.96, 122.47, 123.24, 124.78, 125.72, 127.14, 127.74, 128.12, 128.48, 130.94, 132.13, 133.77, 138.57, 138.91, 141.39, 143.95, 144.19, 146.31, 150.35, 168.28; m/z(ESI+): 475.1(M+H).
[00195] Compound 98 (1.0 g, 1.7 mmol, 1.0 eq.) was dissolved in water (20 mL), followed by addition of DCM (100 nth). The pH of the mixture was adjusted to 7-8 with aq. NaHCO3. Solid material was removed by precipitation. Me0H (20 mL) was added dropwise to the mixture. The organic layer was separated, washed with brine (3 x 20 mL), dried (Na2SO4), and evaporated to dryness. The residue was triturated with MTBE
(30 mL) and filtered to afford compound 48 as a white solid (600 mg, 74.5%):
Ill NMR
(500 MHz, DMSO-d6): 5 2.75 (d, J=4.4 Hz, 3H), 3.74 (d, J=4.2 Hz, 2H), 4.47 (s, 2H), 5.07 (t, J=5.4 Hz, 1H), 7.18 (d, J=6.9 Hz, 1H), 7.38 (dd, J=16.8, 7.2 Hz, 4H), 7.52 (d, J=5.2 Hz, 1H), 7.78 (t, J=11.9 Hz, 2H), 7.86 (t, 1=6.8 Hz, 1H), 7.93 (d, 1=16.4 Hz, 1H), 8.17 (s, 1H), 8.31 (d, J=8.4 Hz, 1H), 8.43 (d, J=4,5 Hz, 1H), 8.65 (d, 1=3.0 Hz, 1H); 13C
NMR (125 MHz, DMSO-d6): 5 26.16, 58.89, 69.45, 116.88, 121.07, 122.35, 123.13, 12337, 127.10, 127.74, 128.04, 130.54, 131.34, 133.91, 134.23, 137.11, 137.49, 138.14, 140.97, 147.00, 149.92, 153.88, 167.88; m/z(ESI+): 475.1(M+H).
(30 mL) and filtered to afford compound 48 as a white solid (600 mg, 74.5%):
Ill NMR
(500 MHz, DMSO-d6): 5 2.75 (d, J=4.4 Hz, 3H), 3.74 (d, J=4.2 Hz, 2H), 4.47 (s, 2H), 5.07 (t, J=5.4 Hz, 1H), 7.18 (d, J=6.9 Hz, 1H), 7.38 (dd, J=16.8, 7.2 Hz, 4H), 7.52 (d, J=5.2 Hz, 1H), 7.78 (t, J=11.9 Hz, 2H), 7.86 (t, 1=6.8 Hz, 1H), 7.93 (d, 1=16.4 Hz, 1H), 8.17 (s, 1H), 8.31 (d, J=8.4 Hz, 1H), 8.43 (d, J=4,5 Hz, 1H), 8.65 (d, 1=3.0 Hz, 1H); 13C
NMR (125 MHz, DMSO-d6): 5 26.16, 58.89, 69.45, 116.88, 121.07, 122.35, 123.13, 12337, 127.10, 127.74, 128.04, 130.54, 131.34, 133.91, 134.23, 137.11, 137.49, 138.14, 140.97, 147.00, 149.92, 153.88, 167.88; m/z(ESI+): 475.1(M+H).
[00196] Example 39: Pharmacokinetic studies (a).
[00197] Test articles were prepared in suspension in a mixture of DMSO (5%) and 0.5%-CMC-Na (95%, v/v), at a concentration of 3 mg/mL axitinib-molar-equivalence for each test article. Male ICR mice (64, body weight ranging18-22 g) were grouped randomly in 4 groups (16 animals per group). Test articles were administered to animals through oral-gavage, at a dose of molar-equivalent to 30 mg/kg of axitinib, after the animals were fasted for 12 h. Blood samples were collected from orbit to heparinized EP
tube at time points of 0.25, 0.5, 1, 2, 4, 6, and 8 h following the administration of the dosing solution. Blood samples were centrifuged at 5,000 rpm and 4 C for 10 min, and plasma samples were collected and kept at -80 C. Sample analysis: Plasma sample (10 i.t.L) was mixed well with acetonitrile (110 ELL). The sample was then centrifuged at 12,000 rpm and 4 C. The supernatant was analyzed with an LC-MS/MS instrument, and the target analytes were axitinib and its corresponding prodrug molecules. The axitinib plasma concentration-time curves are given in FIG. 1 after oral administration of axitinib, compounds 1, 5, and 10 to the animals.
tube at time points of 0.25, 0.5, 1, 2, 4, 6, and 8 h following the administration of the dosing solution. Blood samples were centrifuged at 5,000 rpm and 4 C for 10 min, and plasma samples were collected and kept at -80 C. Sample analysis: Plasma sample (10 i.t.L) was mixed well with acetonitrile (110 ELL). The sample was then centrifuged at 12,000 rpm and 4 C. The supernatant was analyzed with an LC-MS/MS instrument, and the target analytes were axitinib and its corresponding prodrug molecules. The axitinib plasma concentration-time curves are given in FIG. 1 after oral administration of axitinib, compounds 1, 5, and 10 to the animals.
[00198] Example 40: Pharmacokinetic studies (b).
[00199] Male ICR mice (body weight: 18 to 22 g) were divided into 6 groups randomly with 6 animals per group, with blood sample collection from 6 animals at each time point for a total of 6 time points. Dosing solution of a test article was prepared by dissolving or suspending a compound in a solvent system as indicated in Table 2. For all the compounds, the concentration of dosing solution was 3 mg/mL of axitinib molar equivalent, and the dose was 30 mg/kg of axitinib molar equivalent. Animals were fasted for 12 h, and then given the test article in dosing media at a dosing volume calculated according to the above information. After dosing, blood samples were collected at the pre-set time points of 0.5, 1, 2, 4, 6, and 8 h. Blood samples were centrifuged at 5,000 rpm and 4 C for 10 mm, and plasma samples were collected and kept at -80 C.
Sample analysis: Plasma sample (20 lath) was mixed well with acetonitrile (220 LtL).
The sample was then centrifuged at 12,000 rpm and 4 C. The supernatant was analyzed with an LC-MS/MS instrument, and the target analytes were axitinib and its corresponding prodrug molecules. Table 2 gives pharma#cokinetic parameters for some test compounds following administration of the corresponding prodrugs to the animals.
Table 2. PK parameters for axitinib following administration of prodrugs to the animals.
Compd AUC(0.4) t1/2z Tmax Vz/F CLz/F Cmax Solvent number (uwuk h) (h) (h) (L./kg) (Uh/kg) (ug/L) media*
15 3485 1 0.8 9 17 3901 1 1.3 8 19 5515 1 0.8 5 22 300 2.2 146 82 75 300 B
39 2179 1 1.3 14 44 1187 1.4 0.6 32.3 45 693 2.4 0.4 96 27 429 B
46 491 2.6 0.4 158 48 7340.25 1.0 12 7.4 5 2888 F
49 10169 1.5 0.4 5.0 50 9389 1 0.4 3.5 51 4162 1 0.4 7.6 67 3156 1.3 3 12.5 92 11342 0.8 0.4 2.1 1.9 5260 B
98 6394 0.8 0.7 5.75 4.96 2732 B
* A: 0.5% CMC-Na; B: 5% DMSO and 95% 0.5%-CMC-Na; C: 2% DMSO, 10% Et0H, and 88% 0.5%-CMC-Na; D: 10% DMSO and 90% 0.5%-CMC-Na; E: 2% DMSO and 98% 0.5%-CMC-Na; F:
5%DMS0+93% (0.5%CMC-Na)+2%HCOOH.
Sample analysis: Plasma sample (20 lath) was mixed well with acetonitrile (220 LtL).
The sample was then centrifuged at 12,000 rpm and 4 C. The supernatant was analyzed with an LC-MS/MS instrument, and the target analytes were axitinib and its corresponding prodrug molecules. Table 2 gives pharma#cokinetic parameters for some test compounds following administration of the corresponding prodrugs to the animals.
Table 2. PK parameters for axitinib following administration of prodrugs to the animals.
Compd AUC(0.4) t1/2z Tmax Vz/F CLz/F Cmax Solvent number (uwuk h) (h) (h) (L./kg) (Uh/kg) (ug/L) media*
15 3485 1 0.8 9 17 3901 1 1.3 8 19 5515 1 0.8 5 22 300 2.2 146 82 75 300 B
39 2179 1 1.3 14 44 1187 1.4 0.6 32.3 45 693 2.4 0.4 96 27 429 B
46 491 2.6 0.4 158 48 7340.25 1.0 12 7.4 5 2888 F
49 10169 1.5 0.4 5.0 50 9389 1 0.4 3.5 51 4162 1 0.4 7.6 67 3156 1.3 3 12.5 92 11342 0.8 0.4 2.1 1.9 5260 B
98 6394 0.8 0.7 5.75 4.96 2732 B
* A: 0.5% CMC-Na; B: 5% DMSO and 95% 0.5%-CMC-Na; C: 2% DMSO, 10% Et0H, and 88% 0.5%-CMC-Na; D: 10% DMSO and 90% 0.5%-CMC-Na; E: 2% DMSO and 98% 0.5%-CMC-Na; F:
5%DMS0+93% (0.5%CMC-Na)+2%HCOOH.
[00200] Example 41: Anti-tumor activity of selected compounds in an EN1903-3 HT-29 animal model.
[00201] The HT29 model was created using male Balb/c Nude mice, 16-18 g body weight, (Balb/c Nude mice, SPF grade from Shanghai Qinlong Biotechnology Co., Ltd., Shanghai, China), as follows : a) HT29 cells were cultured and expanded until enough cells were obtained, then the cells were collected; b) HT29 cells were suspended in serum-free M5A culture media at a concentration of 3.0 x 107cells/mL, total 15 nth; c) A
total of 130 Balb/c nude mice were subcutaneously inoculated with 0.1 mL cell suspension per mouse (or 3.0 x 106 cells/mouse). After the tumor reached 100 MM3 to 200 MM in size, 90 animals with adequate tumor sizes were grouped randomly (10 animals per group), and assigned to day 1. Each group was given a number as follows:
G 1, Control; G2, axitinib at 10 mg/kg; G3, axitinib at 30 mg/kg; G4, compound 1 at 10 mg/kg molar equivalent of axitinib; G5, compound 1 at 30 mg/kg of molar equivalent of axitinib; G6, compound 5 at 10 mg/kg molar equivalent of axitinib; G7, compound 5 at 30 mg/kg molar equivalent of axitinib; G8, compound 10 at 10 mg/kg molar equivalent of axitinib; G9, compound 10 at 30 mg/kg of molar equivalent of axitinib. All the test articles were dosed in dosing media of 5%DMS0+95%(0.5%CMC-Na) through oral gavage at a dosing volume of 10 mlikg. During the first 7 days (day 1 to day 7), the animals were treated with the test article once a day (QID). From day 8, the treatment was twice daily (BID) until day 19, when the study was terminated. On day 19, the tumor size and weight were measured and recorded. The average tumor size and weight for each group is given in FIG. 2 and FIG. 3. No animal death was observed during the entire study period for all groups.
total of 130 Balb/c nude mice were subcutaneously inoculated with 0.1 mL cell suspension per mouse (or 3.0 x 106 cells/mouse). After the tumor reached 100 MM3 to 200 MM in size, 90 animals with adequate tumor sizes were grouped randomly (10 animals per group), and assigned to day 1. Each group was given a number as follows:
G 1, Control; G2, axitinib at 10 mg/kg; G3, axitinib at 30 mg/kg; G4, compound 1 at 10 mg/kg molar equivalent of axitinib; G5, compound 1 at 30 mg/kg of molar equivalent of axitinib; G6, compound 5 at 10 mg/kg molar equivalent of axitinib; G7, compound 5 at 30 mg/kg molar equivalent of axitinib; G8, compound 10 at 10 mg/kg molar equivalent of axitinib; G9, compound 10 at 30 mg/kg of molar equivalent of axitinib. All the test articles were dosed in dosing media of 5%DMS0+95%(0.5%CMC-Na) through oral gavage at a dosing volume of 10 mlikg. During the first 7 days (day 1 to day 7), the animals were treated with the test article once a day (QID). From day 8, the treatment was twice daily (BID) until day 19, when the study was terminated. On day 19, the tumor size and weight were measured and recorded. The average tumor size and weight for each group is given in FIG. 2 and FIG. 3. No animal death was observed during the entire study period for all groups.
[00202]
Although this invention is described in detail with reference to embodiments thereof, these embodiments are offered to illustrate but not to limit the invention. It is possible to make other embodiments that employ the principles of the invention and that fall within its spirit and scope as defined by the claims appended hereto.
Although this invention is described in detail with reference to embodiments thereof, these embodiments are offered to illustrate but not to limit the invention. It is possible to make other embodiments that employ the principles of the invention and that fall within its spirit and scope as defined by the claims appended hereto.
[00203] The contents of all documents and references cited herein are hereby incorporated by reference in their entirety.
Claims (37)
1. A compound of Formula I, or a pharmaceutically acceptable salt or ester thereof:
t1-13 , R' \
(1) where, RI and R2 are independently a hydrogen or a protecting group selected from acyl group, alkylcarbonyl group, arylcarbonyl group, alkylthiocarbonyl group, arylthiocarbonyl group, alkylcarbamoyl group, arylcarbamoyl group, substituted or unsubstituted acetyl, substituted or unsubstituted aminoalkanoyl, substituted or unsubstituted a-aminoalkanoyl, an acyl group derived from a natural or an unnatural amino acid with or without substitution, an acyl group of a peptide residue, phosphonyl, phosphinyl, aminophophinyl, alkylaminophophinyl, sulfonyl, cycloalkane-carbonyl, heterocycloalkane-carbonyl, alkoxycarbonyl, aryloxycarbonyl, heteroalkoxycarbonyl, heteroaryloxycarbonyl, and 0-substituted hydroxymethyl group with or without substituents; and R3 is absent or a protecting group selected from acyl group, carbonyl group, thiocarbonyl group, carbamoyl group, substituted or unsubstituted acetyl, substituted or unsubstituted aminoalkanoyl, substituted or unsubstituted a-aminoalkanoyl, an acyl group derived from a natural or an unnatural amino acid with or without substitution, an acyl group of a peptide residue, cycloalkane-carbonyl, heterocycloalkane-carbonyl, alkoxycarbonyl, aryloxycarbonyl, heteroalkoxycarbonyl, heteroaryloxycarbonyl, and 0-substituted hydroxymethyl group with or without substituents;
provided that the compound of Formula I is not axitinib.
t1-13 , R' \
(1) where, RI and R2 are independently a hydrogen or a protecting group selected from acyl group, alkylcarbonyl group, arylcarbonyl group, alkylthiocarbonyl group, arylthiocarbonyl group, alkylcarbamoyl group, arylcarbamoyl group, substituted or unsubstituted acetyl, substituted or unsubstituted aminoalkanoyl, substituted or unsubstituted a-aminoalkanoyl, an acyl group derived from a natural or an unnatural amino acid with or without substitution, an acyl group of a peptide residue, phosphonyl, phosphinyl, aminophophinyl, alkylaminophophinyl, sulfonyl, cycloalkane-carbonyl, heterocycloalkane-carbonyl, alkoxycarbonyl, aryloxycarbonyl, heteroalkoxycarbonyl, heteroaryloxycarbonyl, and 0-substituted hydroxymethyl group with or without substituents; and R3 is absent or a protecting group selected from acyl group, carbonyl group, thiocarbonyl group, carbamoyl group, substituted or unsubstituted acetyl, substituted or unsubstituted aminoalkanoyl, substituted or unsubstituted a-aminoalkanoyl, an acyl group derived from a natural or an unnatural amino acid with or without substitution, an acyl group of a peptide residue, cycloalkane-carbonyl, heterocycloalkane-carbonyl, alkoxycarbonyl, aryloxycarbonyl, heteroalkoxycarbonyl, heteroaryloxycarbonyl, and 0-substituted hydroxymethyl group with or without substituents;
provided that the compound of Formula I is not axitinib.
2. A compound of Formula II, or a pharmaceutically acceptable salt or ester thereof:
N/
N---N
RL
(II), where, RI and R2 are independently a hydrogen or a protecting group, wherein:
(a) the protecting group is selected from acyl group, alkylcarbonyl group, arylcarbonyl group, alkylthiocarbonyl group, arylthiocarbonyl group, alkylcarbamoyl group, arylcarbamoyl group, substituted or unsubstituted acetyl, substituted or unsubstituted aminoalkanoyl, substituted or unsubstituted a-aminoalkanoyl, an acyl group derived from a natural or an unnatural amino acid with or without substitution, an acyl group of a peptide residue, phosphonyl, phosphinyl, aminophophinyl, alkylaminophophinyl, sulfonyl, cycloalkane-carbonyl, heterocycloalkane-carbonyl, alkoxycarbonyl, aryloxycarbonyl, heteroalkoxycarbonyl, heteroaryloxycarbonyl, and 0-substituted hydroxymethyl group with or without substituents; or (b) the protecting group is R4W(R5R6C)m¨, where m is an integer selected from to 6; W is oxygen (-Co-), sulfur (-S-), nitrogen (-NM), or absent; R5 and R6 are ORS
independently a hydrogen or a lower alkyl group; and R4 is X ___________________________________ P ___________ I I
fl o , or o , where X is oxygen (-0-), sulfur (-S-), nitrogen (-NH-). or a methylene (-CH2-) group; R6 and R7 are independently a hydrogen, a substituted or unsubstituted alkyl or cycloalkyl, an aryl or heteroaryl group without or with substitution, a PEG moiety, an ester-forming group, or a salt-forming moiety when X is oxygen or sulfur; or, the combination of R6 and X
is an alky or aryl group with or without further substitution;
provided that the compound of Formula II is not axitinib.
N/
N---N
RL
(II), where, RI and R2 are independently a hydrogen or a protecting group, wherein:
(a) the protecting group is selected from acyl group, alkylcarbonyl group, arylcarbonyl group, alkylthiocarbonyl group, arylthiocarbonyl group, alkylcarbamoyl group, arylcarbamoyl group, substituted or unsubstituted acetyl, substituted or unsubstituted aminoalkanoyl, substituted or unsubstituted a-aminoalkanoyl, an acyl group derived from a natural or an unnatural amino acid with or without substitution, an acyl group of a peptide residue, phosphonyl, phosphinyl, aminophophinyl, alkylaminophophinyl, sulfonyl, cycloalkane-carbonyl, heterocycloalkane-carbonyl, alkoxycarbonyl, aryloxycarbonyl, heteroalkoxycarbonyl, heteroaryloxycarbonyl, and 0-substituted hydroxymethyl group with or without substituents; or (b) the protecting group is R4W(R5R6C)m¨, where m is an integer selected from to 6; W is oxygen (-Co-), sulfur (-S-), nitrogen (-NM), or absent; R5 and R6 are ORS
independently a hydrogen or a lower alkyl group; and R4 is X ___________________________________ P ___________ I I
fl o , or o , where X is oxygen (-0-), sulfur (-S-), nitrogen (-NH-). or a methylene (-CH2-) group; R6 and R7 are independently a hydrogen, a substituted or unsubstituted alkyl or cycloalkyl, an aryl or heteroaryl group without or with substitution, a PEG moiety, an ester-forming group, or a salt-forming moiety when X is oxygen or sulfur; or, the combination of R6 and X
is an alky or aryl group with or without further substitution;
provided that the compound of Formula II is not axitinib.
3. The compound of claim 2, wherein the PEG moiety is RicL(OCH2CH2)¨, where n is 1 to 10, and RI is a hydrogen or a lower alkyl.
4. The compound of claim 2 or 3, wherein the ester-forming group is a lower alkyl or an aryl group.
5. The compound of any one of claims 2 to 4, wherein the salt-forming moiety is a sodium, a potassium, a tetraethylammonium, or a tetrabutylammonium.
6. The compound of claim 1, wherein the compound is a compound of Formula III, or a pharmaceutically acceptable salt or ester thereof:
T-I
---___ S
c, 14 1 Y`-' µ = N---mi R' (III), where, R3 is absent or a protecting group, wherein:
(a) the protecting group is selected from acyl group, carbonyl group, thiocarbonyl group, carbamoyl group, substituted or unsubstituted acetyl, substituted or unsubstituted aminoalkanoyl, substituted or unsubstituted a-aminoalkanoyl, an acyl group derived from a natural or an unnatural amino acid with or without substitution, an acyl group of a peptide residue, cycloalkane-carbonyl, heterocycloalkane-carbonyl, alkoxycarbonyl, aryloxycarbonyl, heteroalkoxycarbonyl, heteroaryloxycarbonyl, and 0-substituted hydroxymethyl group with or without substituents;
; or (b) the protecting group is R4W(R5R6C)m¨, where m is an integer selected from to 6; W is oxygen (-Co-), sulfur (-S-), nitrogen (-NFI-), or absent; R5 and R6 are OR&
R7X ¨P¨
I I
independently a hydrogen or a lower alkyl group; and R4 is I I
X ¨P ¨ R7X¨S¨ R7X¨O¨
I I
0 , Or o , where X is oxygen (-OA
sulfur (-SA
nitrogen (-NH-), or a methylene (-CH2-) group; R6 and R7 are independently a hydrogen, a substituted or unsubstituted alkyl or cycloalkyl, an aryl or heteroaryl group without or with substitution, a PEG moiety, an ester-forming group, or a salt-forming moiety when X is oxygen or sulfur; or, the combination of R6 and X
is an alky or aryl group with or without further substitution;
provided that the compound of Formula In is not axitinib.
T-I
---___ S
c, 14 1 Y`-' µ = N---mi R' (III), where, R3 is absent or a protecting group, wherein:
(a) the protecting group is selected from acyl group, carbonyl group, thiocarbonyl group, carbamoyl group, substituted or unsubstituted acetyl, substituted or unsubstituted aminoalkanoyl, substituted or unsubstituted a-aminoalkanoyl, an acyl group derived from a natural or an unnatural amino acid with or without substitution, an acyl group of a peptide residue, cycloalkane-carbonyl, heterocycloalkane-carbonyl, alkoxycarbonyl, aryloxycarbonyl, heteroalkoxycarbonyl, heteroaryloxycarbonyl, and 0-substituted hydroxymethyl group with or without substituents;
; or (b) the protecting group is R4W(R5R6C)m¨, where m is an integer selected from to 6; W is oxygen (-Co-), sulfur (-S-), nitrogen (-NFI-), or absent; R5 and R6 are OR&
R7X ¨P¨
I I
independently a hydrogen or a lower alkyl group; and R4 is I I
X ¨P ¨ R7X¨S¨ R7X¨O¨
I I
0 , Or o , where X is oxygen (-OA
sulfur (-SA
nitrogen (-NH-), or a methylene (-CH2-) group; R6 and R7 are independently a hydrogen, a substituted or unsubstituted alkyl or cycloalkyl, an aryl or heteroaryl group without or with substitution, a PEG moiety, an ester-forming group, or a salt-forming moiety when X is oxygen or sulfur; or, the combination of R6 and X
is an alky or aryl group with or without further substitution;
provided that the compound of Formula In is not axitinib.
7. The compound of claim 6, wherein the PEG moiety is RIckOCH2CH2)11¨, where n is 1 to 1 0, and Rth is a hydrogen or a lower alkyl.
8. The compound of claim 6 or 7, wherein the ester forming group is a lower alkyl or an aryl group.
9. The compound of any one of claims 6 to 8, wherein the salt-forming moiety is a sodium, a potassium, a tetraethylammonium, or a tetrabutylammonium.
1 0. The compound of any one of claims 1 to 9, wherein the compound is:
I \
N --/ \
/ \
N-- /
N -N, N:1 N.' 0 rj-I-41D 0 N--I. tr-H
/
/ \
N--/ \
N' SO
N -if i_j --4.µ0 N,/ 110 40 Ir N
01 a o-rO
, 0-µ
( 0 * r FF4--1 F
101 I( , -ril / \
/ \
ri -/ \
NI- N-N: 0 0 f H N
0f H N
N.:, 0 0 ,,,/
11,N 0 ' NN
11 + 0 Fs--= * N"--H -)---µ0 S 0 N-- FF-)----k s 0 a*
. le " F 0 101 iir WV
s s s s / \
/ \ N.-N-/ \
N
NI
--i_ : 1101 I-I N
' S 0 _... 01-f fk:7 IS N"....
NI: *
N-- N-Alba * isr--H
. Wr-HN, ROC le "
/ \
/ \
/ \ N --N--N-N/
, 0 1-1 1.4 N -1Dizz 0 N- i Ft.-"---V.
157.-4 01 40 FIW.- d 0'---"t. r '0 le N----H
_)-0 -(S) 0 * 11----fii a HN,,,,M F
s s s / \ / \ / µ
N --- NI¨
N ¨
N / ill 0 N ie / ' 0 N/
*
/ 'H p 0 H N S 0 0/ H' N 0 s *=
H
. *
0¨
, , , , , . , N ¨
N ¨
/ \
*
N S 0 -----cee N
di 07'/ 0 s 0 N-9,,,(0--_,A-14.-.J.%
0 lc-- ---__ N
CL " 0 Fr 0 13) H
0 o() _r0 04o 0\h N...-õ
H
.
. 9 / \
N ¨
/ \
N.( 1.0 / \ N---N ¨
4 r i N( 1101 N,/ * N
H
o N=
V
101 ), ¨rjr/
0 , =, / \
N--/ µ
---N ¨
N./ I /\. N`
N S = ¨
hi,/ III
OA
/ 0 SI it S =
0:N
V .- PC
0-21%
*
*
.
. .
/ \
N ---, N:1 0 N S 0 \ / N /
\
H N"--Oa k N f IP
H
== 0, A 11: 0 so ap 40 N.R. ear N
H
S
aN HO 0 , I
_.P-..
HO '0 / \
, / \
, N.- CHaS02- H
l'e 0 s N = N
TI
Ft , rol 0 0 0 j H s o oa ni-le " 40 r J
/ \ / \
/
N-, , , NI
, N 0 =
N 5 = 1-1 1-1H 100 N *
---N"- ,0 0 0=P-0 6 \¨o 0=P-0 L
11:(0.---.%0A ) 0 1 ( 0 frO OyO 0 ?¨
, , , / \
N- N --ci-NI
N
N,/
0) 'PI S 0 iN 1 s 0 o.),..
*
N.--SI) 11 H
H2tc, * 11 , 0 , .
/ \
N -, / \
/ \
N -N---N,./ lip , , , 0, N s o --- %.k N,./ [110 0¨es4r D SI i N
i t O. N--t / /
/ \
ti---, ,... N
N-N :it 1101 N
S Ili i r J 0 s r - N:f 0 N
J..
N*
N
= cA, rj o 140 11( f----' r j040 0 I(' jr-- 0 f goo' - o ?
I
/ \
/ \
N -N-HCI ---___ , NI *
N S 0 N t/14 110 N, 0 N
Cr-4 rrµO
0-4 ri 0 H
it r r., 0 =
-< HO
HO
, , 9 / \
/ µ
N-HCI ----N--HCI ---N:f 0 Nµi 0 N
N
I
N.---04 7 ri 0 . "
ri 0 0 r 0_r [-I
ri er"
HO HO
, , / \
/ \
N-N--___ N
: 0 N.:1 *
/ \ ...-N =
N- i (06i-o =
N- 0.--f ND
0\1 110 Nat? -P-We -____ H
H
NI * cp de' Zo (3 , \'µi I) N i 0.õ
OW r 0,) ( oti 0,) Co Co / /
/
, , , / \ / \
/ \
N ¨ N ¨
N ¨
=
N, N, ''. N: *
/ /
0 H N S 0 0 H N S 0 e/
N'''' "--' g 0 N - I
H
P--0 tre H
)0 ilScj 'It .
/ \
/ \
/ \ N "--N --- N--, N =
, (010 i 01 N,1 0 N-P/-/ 1,/
-N H N
S 0 a 0 Ce---t 0-- SI
-P, -.-- NH
H
H Oil 6 --ID * N
i ty *
/ 1 \
/ \ / 1 \
N -'-. N ¨
N --, N: 01 N: 0 N
µ
,-,-=
0-, 0 H N S 0 H N S. 0 N-151__ 0 -IS N-.D! ,..)_1,11 i W.-H
N ate H
0 ' --CI
1110 N'' H
I II_ I
NH NH
S
/ \
/ \ / \
N -- N --N --, N
: 0 N: 401 N la / /
0 H N S 0 0".H N S 0 .---N In -P, .---Or A co 40 0)----tt -.
* itilf.-._, * N
H
H
N .
Cr-N 0 NH
/
/ /
/ \
/ \
/ \
N '--N -.-, N --Nf 11101 Nf 1101 N I
oz H 'N 0 Z
0, N
i S 0 S
= ...--0/ H N S 0 N - / Orl d 'ID . N
H
N,-N ,--*
H
NH
N
S \
/
/ /
/ \
/ \ N ---/ \
N -'-N -'-N 1 00./ H N
)_ N: 0 0." H N S =
tr" 0 H N S =
t S
14=- pc: N =-- I 0)."-1 '.
411 "
P
0 140 r afif 0-41. ot s 101 r . Now .
/ \
/ \
N ". / µ
N -..-NI -"-)- N./ 110 S 0 P N: *
0 11 N /IS' N / 0 N /
W. 1 OXt Ns N--- a H 'N
o 40 " N-pi,s o AO c").-t 6=
lisi r 00 Ni--th40 "
, a i I es , , / , / , N '--/ \
N `
N ---/ 0 0'0 H RN *
N
S 0 P NI 0 W.- /
Cra--0 H 44 S 0 Rz,s Pr-N i 1µ1== / II' ' 0)---i- ,P---s )---0 "
0 * W.
0 I( ap 0 *
7 0(- 7 / \
/ \
N '-- / \
N "-N -H
a0 N'N *
0 H N S 0 N : *
N ,.
cel i -'0 40 "-- ac, H N S 0 HN A' 0 0 II. N -lc 0 ap 0 le H
ap ...a:
*=
0 wr.
, , , , , , , N--- N ---N -.--N s: 0 Nµ1 0 / /
/
s 001 r i . 0 N .
N
---' N
1 0. The compound of any one of claims 1 to 9, wherein the compound is:
I \
N --/ \
/ \
N-- /
N -N, N:1 N.' 0 rj-I-41D 0 N--I. tr-H
/
/ \
N--/ \
N' SO
N -if i_j --4.µ0 N,/ 110 40 Ir N
01 a o-rO
, 0-µ
( 0 * r FF4--1 F
101 I( , -ril / \
/ \
ri -/ \
NI- N-N: 0 0 f H N
0f H N
N.:, 0 0 ,,,/
11,N 0 ' NN
11 + 0 Fs--= * N"--H -)---µ0 S 0 N-- FF-)----k s 0 a*
. le " F 0 101 iir WV
s s s s / \
/ \ N.-N-/ \
N
NI
--i_ : 1101 I-I N
' S 0 _... 01-f fk:7 IS N"....
NI: *
N-- N-Alba * isr--H
. Wr-HN, ROC le "
/ \
/ \
/ \ N --N--N-N/
, 0 1-1 1.4 N -1Dizz 0 N- i Ft.-"---V.
157.-4 01 40 FIW.- d 0'---"t. r '0 le N----H
_)-0 -(S) 0 * 11----fii a HN,,,,M F
s s s / \ / \ / µ
N --- NI¨
N ¨
N / ill 0 N ie / ' 0 N/
*
/ 'H p 0 H N S 0 0/ H' N 0 s *=
H
. *
0¨
, , , , , . , N ¨
N ¨
/ \
*
N S 0 -----cee N
di 07'/ 0 s 0 N-9,,,(0--_,A-14.-.J.%
0 lc-- ---__ N
CL " 0 Fr 0 13) H
0 o() _r0 04o 0\h N...-õ
H
.
. 9 / \
N ¨
/ \
N.( 1.0 / \ N---N ¨
4 r i N( 1101 N,/ * N
H
o N=
V
101 ), ¨rjr/
0 , =, / \
N--/ µ
---N ¨
N./ I /\. N`
N S = ¨
hi,/ III
OA
/ 0 SI it S =
0:N
V .- PC
0-21%
*
*
.
. .
/ \
N ---, N:1 0 N S 0 \ / N /
\
H N"--Oa k N f IP
H
== 0, A 11: 0 so ap 40 N.R. ear N
H
S
aN HO 0 , I
_.P-..
HO '0 / \
, / \
, N.- CHaS02- H
l'e 0 s N = N
TI
Ft , rol 0 0 0 j H s o oa ni-le " 40 r J
/ \ / \
/
N-, , , NI
, N 0 =
N 5 = 1-1 1-1H 100 N *
---N"- ,0 0 0=P-0 6 \¨o 0=P-0 L
11:(0.---.%0A ) 0 1 ( 0 frO OyO 0 ?¨
, , , / \
N- N --ci-NI
N
N,/
0) 'PI S 0 iN 1 s 0 o.),..
*
N.--SI) 11 H
H2tc, * 11 , 0 , .
/ \
N -, / \
/ \
N -N---N,./ lip , , , 0, N s o --- %.k N,./ [110 0¨es4r D SI i N
i t O. N--t / /
/ \
ti---, ,... N
N-N :it 1101 N
S Ili i r J 0 s r - N:f 0 N
J..
N*
N
= cA, rj o 140 11( f----' r j040 0 I(' jr-- 0 f goo' - o ?
I
/ \
/ \
N -N-HCI ---___ , NI *
N S 0 N t/14 110 N, 0 N
Cr-4 rrµO
0-4 ri 0 H
it r r., 0 =
-< HO
HO
, , 9 / \
/ µ
N-HCI ----N--HCI ---N:f 0 Nµi 0 N
N
I
N.---04 7 ri 0 . "
ri 0 0 r 0_r [-I
ri er"
HO HO
, , / \
/ \
N-N--___ N
: 0 N.:1 *
/ \ ...-N =
N- i (06i-o =
N- 0.--f ND
0\1 110 Nat? -P-We -____ H
H
NI * cp de' Zo (3 , \'µi I) N i 0.õ
OW r 0,) ( oti 0,) Co Co / /
/
, , , / \ / \
/ \
N ¨ N ¨
N ¨
=
N, N, ''. N: *
/ /
0 H N S 0 0 H N S 0 e/
N'''' "--' g 0 N - I
H
P--0 tre H
)0 ilScj 'It .
/ \
/ \
/ \ N "--N --- N--, N =
, (010 i 01 N,1 0 N-P/-/ 1,/
-N H N
S 0 a 0 Ce---t 0-- SI
-P, -.-- NH
H
H Oil 6 --ID * N
i ty *
/ 1 \
/ \ / 1 \
N -'-. N ¨
N --, N: 01 N: 0 N
µ
,-,-=
0-, 0 H N S 0 H N S. 0 N-151__ 0 -IS N-.D! ,..)_1,11 i W.-H
N ate H
0 ' --CI
1110 N'' H
I II_ I
NH NH
S
/ \
/ \ / \
N -- N --N --, N
: 0 N: 401 N la / /
0 H N S 0 0".H N S 0 .---N In -P, .---Or A co 40 0)----tt -.
* itilf.-._, * N
H
H
N .
Cr-N 0 NH
/
/ /
/ \
/ \
/ \
N '--N -.-, N --Nf 11101 Nf 1101 N I
oz H 'N 0 Z
0, N
i S 0 S
= ...--0/ H N S 0 N - / Orl d 'ID . N
H
N,-N ,--*
H
NH
N
S \
/
/ /
/ \
/ \ N ---/ \
N -'-N -'-N 1 00./ H N
)_ N: 0 0." H N S =
tr" 0 H N S =
t S
14=- pc: N =-- I 0)."-1 '.
411 "
P
0 140 r afif 0-41. ot s 101 r . Now .
/ \
/ \
N ". / µ
N -..-NI -"-)- N./ 110 S 0 P N: *
0 11 N /IS' N / 0 N /
W. 1 OXt Ns N--- a H 'N
o 40 " N-pi,s o AO c").-t 6=
lisi r 00 Ni--th40 "
, a i I es , , / , / , N '--/ \
N `
N ---/ 0 0'0 H RN *
N
S 0 P NI 0 W.- /
Cra--0 H 44 S 0 Rz,s Pr-N i 1µ1== / II' ' 0)---i- ,P---s )---0 "
0 * W.
0 I( ap 0 *
7 0(- 7 / \
/ \
N '-- / \
N "-N -H
a0 N'N *
0 H N S 0 N : *
N ,.
cel i -'0 40 "-- ac, H N S 0 HN A' 0 0 II. N -lc 0 ap 0 le H
ap ...a:
*=
0 wr.
, , , , , , , N--- N ---N -.--N s: 0 Nµ1 0 / /
/
s 001 r i . 0 N .
N
---' N
10 , , , / \
/ \ / \
N--N - N--N
/.
:11=1 (16 :" 0 N /
/
Iiii_ p N s 0 0 H . 'm = 1 S 0 N'..-.
NH
.
. .
/ \ / \
/ \
N.-N '-N--/ N:, all N:e *
/ N
0 H 14 . S 0 S. 0 N - i H -H
cell. P;--o H
t a *
i N N--\ II"
s s s / \
N--/ \
N--Ni 0 N
rice *
r_ p -kb 100 r 0 o 40 i---r HOYo HO
rj /1 \
N.---/ \
N1/2/ sti IN r s 0 N ---- fCrb 0 ej H
N, 0 N s 0 firl o r_, 0 SI [sr ri 0¨ro r--r r 0 r-i ,,,,,_, _ Jr.
,----HO ..,0 , , /
/ N
/
N--N-, N= 110 N: 1.1 H S 0 N-it 11 bj 04 r , or N-----N
Oj\
H
HO
or a pharmaceutically-acceptable salt, ester, chelator, hydrate, solvate, stereoisomer, or polymorphic form thereof.
/ \ / \
N--N - N--N
/.
:11=1 (16 :" 0 N /
/
Iiii_ p N s 0 0 H . 'm = 1 S 0 N'..-.
NH
.
. .
/ \ / \
/ \
N.-N '-N--/ N:, all N:e *
/ N
0 H 14 . S 0 S. 0 N - i H -H
cell. P;--o H
t a *
i N N--\ II"
s s s / \
N--/ \
N--Ni 0 N
rice *
r_ p -kb 100 r 0 o 40 i---r HOYo HO
rj /1 \
N.---/ \
N1/2/ sti IN r s 0 N ---- fCrb 0 ej H
N, 0 N s 0 firl o r_, 0 SI [sr ri 0¨ro r--r r 0 r-i ,,,,,_, _ Jr.
,----HO ..,0 , , /
/ N
/
N--N-, N= 110 N: 1.1 H S 0 N-it 11 bj 04 r , or N-----N
Oj\
H
HO
or a pharmaceutically-acceptable salt, ester, chelator, hydrate, solvate, stereoisomer, or polymorphic form thereof.
11. The compound of any one of claims 1 to 10, wherein the compound is a prodrug of axitinib.
12. A pharmaceutical composition comprising the compound of any one of claims 1 to 11 and a pharmaceutically acceptable carrier.
13. A method for the inhibition or modulation of the activity of a tyrosine kinase in a subject, comprising administering to the subject an effective amount of the compound of any one of claims 1 to 11 or the pharmaceutical composition of claim 12, such that the tyrosine kinase is inhibited or modulated in the subject.
14. The method of claim 13, wherein the subject suffers from a tumor or a cancer.
15. The method of claim 14, wherein the tumor or the cancer is a solid tumor.
16. The method of claim 14, wherein the tumor or the cancer is breast cancer, renal cell carcinoma, or thyroid cancer.
17. The method of any one of claims 13 to 16, wherein the effective amount is an amount effective to inhibit abnormal cell growth in the subject.
18. The method of any one of claims 13 to 17, wherein the subject is a mammal.
19. The method of claim 18, wherein the mammal is a human.
20. A method for treatment of a disease state or condition mediated by tyrosine kinases in a subject, comprising administering to the subject an effective amount of the compound of any one of claims 1 to 11 or the pharmaceutical composition of claim 12, such that the disease state or condition is treated in the subject.
21. The method of claim 20, wherein the disease state or condition is a tumor or a cancer.
22. The method of claim 21, wherein the tumor or the cancer is a solid tumor.
23. The method of claim 21, wherein the tumor or the cancer is breast cancer, renal cell carcinoma, or thyroid cancer.
24. The method of any one of claims 20 to 23, wherein abnormal cell growth is inhibited in the subject.
25. The method of any one of claims 20 to 24, wherein the subject is a mammal.
26. The method of claim 25, wherein the mammal is a human.
27. A method for modulating the pharmacokinetic profile of axitinib in a subject, the method comprising administering a prodrug of axitinib to the subject, wherein the prodrug comprises the compound of any one of claims 1 to 11 or the pharmaceutical composition of claim 12, such that the pharmacokinetic profile of axitinib is modulated compared to administration of axitinib itself.
28. The method of claim 27, wherein said modulating of the pharmacokinetic profile comprises increasing bioavailability, changing duration of the effective plasma concentration, decreasing the variability of plasma levels, reducing the side effects, and/or improving the therapeutic effect of axitinib in the subject, as compared to administration of axitinib itself.
29. The method of claim 27 or 28, wherein modulating of the pharmacokinetic profile comprises improving biodistribution, reducing the metabolism, and/or broadening the therapeutic application of axitinib in the subject, as compared to administration of axitinib itself.
30. The method of any one of claims 27 to 29, wherein modulating of the pharmacokinetic profile comprises increasing the half-life of axitinib and thereby decreasing the dose frequency of axitinib in the subject, as compared to administration of axitinib itself
31. The method of any one of claims 27 to 30, wherein the subject suffers from a disease state or condition mediated by tyrosine kinases.
32. The method of claim 31, wherein the disease state or condition is a tumor or a cancer.
33. The method of claim 32, wherein the tumor or the cancer is a solid tumor.
34. The method of claim 32, wherein the tumor or the cancer is a breast cancer, renal cell carcinoma, or thyroid cancer.
35. The method of any one of claims 27 to 34, wherein the subject is a mammal.
36. The method of claim 35, wherein the mammal is a human.
37. A kit comprising the compound of any one of claims 1 to 11 or the pharmaceutical composition of claim 12, and instructions for use thereof.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910818779.0A CN112442011B (en) | 2019-08-30 | 2019-08-30 | Prodrug compound and application thereof in treating cancers |
CN201910817505.XA CN112442009B (en) | 2019-08-30 | 2019-08-30 | Deuterated compounds and their use for treating cancer |
CN201910818779.0 | 2019-08-30 | ||
CN201910817505.X | 2019-08-30 | ||
CN201910818675.X | 2019-08-30 | ||
CN201910818675.XA CN112442010B (en) | 2019-08-30 | 2019-08-30 | Prodrug compounds and application thereof in treating cancers |
US202062994364P | 2020-03-25 | 2020-03-25 | |
US62/994,364 | 2020-03-25 | ||
PCT/CA2020/051177 WO2021035360A1 (en) | 2019-08-30 | 2020-08-28 | Prodrugs of the tyrosine kinase inhibitor for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3147801A1 true CA3147801A1 (en) | 2021-03-04 |
Family
ID=74684795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3147801A Pending CA3147801A1 (en) | 2019-08-30 | 2020-08-28 | Prodrugs of the tyrosine kinase inhibitor for treating cancer |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4021912A4 (en) |
AU (1) | AU2020338490A1 (en) |
CA (1) | CA3147801A1 (en) |
IL (1) | IL290798A (en) |
WO (1) | WO2021035360A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20010306A1 (en) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE |
CN106336397A (en) * | 2015-07-07 | 2017-01-18 | 郭明山 | Novel compound for treating ophthalmic diseases |
CN106317017A (en) * | 2015-07-10 | 2017-01-11 | 李建成 | Novel compound used for treating ophthalmic diseases |
CN106478596A (en) * | 2015-08-25 | 2017-03-08 | 李建成 | A kind of noval chemical compound as treatment ophthalmic diseasess |
WO2019196945A1 (en) * | 2018-04-13 | 2019-10-17 | 成都海创药业有限公司 | Novel method for synthesizing deuterated amides and deuterated sulfonamides |
-
2020
- 2020-08-28 CA CA3147801A patent/CA3147801A1/en active Pending
- 2020-08-28 WO PCT/CA2020/051177 patent/WO2021035360A1/en unknown
- 2020-08-28 AU AU2020338490A patent/AU2020338490A1/en active Pending
- 2020-08-28 EP EP20857153.9A patent/EP4021912A4/en active Pending
-
2022
- 2022-02-22 IL IL290798A patent/IL290798A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL290798A (en) | 2022-04-01 |
WO2021035360A1 (en) | 2021-03-04 |
EP4021912A4 (en) | 2023-08-23 |
AU2020338490A1 (en) | 2022-03-17 |
EP4021912A1 (en) | 2022-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106866784B (en) | Targeted mitochondrial antioxidant and preparation method and application thereof | |
JP2016034960A (en) | Methods, compounds and compositions for delivering 1,3-propanedisulfonic acid | |
KR20080030079A (en) | Inhibitors of fibroblast activation protein alpha | |
CA3104298A1 (en) | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use | |
CA3084030C (en) | Sulfonamide compounds and use thereof | |
US11725020B2 (en) | Prodrugs of a CDK inhibitor for treating cancers | |
BR112020019560A2 (en) | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | |
JP2018509424A (en) | Conjugates for treating diseases | |
WO2017172930A1 (en) | Pbd conjugates for treating diseases | |
US20210078970A1 (en) | Prodrugs of the tyrosine kinase inhibitor for treating cancer | |
JPH03118394A (en) | Novel compound, method of its preparation and pharmaceutical composition containing same | |
CA3147801A1 (en) | Prodrugs of the tyrosine kinase inhibitor for treating cancer | |
CN111995541A (en) | Compound containing stable heavy isotope amide functional group and application thereof | |
CN116284055A (en) | KRAS inhibitor and application thereof | |
AU2018387188A1 (en) | Glucosamine derivatives for the prevention or treatment of joint disorders | |
CN112442011B (en) | Prodrug compound and application thereof in treating cancers | |
CN112442010B (en) | Prodrug compounds and application thereof in treating cancers | |
CN112442009B (en) | Deuterated compounds and their use for treating cancer | |
CN110088098A (en) | Quinazolinones PARP-1 inhibitor and preparation method thereof, pharmaceutical composition and purposes | |
CN106146612B (en) | A kind of glyoxalase I irreversible inhibitor and its preparation method and application | |
ES2249314T3 (en) | BISINDOLILMALEIMIDAS FOR THE INHIBITION OF CELL PROLIFERATION. | |
CA3173095A1 (en) | Stable heavy isotopes in amide functional groups and uses thereof | |
CA3199926A1 (en) | 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxypyrrolidine-2-carboxa|mide derivatives as vhl inhibitors for the treatment of anemia | |
JP2024014933A (en) | Glucosamine derivatives for preventing or treating joint disorders | |
WO2023057812A1 (en) | Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220929 |
|
EEER | Examination request |
Effective date: 20220929 |
|
EEER | Examination request |
Effective date: 20220929 |